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Abstract 
 
 
The avian pathogen Mycoplasma gallisepticum, the etiologic agent of chronic 
respiratory disease in chickens, exhibits enhanced pathogenesis in the presence of a 
co-pathogen such as low-pathogenic avian influenza virus (LPAIV). M. gallisepticum 
Rlow can utilize α-2,3 linked sialic acids, abundant in the avian respiratory tract, to bind 
host cells in vitro. To further investigate the intricacies of this co-pathogenesis, chickens 
were mono- or co-infected with either virulent M. gallisepticum strain Rlow, attenuated M. 
gallisepticum neuraminidase mutant P1C5 and Mycoplasma specific lipoprotein A 
mutant P1H9, or LPAIV H3N8 (A/duck/Ukraine/1963). These chickens were then 
assessed for tracheal histopathology, pathogen load, and transcriptomic host response 
to infection using RNA-sequencing. Chickens co-infected with M. gallisepticum Rlow 
followed by H3N8 exhibited significantly more severe tracheal lesions and mucosal 
thickening in response to infection than chickens infected with H3N8 alone. Viral load 
was also significantly increased in this group over chickens who were infected first with 
H3N8 and subsequently with M. gallisepticum Rlow. The attenuated M. gallisepticum 
mutants P1C5 and P1H9, previously shown to be cleared 14 days post-infection, were 
able to persist 6 to 7 days post-infection in the presence and absence of co-infection  
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with H3N8. P1H9 was able to persist to 14 days post-infection only in the presence of 
H3N8. The transcriptional response to mono- and co-infection with M. gallisepticum and 
LPAIV highlighted the involvement of differential expression of genes such as TLR4, 
TLR15, TLR21, IL-1β, IRF4, MMP1, and MMP9. Pathway and gene ontology analysis of 
these differentially expressed genes suggests that co-infection with virulent M. 
gallisepticum and LPAIV induces a downregulation of ciliary activity in vivo and alters 
the multiple immune-related signaling cascades. Although H3N8 is susceptible to 
neuraminidase inhibition by oseltamivir in vitro, this antiviral treatment was not effective 
in vivo at reducing H3N8 load in the trachea of co-infected chickens. These data 
indicate that the co-pathogenesis of LPAIV and M. gallisepticum is not strictly 
neuraminidase-dependent and warrants further experimental understanding. 
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Chapter 1 – Literature Review 
 
Section 1 – Broad Introduction to Mycoplasmas 
 
 
History and Nomenclature of Mycoplasmas 
 In 1898 an infectious organism, described at the time as a “virus”, was isolated 
from clinical samples taken from a cow stricken with contagious bovine 
pleuropneumonia [1]. This organism was filterable but not entirely invisible and had also 
become associated with mastitis, polyarthritis, and agalactia in goats and sheep [2]. 
Over the coming decades, there was little to no consensus on the nomenclature of 
these agents of disease. The umbrella term of “pleuropneumonia-like organisms” 
(PPLO) was employed to encompass this and related organisms [3].  
 It was not until 1955 that the term “Mycoplasma” became formally used to identify 
these organisms within the order Mycoplasmatales [4] and the genus Mycoplasma [5]. 
In the following decade, a Subcommittee on the Taxonomy of Mycoplasma determined 
that the class Mollicutes should thus be characterized by the lack of a true cell wall and 
a plastic outer membrane [5,6]. It was around this same era that the study of 
Mycoplasmas began in earnest with the determination that Eaton’s agent, the cause of 
primary atypical pneumonia in humans, was classified as a Mycoplasma [8,9].  
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General Mycoplasma Characteristics 
 Although the lack of a classical prokaryotic cell wall became an integral aspect of 
the identity of Mollicutes early on [6,7] there are other crucial elements to the unique 
nature of Mycoplasmas. These organisms are among the smallest, self-replicating 
prokaryotes with a highly reduced genome size ranging between 580 kB in the human 
pathogen Mycoplasma genitalium [10] to 1380 kB in the bovine pathogen Mycoplasma 
mycoides subsp. mycoides [11].  
These small genomes are also comprised of a low guanine/cytosine content [11] 
and are prone to mutation because of poor DNA polymerase proofreading [12]. Another 
feature of Mycoplasmas are their limited biosynthetic abilities as a byproduct of their 
reduced genomic size. This warrants the need for an intimate relationship between 
Mycoplasmas and their host environment for the acquisition of molecules and nutrients 
essential for life [11]. Although this host-microbial relationship is critical, it is not limited 
by a narrow host organism range nor always a pathogen-host dynamic [11].  
 
 
Innate Immune Response to Mycoplasmas 
 The innate host response to Mycoplasmas begins at the mucosal interface. 
These mucosal barriers serve as the first line of defense in the host innate immune 
system. Mycoplasmas of the respiratory tract, for instance, interact with cilia in the host 
respiratory epithelium at sialo-oligosaccharide receptors [13]. Lipoproteins on the 
surface of Mycoplasmas are sometimes involved in this interaction and are sensed by 
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pattern recognition receptors such as toll-like receptors (TLRs) and NOD-like receptors 
(NLRs) [14].  
These mycoplasma lipoproteins most notably are recognized by TLRs 1, 2, and 6 
[14]. These TLRs all serve to recognize pathogen-associated molecular patterns 
(PAMPs) in the form of bacterial lipoproteins [14]. These particular TLRs have a 
concerted relationship in that TLR 2 interacts with TLRs 1 or 6 to bind both tri- and di-
acetylated lipoproteins [15,16]. These lipoproteins are key in Mycoplasmas such as 
Mycoplasma pulmonis, which uses its family of Vsa lipoproteins in evasion of 
phagocytosis by host alveolar macrophages [17,18].  
Mycoplasma lipoproteins, such as those from Mycoplasma fermentans and 
Mycoplasma salivarium are associated with activation of the inflammasome of the host 
[19]. Mycoplasma genitalium is also recognized by TLRs 2 and 6 in the host, activating 
NFκB and leading to downstream induction of interleukin (IL) 6, IL-7, IL-8, monocyte 
chemoattractant protein 1 (MCP1) early in infection [20,21]. Other notable instances of 
Mycoplasma lipoproteins involved in pathogenesis and immune evasion will be 
discussed in later portions of this dissertation among a wide range of hosts. 
The activation of the host inflammasome can also be mediated by extracellular 
ATP production and macrophage stimulation, as seen in Mycoplasma hominis, which 
subsequently leads to IL-1β production contributing to the pro-inflammatory immune 
response [19,22]. The inflammasome can also be stimulated by Mycoplasma 
pneumoniae exotoxin, community-acquired respiratory distress (CARDS) toxin, by its 
ADP-ribosylation activity [23]. M. pneumoniae has also been shown to induce IL-8, IL-
1β, tumor necrosis factor (TNF) α, and regulated on activation, normal T cell expressed 
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and secreted (RANTES) [24]. Other pathogens, such a Mycoplasma hyopneumoniae 
increase the expression of IL-5 and IL-13 in the host [25].  
Mycoplasmas have also been documented to induce the release of neutrophil 
extracellular traps (NETs). NETs are released by neutrophils in response to microbial 
infection and consist of chromatin, cytoplasmic proteins, antimicrobial peptides, and 
enzymes to neutralize microbial pathogens [26,27]. This release of NETs from the 
cytoplasm of neutrophils is classified as NET-osis, or a variety of cellular death [26]. 
Infection with Mycoplasma bovis stimulates reactive oxygen species production and the 
later release of these NETs [28]. Mycoplasmas can also inhibit cell cycle checkpoints by 
modulating p53 and cellular apoptosis [29]. 
Another facet of host immunity relevant to Mycoplasma infection is the family of 
matrix metalloproteinases (MMPs). These MMPs are produced by an array of immune 
cells such as macrophages and T cells in response to cytokine stimulation and 
contribute to tissue remodeling and inflammation mediation [30]. Mycoplasma hyorhinis, 
for instance, activates MMP-2 with its antigen p37 which can contribute to 
carcinogenesis [31]. MMP-2, as well as MMP-9 are increased in expression in response 
to infection with Mycoplasma pulmonis in the respiratory tract [32]. Mycoplasma 
pneumoniae also induces MMP-9 in human circulation during infection of the airway 
[33]. The innate immune response to Mycoplasmas will be further described throughout 
this dissertation with a focus on response to infection with Mycoplasma gallisepticum.  
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Mycoplasma Sialidases (Neuraminidases) 
 Sialidases, also referred to as neuraminidases, are glycosyl hydrolase enzymes 
present in prokaryotes, eukaryotes, and viruses [34]. These sialidases release terminal 
N-acetylneuraminate, also known as sialic acid, residues from glycoproteins, glycolipids 
and polysaccharides [34]. Sialic acids are nine-carbon sugars that exist in four different 
categories: N-acetylneruaminic acid (Neu5Ac, NANA) which is most relevant to 
vertebrates, N-glycolneuraminic acid (Neu5Gc), deaminated neuraminic acid (KDN), 
and neuraminic acid (Neu) [34]. These sialic acids can have an array of modifications at 
the hydroxyl group position that can influence recognition by sialic acid binding proteins 
[34]. Linkages of sialic acids to galactose molecules on the cell surface are commonly 
seen in α(2,3)-, α(2,6)-, and α(2,8)- confirmations [34]. 
 Bacteria can utilize sialidase activity to recognize host cells, colonize and 
disseminate within the host, degrade the extracellular matrix and scavenge sialic acids 
as nutrients [35,36,37,38]. Certain species, such as Streptococcus pneumoniae, have 
specific sialidase activity for only α(2,3)-linked sialic acids [34]. Other organisms, such 
as Actinobacter urefaciens utilize sialidase to hydrolyze α(2,3)-, α(2,6)-, and α(2,8)-
linked sialic acids [34]. In many bacterial genomes, the gene for sialidase is often 
located in close proximity to genes encoding enzymes facilitating the transport and 
intracellular metabolism of sialic acids and their byproducts for glycolysis [36]. 
Sialidase activity is frequently associated with bacterial virulence. For instance, 
the sialidase gene nanA in Streptococcus pneumoniae is critical for virulence in the 
nasopharyngeal tract of the host and both nanA and nanB sialidase genes are 
associated with upper and lower respiratory tract infections and sepsis [39]. The first 
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Mycoplasma with reported sialidase activity was the avian pathogen Mycoplasma 
gallisepticum [40,41,42]. The activity of sialidase varies widely among Mycoplasma 
species [43,44].  
Notably, another avian Mycoplasma pathogen, Mycoplasma synoviae, retains the 
genes for sialic acid degradation and metabolism in its genome [45], whereas 
Mycoplasma gallisepticum does not [46]. It is hypothesized that these genes were 
transferred between these two species and that M. gallisepticum has lost the sialic acid 
metabolism genes over time [47]. A more detailed discussion of sialidase in different 
Mycoplasma species can be found in the subsequent review of pathogenic 
Mycoplasmas and their hosts. There is evidence that sialidases from co-infecting 
pathogens, i.e. a viral and bacterial pathogen, may have a synergistic relationship 
contributing to the enhancement of disease. Instances of this pathogenic phenomenon 
will also be discussed later in this dissertation. 
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Sub-Section 1-1: Pathogenic Mycoplasmas 
 
Mycoplasmas of Mammals - Humans 
 Humans play host to multiple Mycoplasmal pathogens in both the respiratory and 
reproductive tract. Mycoplasma pneumoniae, formerly known as Eaton’s agent [8] is 
responsible for 4-8% of all community acquired bacterial pneumonia cases [48]. This 
proportion can increase to 20-40% during an endemic and 70% within a closed 
population such as a household or school [48]. Mycoplasma pneumoniae is readily 
spread within a closed community, such as a family unit, and has an incubation period 
of 23 days [49].  
The atypical or “walking” pneumonia, caused by M. pneumonia is characterized 
by tracheobronchitis, a cough either with or without sputum, and general malaise [50]. 
Infection with M. pneumoniae becomes even more serious in patients with chronic 
asthma or chronic obstructive pulmonary disorder (COPD) due to dysregulation of host 
inflammatory responses [51]. This pathogen can migrate to extrapulmonary sites in the 
host causing encephalitis in 13% of cases, as well as stroke and psychological 
disorders, dermatological pathology, gastrointestinal symptoms, carditis, and septic 
arthritis [48,52]. Natural immunity to M. pneumoniae is not long-lived and a patient will 
shed the pathogen over a chronic period [48].  
One unique feature of M. pneumoniae is the presence of an endotoxin named 
the community-acquired respiratory distress (CARDS) toxin [53,54]. This endotoxin has 
ADP-ribosylation activity and its expression is induced when M. pneumoniae encounters 
a host [54]. This association with the host respiratory tract requires the cytadherance 
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and gliding motility of M. pneumoniae mediated by the adhesin molecules P1, P90, P40 
and P30 which assemble into an attachment organelle structure [55]. 
Another human respiratory pathogen is Mycoplasma amphoriforme which was 
originally isolated in 1999 from a patient with x-linked agammaglobulinemia and chronic 
bronchitis [56]. It has since been isolated from immunocompromised patients with 
respiratory tract infections in Europe [56,57]. Similar to M. pneumoniae, M. 
amphoriforme also utilizes an attachment organelle structure in cytadherance and has 
gliding motility [58].  
In addition to the respiratory tract, Mycoplasmas are also associated with disease 
in the human urogenital tract. One such pathogen is Mycoplasma genitalium which was 
first detected in 1981 in male patients with non-gonococcal urethritis [59]. M. genitalium 
has since been associated with urethral inflammation and discharge in male patients 
and cervicitis with chronic persistence in female patients [60]. The M. genitalium cell has 
a flask-shaped morphology and has a similar attachment organelle to M. pneumoniae 
that is mediated by the proteins MgpB and MgpC [61,62]. These attachment proteins 
also experience genetic variation by recombination [63,64]. 
Another noteworthy urogenital pathogen is Mycoplasma hominis which is 
associated with pelvic inflammatory disease (PID), bacterial vaginosis, spontaneous 
abortion, and neonatal bacteremia and meningitis [65,66]. The pathobiology of M. 
hominis is complicated by aberrant inflammatory cytokine signaling from pregnant 
mother and fetal hosts which ultimately leads to pre-term birth and fetal disease in 
affected patients [67]. M. hominis also possesses variable adherence associated (Vaa) 
antigens which are phase variable and immunogenic in the human host [68].  
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Other relevant human Mycoplasma pathogens include Mycoplasma penetrans, 
which employs an attachment organelle and gliding motility to cause disease in the 
urogenital tract [69]. M. penetrans is strongly associated with disease in patients with 
acquired immunodeficiency syndrome (AIDS) [70]. Lastly, Mycoplasma fermentans is a 
urogeneital Mycoplasma implicated in genital tract infections, genital ulcers, and also 
rheumatoid disease and respiratory infections [71,72].  
 
Mycoplasmas of Mammals - Swine 
 There are two predominant Mycoplasma pathogens of porcine species: 
Mycoplasma hyopnumoniae and Mycoplasma hyorhinis. The first pathogen, M. 
hyopneumoniae, is responsible for enzootic pneumonia and a member of the porcine 
respiratory disease complex (PRDC) [73]. This makes M. hyopneumoniae of great 
relevance and concern to the agricultural industry. Infected pigs are susceptible to co-
infection with other respiratory pathogens, as will be discussed later in this review, and 
can be exposed to M. hyopneumoniae through lactation [74]. M. hyopneumoniae uses 
an array of cytadhesins (P97, P102, P159, and P146) to bind the pig respiratory tract 
resulting in ciliostasis and ciliary loss in these animals [75,76].  
 Another Mycoplasma pathogen of swine is Mycoplasma hyorhinis which is 
associated with polyserositis and polyarthritis in nursing piglets [Kobish and Friis, 1996]. 
This pathology results in reduced weight gain in piglets as they age and lameness, 
making M. hyorhinis infection another agriculturally relevant Mycoplasma [77. M. 
hyorhinis employs a family of variable lipoproteins (Vlp) such as VlpA, VlpB, and VlpC 
which serve as variable surface antigens [77]. In addition, M. hyorhinis has been 
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recently associated with extracytoplasmic binding via P37, which can induce the 
migration of cancer cells by n-terminal annexin A2, leading to tumor progression [78]. 
 
 
 
Mycoplasmas of Mammals - Bovids 
In cattle, Mycoplasma bovis is a pathogen of great economic relevance to the 
agricultural industry as it is the most common cause of Mycoplasma mastitis in cows 
[79]. This pathogen is also an agent of chronic pneumonia and poly-arthritis syndrome 
(CPPS) and bovine respiratory disease (BRD) in cattle [80,81]. Infection with M. bovis is 
often associated with co-infection in immunosuppressed animals afflicted with viral 
infections such as bovine diarrheal virus and bovine herpes virus 1 [82,83]. As with 
other notable Mycoplasma pathogens, M. bovis also utilizes a family of variable surface 
proteins (Vsp) that are involved in attachment and host-pathogen recognition [84]. 
 There is also a group of closely related Mycoplasma species that infect bovine or 
caprine hosts denoted as the Mycoplasma mycoides Mycoides cluster [85]. This cluster 
consists of one bovine pathogen, M. mycoides subsp. mycoides Small Colony (SC), and 
four caprine pathogens; M. mycoides subsp. capri (Mmc), M. capricolum subsp. 
capricolum (Mcc), M. capricolum subsp. capripneumoniae (Mccp), and M. leachii (Ml) 
[85,86]. Previously, M. mycoides subsp. mycoides Large Colony (LC) was a member of 
this cluster, however it has since been classified as serovars within Mmc [86]. The 
evolution of this cluster of pathogens coincides with the historical domestication of 
ruminants by humans [87].  
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 The first pathogen in this cluster, M. mycoides subsp. mycoides SC is the 
causative agent of contagious bovine pleuropneumonia (CBPP) [87,88]. This disease is 
classified by respiratory disease with extremely high mortality in infected animals as well 
as weight loss, reduction in fertility, and crippling economic impact to the cattle industry 
from quarantine and disease control measures [88]. In Africa, the Pan African Control of 
Epizootics (PACE) has declared CBPP the second most important transboundary 
disease in Africa, preceded only by Rinderpest [88]. M. mycoides subsp. mycoides SC 
is the only bacterial pathogen to be classified as an OIE List A pathogen [89].  
 Infected cattle can be either symptomatic or asymptomatic carriers of the 
disease, and this infection can transition to a chronic form over time [88]. The immune 
response to M. mycoides subsp. mycoides SC is characterized by an overly robust 
inflammatory response in the lung which sets the stage for mortality by respiratory 
distress in as many as 30% of infected cattle [89]. This pathogen is equipped with 
surface lipoproteins LppA, LppB, and LppQ as well as a family of phase-variable 
surface proteins (Vmm), all of which are involved in the pathogenesis of CBPP [88,90].  
  
 
Mycoplasmas of Mammals – Caprids 
 As mentioned previously, a portion of the Mycoplasma mycoides Mycoides 
cluster are pathogens of caprine species. To begin, M. mycoides subsp. capri (Mmc) is 
associated with systemic disease in caprine species known as mastitis, arthritis, 
keratitis, pneumonia and septicemia (MAKePS) syndrome [91,92]. Another Mycoides 
cluster pathogen, M. capricolum subsp. capricolum (Mcc), is responsible for contagious 
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agalactia and is the foremost cause of this disease in caprine species in France and 
Spain and effects goat populations worldwide [93].  
 Lastly, M. capricolum subsp. capripneumoniae (Mccp) is the pathogen 
responsible for contagious caprine pleuropneumonia (CCPP) in goats, sheep and wild 
ruminants [92]. Mccp, formerly known as Mycoplasma biotype F38, induces a 
serofibrinous pleupneumonia and ciliostasis in the respiratory tract with approximately 
100% morbidity and mortality [94]. The disease process is often more acute in young 
animals and chronic in older animals [94]. Currently, it can be detected in over 40 
countries worldwide with the exception of those on the American continent [95]. As with 
other members of the Mycoides cluster, Mccp is of great concern to the agricultural 
industry causing over $507 million dollars in losses per year in endemic areas [95].  
 Outside of the Mycoides cluster, Mycoplasma agalactiae is a pathogen of sheep 
and goats causing contagious agalactia [94]. M. agalactiae can be transmitted vertically 
through milk feeding [94]. This pathogen also carries immunodominant surface 
lipoproteins (Vpma) that are involved in pathogenesis in the host [96]. Lastly, 
Mycoplasma ovipneumoniae is a common pathogen of sheep, effecting approximately 
90% of sheep operations in the United States [97]. It is also the primary cause of 
epizootics of pneumonia in bighorn sheep [98]. M. ovipneumoniae induces interstitial 
pneumonia and is often detected in animals co-infected with pathogens such as 
Mannheimia haemolytica [99].  
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Mycoplasmas of Mammals – Felines 
 Mycoplasma haemofelis is a hemotropic Mycoplasma, also known as a 
Hemoplasma, that binds to feline red blood cells and can cause severe hemolytic 
anemia in wild and domestic cats [100]. This infection state can be acute or can 
transition to a chronic carrier state when infected cats receive antibiotic treatment and 
later re-activate M. haemofelis infection [101]. Other feline pathogens include 
Mycoplasma felis, which causes upper respiratory tract infections, and Mycoplasma 
gatae, which is associated with arthritis and tenosynovitis [102,103].  
 
 
Mycoplasmas of Mammals – Canines 
 Mycoplasma canis is an opportunistic pathogen of dogs which otherwise resides 
as a commensal organism in the respiratory or urogenital tract [104,105]. It has been 
found in the brains of dogs exhibiting granulomatous meningoencephalitis and 
necrotizing meningoencephalitis [104].  Another pathogen, Mycoplasma cynos, is a 
respiratory pathogen first isolated from a fatal infection in a puppy [106]. M. cynos 
employs the hemagglutinin HapA in cytadherance to host cells [106]. In addition, both 
M. canis and M. cynos are positive for sialidase activity as well as the other canine-
associated Mycoplasma edwardii, Mycoplasma spumans, and Mycoplasma molare 
[107].  
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Mycoplasmas of Mammals – Rodents 
 The respiratory pathogen, Mycoplasma pulmonis, is often detected in animal 
care facilities in rodents and is the etiologic agent of murine respiratory mycoplasmosis 
(MRM) and arthritis [108]. This disease can be transmitted both vertically and 
horizontally, although different strains of laboratory rodents have altered susceptibility to 
M. pulmonis infection [108,109]. Recently, evidence suggests that IL-17A exacerbates 
M. pulmonis disease in Balb/c mice [109].  
 Another rodent pathogen is Mycoplasma arthiditis which possesses the 
Mycoplasma arthritidis-derived mitogen (MAM) superantigen [110]. M. arthriditis is 
associated with arthritis, toxic shock and necrotizing fasciitis in rodent species 
[111,112]. Additionally, Mycoplasma neurolyticum is associated with neurologic 
pathology in young mice and rats and possesses weak sialidase activity [113].  
 
 
Mycoplasmas of Aquatic Vertebrates 
 The host range of Mycoplasmas are not limited to mammalian species. For 
instance, Mycoplasma agassizii is the causative agent of upper respiratory tract disease 
(URTD) in Mojave Desert tortoises, North American tortoises and gopher tortoises 
[114,115].  
 There are two other notable pathogenic Mycoplasmas of reptiles. The first of 
which is Mycoplasma alligatoris which is associated with invasive, multisystemic 
inflammatory disease in alligators and caimans [116,117]. This pathogen has both 
hyaluronidase and sialidase activity and can scavenge N-acetylneuraminate for 
 15 
catabolism [116,117,118]. M. alligatoris also induces apoptosis in host cells by 
promoting CD95, or FasR, expression in fibroblasts [119].  
 A closely related pathogen of reptiles is Mycoplasma crocodyli, first isolated in 
1997 from the joints and lungs of a crocodile [117,120]. In contrast to M. alligatoris, M. 
crocodyli is associated with less invasive disease such as mild pneumonia or 
polyarthritis [117]. Another key difference between these two pathogens is that M. 
crocodyli is free of any sialidase or N-acetylneuraminate catabolism genes, although it 
does have hyaluronidase activity [117]. This pathogen also has no identified adhesin or 
variable surface antigen genes [117].  
 Another pathogen of aquatic hosts is Mycoplasma mobile which is responsible 
for necrosis in the gill organs of freshwater fish [121]. Like some Mycoplasmas of 
mammalian hosts, M. mobile possesses gliding motility and data suggests that M. 
mobile has the fastest motility among the Mycoplasmas [122]. This pathogen also 
employs mobile variable surface proteins (Mvsp) as variable surface antigens [123].  
 
 
Mycoplasmas of Avians 
 There are many Mycoplasma pathogens of various avian species. Mycoplasma 
meleagridis is a pathogen of turkeys which causes stunted growth, airsacculitis and 
decreased egg production [124]. Similar to other pathogenic Mycoplasmas, M. 
meleagridis is positive for sialidase activity [113]. Another sialidase positive pathogen is 
Mycoplasma corogypsi which causes polyarthritis and tenosynovitis in black vultures 
[113,125].  
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 In waterfowl, Mycoplasma cloacale, Mycoplasma anatis, and Mycoplasma 
anseris have been associated with airsacculitis, nervous system disease and 
reproductive disease [126]. Mycoplasma gallinarum is responsible for fatty liver 
hemorrhagic syndrome in commercial layer chickens and can also impact egg quality 
[127]. Another avian pathogen with relevance to reproductive disease is Mycoplasma 
iowae which can colonize avian embryos as well as reside within the gastrointestinal 
tract [128]. The pathogenesis of M. iowae is controlled by exposure to atmospheric 
oxygen impacting activity of its catalase, KatE [129]. Also of note, M. iowae carries a 
homologous gene to the Mycoplasma pneumoniae CARDS toxin [130].  
 In wild birds, Mycoplasma sturnii is often isolated from conjunctival lesions 
alongside the pathogen Mycoplasma gallisepticum, which will be discussed in greater 
detail in a later section of this review [131,132]. However, M. sturnii does not cause 
disease when used as the lone inoculum of experimentally infected house finches [132]. 
Lastly, Mycoplasma synoviae causes osteoarthritis, respiratory lesions and synovitis in 
landfowl [133].  
Infection with M. synoviae is often accompanied by co-infecting pathogens such 
as Newcastle disease virus, infectious bronchitis virus, Escherichia coli, Mycoplasma 
gallisepticum, or Mycoplasma meleagridis [134,135]. As with other notable 
Mycoplasmas mentioned, M. synoviae is also positive for sialidase activity and 
possesses the genes required for sialic acid catabolism which may have been 
transferred from Mycoplasma gallisepticum [47,135].  
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Spiroplasmas and Phytoplasmas of Plants, Insects, and Invertebrates 
 Within the Mollicutes, there are also relevant pathogens such as Spiroplasmas 
and Phytoplasmas. In the 1980’s, Spiroplasmas were first isolated from crops stricken 
with citrus stubborn disease and the surfaces of plants [136]. These organisms are also 
associated with arthropod and crustacean hosts, likely using them as a reservoir host 
with horizontal transfer between these hosts occurring through interaction with infected 
plants [137]. Notable example species of these Spiroplasmas include S. apis, S. 
floricola, and S. citri [138]. 
 Phytoplasmas, on the other hand, are limited to plant hosts and were first 
characterized in 1967 from plants effected by Yellow’s disease [139]. Although 
Phytoplasmas were initially implicated in plant disease, they can also result in 
ornamental flora manifestation in host plants such as poinsettias [140]. These 
pathogens are uncultivable outside of the host [138].  
 
 
  
 18 
Sub-Section 1-2: Mycoplasma gallisepticum 
 
Significance  
 Mycoplasma gallisepticum is an avian pathogen of great agricultural relevance 
and will be the Mycoplasma of interest for this dissertation. This pathogen is an etiologic 
agent of chronic respiratory disease (CRD) in chickens, which is characterized by 
coughing, sneezing, respiratory rales, and nasal and ocular discharge [141,142,143]. 
The respiratory pathology of M. gallisepticum infection is composed of tracheal lesions, 
airsacculitis, squamous cell metaplasia, ciliary loss in the respiratory epithelium, and 
thickening of the tracheal mucosa [144].  
 Within a flock, M. gallisepticum is readily transmitted by horizontal transmission 
via respiratory droplets or conjunctival exposure [145,146], as well as vertical 
transmission via egg laying [147]. The easy spread of M. gallisepticum necessitates 
culling of infected flocks to contain the infection, as well as losses in egg production and 
egg quality [148,149]. It has been estimated that M. gallisepticum is responsible for 
$588 million dollars in yearly economic losses in the broiler chicken industry and $132 
million dollars yearly in the egg industry [150,151].  
 In addition to chickens, M. gallisepticum is a pathogen of other avian species. 
This pathogen causes sinusitis in turkeys and conjunctivitis in wild passerines such as 
the house finch [11,152]. Transmission of M. gallisepticum readily occurs within 
populations of wild birds in wildlife rehabilitation facilities and is impacted by the density 
of bird feeders in outdoor environments [153,154]. Notably, M. gallisepticum appears to 
exhibit marked host adaptation over time. The M. gallisepticum strain isolated from 
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house finches in 1996 (Virginia 1994, VA94) induces severe pathology in chickens, 
whereas a more house finch adapted isolate (Virginia 2013, VA13) is attenuated in the 
chicken host [155].  
 Efforts to control M. gallisepticum infection began as early as the 1960’s when 
the United States federal government instituted its National Poultry Improvement Plan 
(NPIP) [156]. More recently, M. gallisepticum is among the top three avian pathogens of 
concern in the United States as stated by the USDA Agricultural Research Service 
(ARS) and Cooperative State Research, Education, and Extension Service (CSREES) 
[157].  
 Over time there have been many iterations of vaccination strategies against M. 
gallisepticum. Bacterins (inactive suspensions of whole M. gallisepticum cells) showed 
promise early on, however further study suggested that this vaccine was not efficacious 
in reducing bacterial load or infection with related M. gallisepticum strains 
[158,159,160,161]. The addition of an adjuvant, such as chitosan, does appear to 
enhance protection in layer hens [162].  
 Live attenuated M. gallisepticum vaccines are a much broader area of vaccine 
research. The attenuated F strain of M. gallisepticum elicits a robust serological 
response in vaccinated birds, however this response is not as strong as a natural 
infection with virulent M. gallisepticum [163,164]. F strain has also been associated with 
respiratory lesion formation in turkeys and young chickens which limit its appeal as a 
vaccine [165]. Overall, vaccination through the ocular route is more efficacious than the 
nasal route with the F strain vaccine MycoF [166].  
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The temperature-sensitive M. gallisepticum mutant ts-11 has been shown to be a 
safer vaccine candidate than F strain, but with reduced immunogenicity [167]. Similarly, 
the in vitro passage attenuated strain 6/85 is a fairly safe vaccine candidate but also is 
less efficacious [168]. The systemic antibody response to ts-11 is acutely strong and 
wanes over time, whereas the response to 6/85 is initially weak and slowly increases 
over time 169]. In recent years two laboratory-generated attenuated M. gallisepticum 
variants, GT5 and Mg7, have undergone study as promising vaccine candidates 
[170,171,172,173]. 
 
 
Virulence Factors 
 There is an array of virulence factors that have been characterized in 
Mycoplasma gallisepticum. The sequencing of the virulent Mycoplasma gallisepticum 
strain Rlow genome was instrumental in outlining and describing some of these virulence 
factors [46].  
A subset of genes are lost after serial in vitro passage of the virulent, low 
passage Rlow strain to its attenuated, high passage Rhigh strain. These genes are two 
cytadhesins, GapA and CrmA, and one the high-affinity transporter HatA [174,175]. 
GapA and CrmA have homology to Mycoplasma pneumoniae adhesins [173,174]. 
Complementation of the attenuated Rhigh with both GapA and CrmA restores 
cytadherance and virulence in vivo, whereas complementation with only GapA results in 
an attenuated variant, GT5, which has diminished cytadherance properties [174,175]. 
Other adhesion related proteins include Hlp3 and PlpA, which also share homology with 
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adhesins of M. pneumoniae, and are capable of binding the gelatin and heparin binding 
domains of fibronectin [176].  
 Metabolism-related factors also contribute to M. gallisepticum virulence. The 
dihydrolipoamide dehydrogenase (lpd) gene within the pyruvate dehydrogenase 
pathway contributes to the production of ATP in glycolysis [171]. Transposon 
inactivation of lpd results in a metabolically weakened variant, Mg7, which is attenuated 
in chickens and a promising vaccine candidate [171]. The ABC sugar transport 
permease MalF is also a factor required for proper metabolism of M. gallisepticum and 
transposon inactivation of MalF ablates M. gallisepticum persistence in vivo [177]. 
Conversely transposon mutants in the glycerol transport and hydrogen peroxide 
production pathway, GlpO, GlpK, and GlpF, retain their virulent phenotype in vivo [178]. 
Some, but not all, M. gallisepticum vaccine strains do not produce hydrogen peroxide so 
the role of this pathway in M. gallisepticum is not fully understood [178]. 
 As mentioned previously in this dissertation, sialidases are known to be bacterial 
virulence factors. Sialidase, or neuraminidase, activity had been described in some 
strains of M. gallisepticum historically, but its role was not deeply explored [41,179]. The 
M. gallisepticum Rlow gene MGA_0329 was identified as a sialidase with robust activity 
[46,180]. Transposon insertional inactivation of this gene in three M. gallisepticum 
mutants results in a loss of sialidase activity, persistence, and reduction of virulence in 
vivo compared to virulent Rlow [180]. One such M. gallisepticum mutant, P1C5, was 
complemented with MGA_0329 and this complementation successfully restored 
sialidase activity but not virulence or persistence in chickens 14 days post-infection 
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[180]. These data suggest that the relationship between M. gallisepticum sialidase and 
its virulence in the host is not yet fully elucidated. 
 Another virulence factor within M. gallisepticum Rlow, MGA_0674, has been 
characterized as Mycoplasma-specific lipoprotein A (MslA) [181]. The mslA gene has 
paralogues in Mycoplasma pneumoniae and homologs in other Mycoplasma species 
[181]. MslA is immunogenic and differentially expressed between the virulent strain Rlow 
and the attenuated F strain [181]. Transposon insertional inactivation of mslA yielded 
the mutant P1H9, which cannot persist nor cause disease in chickens 14 days post-
infection [181]. Evidence indicates that MslA has polynucleotide binding activity for 
ssDNA, dsDNA, and ssRNA and may use this binding activity to scavenge and utilize 
these nucleotides [182].  
 A family of genes, the variable lipoprotein hemagglutinin A (vlhA) genes, have 
been described in both chicken and passerine Mycoplasma gallisepticum strains 
[46,183]. The expression of these vlhA genes appears to be coordinated, and changes 
over time in the tracheae of infected chickens [155,184]. One vlhA in particular, vlhA 
3.03, is the predominantly expressed vlhA in both virulent and attenuated M. 
gallisepticum variants in vivo, early in infection [155,184]. However, transposon 
inactivation of vlhA 3.03 does not diminish virulence and the expression pattern of the 
remaining vlhA genes remains unchanged from its wild-type counterpart [185]. Two of 
these VlhA’s, VlhA 1.07 and VlhA 4.01, alongside GapA and PlpA and others are 
considered to be immunogenic, in vivo induced antigens in chickens [186]. Overall, the 
role of VlhA expression in virulence of M. gallisepticum is not yet fully understood.  
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Host-Pathogen Interactions in the Respiratory Tract 
 The specific interactions between Mycoplasma gallisepticum and the host cell 
are mediated by not only its primary adhesins mentioned previously, but the receptors 
of the host cell. Sialoglycoconjugates serve as receptors for an array of Mycoplasmas 
including M. pneumoniae, M. genitalium, M. synoviae and M. gallisepticum [11]. 
Specifically, M. gallisepticum can utilize these sialic acid moieties to bind human 
erythrocytes and other eukaryotic cells in vitro [186,43]. This pathogen, as discussed 
previously, can bind components of the extracellular matrix such as heparin, collagen 
type IV, fibronectin, and plasminogen [188,189,176].  
 Cytadherance is crucial in the respiratory epithelium and navigation of the 
mucociliary elevator is required for persistence. Other Mycoplasmas, such as M. 
hyopneumoniae, colonize the cilia of the trachea and bronchi by adherence to 
glycolipids in the pig epithelium [190]. This binding induces ciliostasis or stalling of the 
ciliary movement in the respiratory epithelium, allowing M. hyopneumoniae to traffic to 
the ciliary base [191]. M. pneumoniae exhibits a similar behavior of ciliary adherence 
utilizing gliding motility [192].  
Ciliostasis has also been documented in M. gallisepticum infection of the avian 
respiratory tract. M. gallisepticum strain S6 and J1 induces ciliostasis in chicken 
tracheal organ cultures [193,194,195]. Chicken embryos infected with M. gallisepticum 
strain S6 also exhibit deciliation and erosion of the respiratory epithelial surface as early 
as 5 days post-infection, and this same effect was seen as early as 6 hours post-
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infection when embryonic tracheas were infected ex vivo [196]. This phenomenon has 
also been described in turkeys infected with M. gallisepticum, which displayed 
lymphocytic infiltration in the nasal submucosa and ciliary loss in the sinuses [197].  
 
 
Innate Immune Response  
 Upon infection with Mycoplasma gallisepticum, the avian host employs pattern 
recognition receptors (PRR) to recognize the invading pathogen. Chickens, the primary 
host of interest for M. gallisepticum in this dissertation, have a suite of pattern 
recognition receptors in the toll-like receptor (TLR) family that differ from their 
mammalian counterparts.  
One example is TLR15, which is unique to avian and reptile organisms [198]. 
TLR15 was originally characterized as a sensor of yeast-derived compounds inducing 
the activation of NFκB signaling and subsequent IL-1β production [198]. Further study 
revealed that the expression of TLR15 was upregulated in response to bacterial 
infection [199,200,201] and may be directly induced by binding proteases during 
infection [202].  
 Another TLR of interest is TLR21, which is functionally homologous to human 
TLR9 [203]. This TLR recognizes CpG oligodeoxynucleotides, which are single-
stranded DNA molecules that are present in microbial genomes and serve as pathogen-
associated molecular patterns (PAMPs) to be recognized by PRRs during infection 
[203]. In contrast, TLR4 exists in both mammals and chickens but with only 46% identity 
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common between them [204]. TLR4 is able to sense bacterial lipopolysaccharide (LPS) 
during infection when associated with myeloid differentiation protein-2 (MD-2) [205].  
TLR2 is also not unique to chickens and is associated with the sensing of 
peptidoglycan and lipoproteins in association with TLRs 1 and 6, and polymorphisms of 
TLR2 exist among various breeds of chickens who differ in their susceptibility to 
bacterial infection [206]. Heterophils, the polymorphonuclear cell of avian species 
similar to mammalian neutrophils, express TLR1/6/10, TLR2 types 1 and 2, TLR3, 
TLR4, TLR5, and TLR7 in chickens [207].  
 Lipoproteins of the virulent Mycoplasma gallisepticum strain Rlow are recognized 
by chicken TLR2 in cultured, primary tracheal epithelial cells leading to the increased 
expression of pro-inflammatory genes related to NFκB signaling such as IL-1β, IL-6, IL-
8, IL-12p40, CCL20, NOS-2 [208]. These effects are mirrored in DF-1 chicken embryo 
fibroblasts, in which both TLR2 and TLR6 upregulated in response to M. gallisepticum 
infection as well as downstream inflammatory genes such as MyD88, NFκB, IL-2, IL-6, 
and TNFα [209]. In chickens, M. gallisepticum infection induced increased expression of 
genes such as lymphotactin, CXCL13, CXCL14, RANTES, IL-6, and MIP-1β [210].  
 Recently, next-generation sequencing has allowed for a global, transcriptomic 
view of the tracheal immune response of chickens to infection with virulent M. 
gallisepticum Rlow over time. Within the first 7 days after initial infection, a multitude of 
immune signaling pathways were found to be upregulated in response to M. 
gallisepticum including, but not limited to, TLR signaling, mitogen activated protein 
kinase (MAPK) signaling, Jak-STAT signaling, and nucleotide oligomerization domain 
(NOD)-like receptor signaling pathways [211]. The peak amount of differential gene 
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expression, both increased and decreased expression, occurred 3 days post-infection 
[211]. Interestingly, TLR4 and TLR15 were the most abundantly expressed TLRs in 
chickens across this 7-day time course of infection [211]. Metabolic pathways in the 
chicken host were also significantly activated 1- and 3-days post-infection, likely due to 
cellular stress in response to infection with virulent M. gallisepticum [211]. This cellular 
stress also relates to the abundant expression of two matrix metalloproteinases (MMPs) 
early in infection, MMP7 and MMP9, which are involved in extracellular matrix and 
tissue remodeling [211]. 
 Two attenuated variants of M. gallisepticum discussed earlier in this dissertation, 
GT5 and Mg7, induced metabolic and immune-related genes to a much lower degree 
than virulent Rlow in chickens during the first two days of infection [172]. The increases 
in TLR4 and TLR15 were not recapitulated in the attenuated M. gallisepticum infected 
chickens 1-day post-infection [172]. However, 2 days post-infection, the metabolic 
mutant Mg7 induced an increase in TLR4 and TLR15 expression above that of GT5, but 
not to the extent of virulent Rlow [172]. Interestingly, TLR21 expression was significantly 
increased in Rlow and GT5 infected chickens and decreased in Mg7 infected chickens 
both 1- and 2-days post-infection [Beaudet et al., 2019]. Induction of genes related to 
the Nlrp3 inflammasome in response to cell stress were also induced in response to 
infection with Rlow or Mg7, such as caspase 1 (CASP1) and IL-1β [172].  
 In another one of its primary avian hosts, the house finch, virulent M. 
gallisepticum isolates Virginia 1994 (VA94) and North Carolina 2006 (NC06) induced 
the expression of pro-inflammatory cytokines in the nictitating membrane and Harderian 
gland [212]. Isolate NC06 was more virulent in house finches, and thus triggered a 
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stronger inflammatory immune response 3- to 6-days post-infection [212]. Notably, the 
expression of IL-1β strongly correlated with the load of M. gallisepticum in the 
conjunctival tissue of infected house finches [212]. 
 Another growing area of research into the host response to M. gallisepticum 
infection is the induction of microRNAs (miRNAs). These miRNAs are differentially 
expressed during M. gallisepticum infection [213]. For instance, gga-miR-16-5p has 
been shown to promote apoptosis in DF-1 cells infected with M. gallisepticum which 
inhibits PI3K/Akt/NFκB signaling pathways [214]. In contrast, another miRNA, miR-
130b-2p activates this same pathway in response to M. gallisepticum infection in vitro 
[215]. This differential effect on miRNA expression during infection may elude to 
mechanisms by which M. gallisepticum dysregulates the host immune response.  
 The cell-mediated innate immune response to virulent M. gallisepticum Rlow 
challenge is characterized by an abundance of aggregates of B cells, CD4+ and CD8+ 
lymphocytes infiltrating the lamina propria of the trachea of infected chickens with 
expansion of lymphoplasmacytic and histiocytic infiltrates expanding in the tissue [216]. 
Chickens vaccinated with M. gallisepticum GT5 and subsequently challenged with 
virulent Rlow yield lower numbers of these lymphocytes in the lamina propria of the 
trachea but have a larger population of IgA and IgG-secreting plasma and B cells in the 
trachea as early as 4 days post-challenge [216]. These same cells infiltrate not only the 
tracheal mucosa, but the air sacs of M. gallisepticum infected chickens and turkeys 
[217]. The pathologic manifestation of these responses results in the release of mucous 
granules in the respiratory epithelium and exfoliation of both ciliated and non-ciliated 
cells [218]. These epithelial cells lyse, and their cellular debris intermix with mucus to 
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form an exudate within the tracheal lumen and air sac [218]. Cells in the tracheal lumen 
are hypertrophic and exhibit a loss of ciliated cells compounded by increased mucosal 
thickness due to cellular infiltrates and edema in response to infection [218].  
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Section 2 – Broad Introduction to Influenza Viruses 
 
 
History and Nomenclature of Influenza Viruses 
 The term “influenza” was originally used as a general descriptor for disease for a 
majority of history [219]. Until 1918, Pfeiffer’s bacillus, now known as the bacterium 
Haemophilus influenzae, was thought to be the cause of influenza before a filterable 
agent was isolated from influenza patient sputum as the true etiologic agent [220]. This 
filterable agent was used to reproduce disease in humans and ferrets, and thus 
described as the influenza virus [220].  
 Influenza viruses were named as “mucin-reacting” viruses, or myxoviruses [221]. 
This naming was then adjusted to orthomyxovirus to differentiate them from 
paramyxoviruses by differential structures [221]. Within this category, influenza viruses 
were named in alphabetical order by the chronological order of their isolation (i.e. 
Influenza A, B, C or D) [221].  
 Influenza A viruses can infect a range of hosts such as humans, pigs, horses, 
dogs, marine mammals and birds [222]. This particular subtype of influenza virus will be 
described in greater detail in the subsequent sections of this dissertation. 
 Influenza B viruses, first identified in 1940, primarily infect humans but can also 
cause disease in seals, horses, dogs, and pigs [223,224,225]. This subtype of influenza 
virus can cause more severe disease in immunocompromised humans and may be 
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responsible for annual epidemics, but not pandemics as with influenza A viruses 
[222,224].  
 Similarly, influenza C viruses, isolated in 1947, can infect humans and induces 
mild respiratory disease [226,227]. These viruses broadly circulate in areas across the 
globe, primarily in children [224]. Influenza C viruses can also be isolated from pigs, 
dogs, and camels with documented transmission between humans and pigs [224,228]. 
Most recently, influenza D viruses were identified in 2014 in swine, cattle and sheep 
with cattle being the natural reservoir [224,229]. These viruses share a 50% homology 
with influenza C viruses [224].  
 
 
Influenza A Virus Characteristics 
 All influenza viruses are characterized by a segmented, negative-sense single 
stranded RNA (ssRNA) genome which replicates via RNA-dependant RNA polymerase 
activity [230,231]. The influenza A virus genome is contained in 8 RNA segments, 
encoding between 10 and 15 viral proteins depending on the specific isolate [232]. The 
influenza virion is spherical and particles range from 80 to 120 nanometers in diameter 
[222]. The viral particle is surrounded by a lipid bilayer containing approximately 500 
protein spike projections per virion [222]. 
 These protein spikes consist of the transmembrane hemagglutinin (HA), 
comprising 80% of the protein spikes, and the integral membrane protein 
neuraminidase (NA) which makes up the remaining 20% [222]. To date, there are 18 
characterized subtypes of HA and 11 subtypes of NA in influenza A viruses [233]. 
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Subtypes of influenza virus are named by their antigenic type (A, B, C, or D), host of 
origin, geographical origin, strain number, year of isolation, and combination of HA (H) 
and NA (N) subtype [234]. Famous influenza A pandemics include the Spanish flu of 
1918 (H1N1), Asian flu of 1957-1958 (H2N2), Hong Kong flu of 1968-1969 (H3N2), and 
the Swine flu of 2009 (H1N1) [222]. 
 Both HA and NA are crucial components of influenza virulence. Hemagglutinin 
(HA) binds to host ligands containing N-acetylneuraminic acid, or sialic acids, and this 
binding specificity determines tissue and species tropism of the virus [34,235]. For 
instance, influenza A viruses of human hosts preferentially bind the terminal α(2,6)-
linked sialic acids abundant in the human upper respiratory epithelium and viruses of 
avian hosts bind the α(2,3)-linked sialic acids of the avian respiratory and 
gastrointestinal epithelium [34]. Porcines, however, can become infected with both 
mammalian and avian strains of influenza A virus due to the abundance of both α(2,3)- 
and (2,6)-linked sialic acids in their tracheae [34]. The implications of two cohabitating 
influenza A viruses within a single host will be discussed in a later section of this 
dissertation. 
 
 
Viral Replication, Assembly, and Release 
 The HA protein is the mediator of fusion of influenza virus to the host cell 
membrane. HA binds sialylated receptors on the host cell and is engulfed via 
endocytosis into the host cell [236]. The virus then forms an endocytic vesicle which will 
fuse with the endosomal compartment and release the virus into the endosome 
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[237,238]. Once within the endosome, the virus responds to the low pH environment by 
a conformational change in the structure of HA to expose the fusion peptides in its 
trimeric stem region [239]. This allows for a membrane fusion between the viral lipid 
bilayer and the host endosome, as well as opening of the M2 ion channel [240].  
 Within the endosome, the virus will un-coat and export viral ribonuclear protein 
(RNP) comprised of viral RNA, RNA-polymerase, and viral nucleoprotein (NP) 
[241,242]. Viral RNA is trafficked to the host cell nucleus and new viral genome is 
synthesized there utilizing host pre-mRNA caps before export [243,244]. The freshly 
transcribed viral RNAs are transported into the host cell cytoplasm for translation on 
host ribosomes [245]. Progeny virions are finally assembled at the membrane and 
released by budding from the host cell mediated by NA and the matrix protein, M1 
[245,246,247,147].  
 There are an array of proteins encoded by influenza A virus that contribute to 
various stages of the viral life cycle. Polymerase basic protein 2 (PB2), is involved in the 
transcription of viral genomic RNA [249]. Polymerase basic protein 1 (PB1) interact with 
polymerase acidic protein (PA) in the elongation of viral RNA [250]. PB1-F2 targets host 
mitochondria and trigger apoptosis [251]. PA also works to bind PB1 in the assembly of 
viral RNPs alongside NP during replication [252,253].  
The matrix protein (M1) is involved the assembly of progeny virions by binding to 
viral RNP to associate with non-structural protein 2 (NS2), the viral nuclear export signal 
[254,255]. Non-structural protein 1 (NS1), however has many functions including anti-
interferon activity and the regulation of viral RNA nuclear export [254,255]. The ion 
channel protein, M2, mediates the uncoating of the viral capsid and controls the pH of 
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the host Golgi apparatus to prevent a premature change in HA confirmation 
[240,256,257,258]. Lastly, influenza NA, as mentioned earlier with bacterial sialidases, 
cleaves host sialic acids during viral maturation and budding from infected host cells 
[259]. NA is a popular target for anti-influenza drug development and may work in 
concert with bacterial NAs or sialidases during infection, as will be discussed later in this 
dissertation. 
 
 
Antigenic Shift and Drift 
 When a singular host cell is infected with multiple different influenza viruses, a 
phenomenon known as antigenic shift can occur. Within the host cell, there is 
reassortment of the segments of viral RNA which will then swap parts of the genome 
between viruses when they assemble and bud from the host [260]. This reassortment 
can lead to a broadening of tissue or host tropism and can be the start of an influenza 
pandemic [224].  
The most common hosts for these antigenic shifts are pigs, quails and bats due 
to the abundance of both α(2,3)- and (2,6)-linked sialic acids to accommodate 
mammalian and avian influenza A viruses [224].  Antigenic drift, however, is the gradual 
accumulation of viral RNA mutations over time due to the error prone nature of influenza 
RNA-dependent RNA polymerase [261]. These mutations lead to more subtle changes 
in the virus which can be responsible for seasonal variations in the circulating influenza 
A strains [261].  
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Antiviral Drugs and Vaccines 
 There are two main classes of anti-influenza dugs; M2 ion channel inhibitors and 
neuraminidase inhibitors. M2 inhibitors are effective in both preventing infection with 
influenza A virus and reducing the duration of infection by inhibiting viral replication 
[262,263]. Examples of M2 inhibitors include amantadine (Symmetrel) and rimantadine 
(Flumadine) [262]. Although initially effective, M2 inhibitors are no longer a 
recommended course of treatment because of emerging resistance to the available 
inhibitors [263].  
 The other class of anti-influenza drugs is neuraminidase (NA) inhibitors. One 
such inhibitor is zanamivir (Relenza), which is an altered form of another NA inhibitor 2-
deoxy-2,3-dehydro-N-acetyl-neuraminic acid (DANA) to enhance specificity for viral NA 
over host NA [34]. This drug has poor oral bioavailability and must be inhaled for 
efficacy [264,265]. Perhaps the most popular NA inhibitor is oseltamivir (Tamiflu). 
Oseltamivir is administered orally and is commonly stockpiled in anticipation of avian 
influenza pandemics [265]. This drug was designed for competitive inhibition of the 
active site of the viral NA [264,265]. The pro-drug form, oseltamivir phosphate, is 
prescribed to patients and when ingested, undergoes an ester hydrolysis reaction in the 
patient’s liver to its active form, oseltamivir carboxylate [266].  
 Neuraminidase inhibitors, such as oseltamivir and zanamivir, have been effective 
in shortening the length of illness and viral shedding in human patients if given within 
the first 24 to 48 hours of symptom onset [267]. Both zanamivir and oseltamivir are 
available worldwide for human use [277]. Similar drugs, such as laninamivir (Inavir) are 
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available in Japan and peramivir (Rapiacta or Permaflu) are available in China, Japan, 
South Korea and the United States [268]. Oseltamivir and zanamivir can be prescribed 
as prophylactic measures, however this is not recommended for peramivir and 
laninamivir [267].  
This prophylactic use, however, can lead to the development of neuraminidase 
inhibitor resistance in circulating influenza strains after prolonged use of sub-therapeutic 
concentrations of drug [267]. Emerging resistance to these neuraminidase inhibitors is a 
growing area of research to develop new drugs and drug targets. Recently, the World 
Health Organization (WHO) analyzed 13,581 neuraminidase gene sequences from 
public databases of influenza A virus strains from the 2016-2017 influenza season 
[267]. Of the influenza viruses tested, 94% were sampled from the Western Pacific 
region, North and South America, and Europe, whereas the remaining portion 
represented the Eastern Mediterranean region, Africa, and South East Asian region 
[269]. Only 0.5% of the neuraminidase sequences from these viruses displayed likely 
neuraminidase inhibitor resistance, or reduced inhibition of activity, however this 
proportion may grow over time and does not encompass the global influenza 
distribution.  
 Vaccination for human influenza is a major public health endeavor, headlined by 
the WHO. The FLUVACS clinical trial analyzed influenza vaccination strategies during 
the 2007-2008 influenza season [270]. The live-attenuated nasal influenza vaccine, 
FluMist, is efficacious but this does not correlate with an increase in HA or NA inhibition 
titers in human patients [270]. The inactivated vaccine, Fluzone, however does correlate 
increased efficacy with NA inhibition titers in vaccinated patients [270]. The most widely 
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used influenza vaccine is an inactivated, trivalent vaccine administered by injection 
[270]. Another type of influenza vaccine, FluBlok made by Protein Sciences, is a 
recombinant HA vaccine marketed to patients with an egg allergy, as its development 
does not merit the use of embryonated chicken eggs with an up to 40% reduction in 
influenza infection in elderly recipients [271]. These vaccines are carefully designed to 
protect against the forecasted influenza strains of relevance for a given season, which 
lasts 7 to 8 months [271]. 
 Vaccination efforts also exist for cases of animal influenza and will be discussed 
in more detail in subsequent sections of this dissertation. The World Organization for 
Animal Health (OIE) and Food and Agriculture Organization of the United Nations (FAO) 
collaborated to form a team of experts on animal influenza (OFFLU) as a means to 
advise veterinary, scientific, and agricultural professionals on risk and management of 
animal influenza infections [272]. In 2009, the U.S. Department of Agriculture (USDA) 
formed a national swine influenza A virus surveillance system which has paved the way 
for similar systems in European nations [273,274].  
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Sub-Section 2-1: Avian Influenza Viruses 
 
Pathobiology 
 As mentioned earlier, a noteworthy group of hosts of influenza A virus are avian 
species. Of the possible 16 HA and 9 NA subtypes of influenza a virus, most have been 
found in waterfowl which serve as a common reservoir host for influenza [224]. These 
strains of avian influenza A virus (AIV) preferentially bind α(2,3)-linked sialic acid 
moieties present in the respiratory and gastrointestinal tract of galliform birds and 
waterfowl [275]. Chickens, quails, partridges, turkeys, pheasants, ostriches, and mallard 
ducks express both α(2,3)- and α(2,6)-linked sialic acids differentially in abundance 
within their nasal cavities, tracheae, and lungs which contributes to the varied host and 
tissue tropism of different AIV strains [276].  
 AIVs are categorized into two broad types based on their pathogenicity in avian 
species; highly-pathogenic AIV (HPAIV) and low-pathogenic AIV (LPAIV). HPAIV has 
been referred to as “fowl plague” throughout history before AIV was better understood 
[277]. HPAIV primarily replicates in the avian respiratory tract and sheds readily from 
the trachea [275]. This infection can spread readily to other internal organs such as 
muscle, intestinal tract and central nervous system causing severe mortality [275].  
HPAIV strains are typically limited to the H5 and H7 HA subtypes of influenza A 
virus [278]. Notably, HPAIV strains that cause severe mortality in gallinaceous birds 
often do not do the same in waterfowl and wild birds and vice versa [278]. These 
HPAIVs are thought to have evolved from LPAIVs as they persist in a wild bird 
population over time [278].  
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 Gallinaceous birds infected with high mortality strains of HPAIV may exhibit 
central nervous system lesions such as multifocal gliosis, neuronal degradation and 
lymphocytic meningitis [279]. These lesions may be accompanied by heart lesions such 
as diffuse lymphocytic perivascular cuffing, vacuolation of myocardial cells, as well as 
general histiocytic infiltration, coagulative necrosis of the thymus, kidney and bursa, 
fibrosis, catarrhal tracheitis, and pneumonia [279].  
 The majority of AIVs belong to the LPAIV category [280]. LPAIV replicates in the 
intestinal tract of infected birds and is this shed from the cloaca for fecal-oral 
transmission in a waterfowl [275]. These viruses, in contrast to HPAIVs, are limited to 
the epithelial tissues in infected hosts and due to the subversive nature of disease, 
transmission to poultry hosts may easily go unnoticed [275]. Lesions in LPAIV H5N2 
(A/chicken/Pennsylvania/21525/83) and H4N8 (A/chicken/Alabama/7395/75) infected 
chickens may present as a diffuse epithelial hyperplasia in the trachea with lymphocytic 
infiltrates in the tracheal submucosa [279]. This may present clinically as general upper 
respiratory signs, swelling of the head, and lethargy [280]. More severe cases may yield 
diffuse lymphocytic pneumonia, necrosis of the spleen, bursa, thymus and kidneys, and 
enteritis [279]. In waterfowl, the airway becomes infected with LPAIV when the birds 
exhibit dabbling behavior in the water [275]. This results in a mild tracheitis and 
pneumonia 2 days post-infection but is undetectable in the airway as soon as 3 to 4 
days post-infection [275].  
 Certain LPAIVs, such as H9N2, are endemic in poultry populations in the Middle 
East, North Africa, and Asia after circulating from China in 1994 [280]. The significance 
of such LPAIV outbreaks will be discussed further in later sections of this dissertation. 
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However, most LPAIV infections often goes unnoticed due to the mild and often 
subclinical nature of disease in most avian hosts [281]. In the field, LPAIV can be 
suspected when populations of birds show a decrease in water and feed consumption 
and minimal movement toward food or water [281]. Infected birds typically recover from 
LPAIV infection in the respiratory tract if they do not have compounding health issues, 
however effects on egg production can be severe in chickens and turkeys making the 
disease of concern to agricultural professionals [281].  
 
 
Significance and Control Measures 
 AIV is a pathogen of importance not only for animal health, but human health and 
industrial practices as well. It has been estimated that a pandemic of AIV would initiate 
an economic loss of between $100-200 billion dollars in the United States alone in 2004 
currency values [282]. Asian nations experienced outbreaks of HPAIV in 2003 and 2004 
which resulted in the direct loss of 44 million birds, accounting for around 17.5% of the 
total poultry population in Vietnam [282]. This loss accounts for as much as 1.8% of the 
gross domestic product of the entire nation, equating to approximately $76-450 million 
United States dollars in 2004 currency values [281]. Such a pandemic would be 
crippling in nations such as the United States or Brazil who account for almost 70% of 
the global supply in the poultry trade [282].  
 These economic concerns are not limited to HPAIV isolates. For example, LPAIV 
strain H9N2 was identified as the culprit of an outbreak in China between 1992 and 
1994, leading to drastic economic losses resulting from losses in egg production and 
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poultry mortality [283]. LPAIV H9N2 was also responsible for a field outbreak in Korea in 
1996 which lead to efforts to stamp out the disease in infected chickens [283].  
 Control measures for AIV are crucial in preventing outbreaks of disease in wild 
and agricultural populations of birds. Although LPAIV does not carry the same stigma of 
rapid mortality and severe disease as HPAIV, surveillance for this often subclinical, 
underestimated pathogen is still of great importance [275]. LPAIVs of the H7 subtype in 
particular can be readily transmitted between chickens and turkeys, so field surveillance 
measures are critical in controlling spread between wild and domestic birds [284].  
 Vaccination efforts against AIV vary across the globe. Surprisingly, many 
countries do not vaccinate against HPAIV. In the 1990s, some prophylactic use of 
inactivated AIV vaccines were employed in Mexico and Pakistan to control outbreaks of 
both HPAIV and LPAIV [272]. In the years following, inactivated virus vaccines have 
been the recommended course of action over live-attenuated vaccines, regardless of 
the subtype per OIE standards [272,285]. Overall, AIV vaccines are comprised of 
inactivated virus in oil-emulsion, and only a minority of AIV vaccines remain live, viral 
vectored vaccines [286]. In nations such as Egypt, Vietnam, China, Mexico, and 
Indonesia, vaccination is targeted against H5, H7, and H9 AIVs to combat endemic 
AIVs in those regions [287]. These vaccination protocols have also been useful in the 
control of HPAIV to prevent nations from culling, or stamping out, populations of wild 
and domestic birds to protect the food supply [281].  
One concern, however, is that vaccination may prevent the manifestation of 
clinical signs, but not infection, with HPAIV and may unintentionally contribute to the 
spread of the virus to endemic status in a given region [288]. Targeted vaccine 
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strategies for HPAIV in specific geographic locations and host species is rare, 
accounting for less than 1% of all AIV vaccinations [286]. Vaccination strategies for AIV 
are primarily focused on poultry, however limited vaccinations effots have been 
employed on captive birds such as zoo animals [286]. Wild birds, although often a 
resevior for AIV, are not a target of vaccination efforts due to logistical concerns [286].  
Vaccination against LPAIV is a growing effort due to the probability of the 
mutation of a subclinical infection of LPAIV to HPAIV when circulating in the field [281]. 
In the 1970s, inactivated virus vaccines against H5 and H7 LPAIV strains have been 
used in turkeys, as well as preventative vaccination against H5N1 AIV in outdoor poultry 
and zoo birds in Europe [272].  
Even in regions where vaccination is not supported, some poultry farmers will 
expose pullets, or young chickens, to AIV to prevent a later outbreak that would cause 
severe losses in production due to disease or eradication measures [289]. Evidence 
also suggests that oseltamivir, the NA inhibitor used to treat human influenza infections, 
is effective in reducing the load of H9N2 and H6N2 LPAIV in the tracheae and cecal 
tonsils of infected chickens and ducks [291]. Prevention of LPAIV infection is also 
crucial in that, when compounded by a secondary infection, disease severity can be 
dramatically enhanced. These co-infection scenarios will be discussed in greater detail 
in later sections of this dissertation. 
 
 
Host Innate Immune Response 
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 Upon infection with influenza virus, the host can sense and respond to this 
invasion with an assortment of signaling cascades. For instance, innate sensors of 
influenza virus infection include TLR3, TLR7, RIG-I, NLRs, and NLRP3 [292]. An 
associated signaling molecule, MyD88, is a critical member of the signaling cascade to 
recruit innate immune cells and to coordinate cytokine and chemokine production upon 
viral infection [292]. One such class of innate immune cells are natural killer (NK) cells, 
activated by TLR7 during influenza infection [293].  
 Although the host is equipped with an array of pattern recognition receptors to 
respond to infection, influenza virus has adapted with mechanisms of immune evasion 
and modulation. One such mechanism is the induction of suppressor of cytokine 
signaling (SOCS) by influenza, which in turn inhibits TLR and antiviral IFN signaling 
[294]. The viral protein NS1 is another facet of influenza immune evasion. One innate 
response to influenza infection is signaling through the retinoic acid-inducible gene I 
(RIG-I). This response also involves melanoma differentiation-associated gene 5 
(MDA5), interferon-beta promoter stimulator 1 (IPS-1), and interferon-regulated factor 4 
(IRF3), all contributing to an anti-influenza IFN-β response [295]. The NS1 protein of 
influenza virus can negate this response by repressing RIG-I signaling and evading the 
subsequent IFN-β activity [295]. 
 Influenza infection can also trigger cell death in the host in a variety of ways. 
Infection of a host cell with influenza can induce the expression of Fas and Fas-ligand 
on the cell surface, which then triggers programmed cell death via apoptosis [296]. 
Apoptosis can also be induced during infection by the viral dysregulation of the host 
type 1 interferon response [297]. In a human host, this dysregulation induces pulmonary 
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injury from alveolar macrophages expressing IFN-β, thus contributing to alveolar 
epithelial damage [297]. This response triggers expression of TNF-related apoptosis-
inducing ligand (TRAIL), contributing to cell death in the host respiratory tract and a 
subsequent manifestation of pneumonia [297]. Apoptosis can also be directly induced 
by the influenza proteins PB1-F2 which target the host mitochondria and induce pore 
formation [298]. 
 Another mechanism of cell death induction in response to influenza infection is 
the activation of the host inflammasome. To accomplish this, the host must recognize 
the virus by activation of PRRs which will then signal with other members of the 
inflammasome complex, such as NLRP and its adaptor Apoptosis-Associated Speck-
Like Protein Containing CARD (ASC) [298]. This adaptor then activates the maturation 
of caspase-1 which cleaves pro-IL-1β and pro-IL-18 cytokines for secretion and 
inflammatory action [298]. This caspase-1 activity is a facet of pyroptosis, or cell death 
by inflammation [298]. The inflammatory cytokines IL-1β and IL-18 are also critical in 
activation of the inflammasome [298]. This activation of ASC and caspase-1 signaling 
serves as a primer for later CD8+ T cell responses to immunodominant influenza 
antigens, and the downstream production of IgA by B cells [298]. 
The influenza porin protein M2 can also trigger NLRP3 activation of the 
inflammasome by modulating the intracellular ion concentrations within the host cells 
[298]. The NLRP3 inflammasome activation induces a TH17 and TH1 response in the 
host, which promotes CD4+ T cell and memory T cell responses [298]. 
  In the human respiratory tract, the induction of pro-inflammatory IL-6 and IFN-α 
increases up to 2 days post-infection, and this increase correlates with climbing 
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influenza titers, increases in body temperature, mucous production, and clinical 
symptom severity [299]. IL-6 is also abundant in the circulatory system at this time 
[299]. At 3 to 4 days post-infection, TNF-α peaks in concentration in both the upper 
respiratory tract and serum, followed by IL-8 four to six days post-infection both of which 
correlating with decreasing viral loads and respiratory symptoms of infection [299]. In 
humans with autosomal deficiencies in TLR3, the dysfunctional TLR3-dependent type I 
and type III interferon response contributes to influenza virus infection progression to 
pneumonitis [300].  
The innate immune response to AIV is somewhat unique, and the response in 
avian hosts yield even further intricacies to the innate response to influenza. For 
instance, in contrast to LPAIV, HPAIV has tropism for endothelial cells in poultry due to 
its trypsin-independent HA cleavage during replication [301]. Within the possible avian 
hosts, the response to influenza infection varies even further. In ducks, infection with 
HPAIV induces a more robust innate immune response overall compared to LPAIV, and 
this response can produce inflammation in the brain [302]. HPAIV infection induces the 
inhibition of the anti-inflammatory mediator STAT-3 by HPAIV H5N1 in chickens 
[310,311]. This induces a unique pro-inflammatory cytokine storm in the chicken host, 
which is not replicated in ducks during the same infection [310,311]. 
Although LPAIV typically replicates slower than HPAIV, it does induce a more 
significant IFN-β and interferon stimulating gene (ISG) response [230]. These LPAIVs, 
such as H9N2, also stimulate a weak IFN-α response but still contribute to increased 
expression of interleukins, TLR activation, and RIG-I, Jak-STAT, and NF-κB signaling 
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[294]. HPAIVs, on the other hand, induce a drastic type 1 interferon response in the 
lung during infection of an avian host [294].  
In contrast to ducks, chickens do not possess RIG-I which contributes to a 
differential susceptibility to HPAIV infection between ducks and chickens [275,294]. 
During LPAIV infection in mallards, RIG-I and myxovirus resistance gene (Mx) are 
upregulated initially, then returning to a baseline level by 2 days post-infection [304]. In 
place of RIG-I, chickens utilize MDA5 in its place to signal the same type 1 IFN 
response via MAVS, IRF3 and IRF7 [294].  
Another unique aspect of the avian response to AIV is the downstream signaling 
of TLR3. In mammalian hosts, TLR3 recognizes dsRNA for the later activation of NFκB 
and type 1 interferons [305]. In geese, TLR3 is upregulated in the lungs and brain 
during AIV H5N1 infection alongside IL-6 and IFN-γ [305]. This type 1 interferon 
response in mammals is mediated by IRF3, which is absent in chickens who instead 
utilize IRF1 to regulate an IFN-β antiviral response [306]. TLR3 is also protective 
against LPAIV H4N6 infection in chicken eggs [307].  
 Other relevant TLRs in AIV include TLR21, which is upregulated in response to 
LPAIV H9N2 infection in geese [308]. In chickens pro-exposed to LPAIV H9N2 followed 
by HPAIV H5N1, several TLRs are differentially expressed. TLR1, TLR2, TLR5 and 
TLR7 are decreased in expression after the secondary infection with HPAIV in contrast 
to TLR3 and TLR15 which are increased in expression [309]. Other genes of interest 
include the downregulation of IFN-α, IFN-β, IFN-γ, IL-1β, IL-2, IL-4, IL-8 and TGF-β and 
the upregulation of TNF-α [309]. Overall, the innate immune response to AIV is a 
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nuanced process made further complex by the viral evasion and modulation of the host 
response. 
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Sub-Section 2-2: Influenza A Virus H3N8 
 
Mammalian H3N8 
 The influenza A virus subtype H3N8 has been recently implicated in disease in 
an array of mammalian species. In 2015, there was an outbreak of H3N8 equine 
influenza in Malaysia [312]. Infected horses treated with oseltamivir phosphate had 
reduced viral shedding and fever with an additional reduction in the likelihood of a 
secondary bacterial pneumonia from Streptococcus equi subsp. zooepidemicus 
infection [312]. It is hypothesized that this equine H3N8 was transmitted to canines, 
resulting in the current H3N8 canine influenza with associated respiratory disease 
[313,314].  
This proposed introduction occurred in 2004, when H3N8 was first isolated in 
greyhounds in the United States exhibiting respiratory disease [315]. Once established 
in the canine host, H3N8 is easily horizontally transmitted between dogs in a closed 
environment such as a shelter [316]. This canine H3N8 has experienced robust host-
adaptation and cannot be transmitted between dogs and avian species such as 
chickens, turkeys, or ducks [317]. The respiratory disease caused by canine H3N8 is 
variable in severity, however co-infection in dogs with other respiratory pathogens such 
as S. equi subsp. zooepidemicus can be common and vaccination against canine H3N8 
has been effective in reducing disease in co-infected dogs [318].  
In 2011, an outbreak of H3N8 was detected in 162 New England harbor seals 
with drastic mortality from pneumonia [320]. Unlike canine H3N8, the H3N8 isolated 
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from New England harbor seals retains the ability to bind α(2,3)-linked sialic acids 
similarly to AIV which could indicate possibility for cross-species transmission [321].  
 
 
Avian H3N8 
 In avian hosts, influenza A virus H3N8 is classified as a low pathogenic avian 
influenza virus (LPAIV). This virus has been detected in areas across the globe in an 
array of hosts. For instance, H3N8 was detected in wild birds on the central Peruvian 
coast from 2006 to 2007 [322]. H3N8 and H4N6 are the most prevalent AIV strains 
isolated in mallards in northwestern Minnesota in the United States between the years 
of 2007 and 2016 [323].  
In China, H3N8 accounts for 25% of AIV detected in domestic ducks and wild 
birds among other hemagglutinin subtype 3 viruses and has the ability to cross into 
chicken hosts [324]. H3N8 also co-circulates with H3N2 and a newly emerged H3N6 in 
Chinese wild and domestic birds [325]. In Europe, oropharyngeal and cloacal H3N8 
shedding is limited in passerine birds such as house sparrows and European starlings 
[326].  
 H3N8 (A/Mallard/MN/199106/99) does not produce gross lesions in 
experimentally infected mallards, however it does induce lymphocytic tracheitis and 
laryngitis early in infection and can be shed up to four days after infection [326]. It has 
also been documented that H3N8 infection can result in the decrease of α(2,3)-linked 
sialic acids in the bursa of Fabricius and enterocytes of experimentally infected ducks 
[326]. In young mallards, H3N8 is shed more abundantly than in older ducks [327]. 
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Ducks that were previously infected with H3N8 are later protected from infection with 
closely related strains of AIV [328,329,330].  
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Section 3 – Viral and Bacterial Co-Infections of the Respiratory Tract 
 
 
Mammalian Respiratory Co-Infections 
 Concurrent infection with viral and bacterial pathogens in the respiratory tract are 
a common phenomenon among humans and other mammals. These co-infections, also 
referred to as superinfections, thrive in a compromised host and often lead to drastic 
increases in disease severity and mortality. The underlying mechanisms of these co-
pathogen relationships include dysfunction of the lung and airway physiology, changes 
in viral tropism, increased availability of receptors for pathogen attachment, 
immunomodulation of the host, and increases in inflammatory signaling [331].  
 As mentioned earlier in this dissertation, Mycoplasmas infect a wide variety of 
mammalian hosts and these infections can be compounded by viral co-infection. 
Mycoplasma hyorhinis has been documented as a co-pathogen of porcine reproductive 
and respiratory syndrome virus (PRRSV) in pigs, both contributing to more severe lung 
lesions and the development of the porcine respiratory disease complex (PRDC) [332].  
A similar dynamic exists between PRRSV and Mycoplasma hyopneumoniae 
within the PRDC. Pigs co-infected with M. hyopneumoniae and PRRSV are protected 
from exacerbation of disease from co-infection when given a vaccine against M. 
hyopneumoniae [333,334,335]. M. hyopneumoniae and PRRSV are also co-pathogens 
of porcine cirovirus type 2 (PCV2), the causative agent of postweaning multisystemic 
wasting syndrome in pigs [336]. Co-infection with M. hyopneumoniae and PCV2 
enhances viral replication in vitro [337].  
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 In humans, there have been a number of cases of co-infection with Mycoplasma 
pneumoniae and influenza virus. One such case was an elderly female patient in China 
co-infected with M. pneumoniae and AIV H7N9 [338]. In this patient, M. pneumoniae 
persisted to a more chronic state of 33 days after initial treatment, whereas H7N9 was 
no longer detected after NA inhibitor treatment [338]. Another case related to a young 
adult female patient co-infected with M. pneumoniae and influenza B virus [339]. This 
patient experienced severe fever and respiratory signs for over 1 week after initial 
treatment [339]. A recent survey of 445 patients suffering from acute febrile respiratory 
syndrome in China demonstrated that co-infections with influenza virus and M. 
pneumoniae were among the most commonly detected in this population [340].  In 
these cases of influenza and M. pneumoniae co-infection, very little is understood about 
the precise mechanistic relationship between the two pathogens. 
 Influenza co-infections are among the most commonly studied in the respiratory 
tract among many hosts. For instance, canine influenza and Staphylococcus 
pseudointermedus co-infection often causes severe respiratory disease in canines 
[341]. A mouse model of this co-infection showed increases in both bacterial and viral 
load in co-infected animals over their mono-infected counterparts [341]. Co-infected 
mice also exhibited more severe histologic lesions in the brain, spleen, and lung as well 
as increased expression of IFN-γ, IL-6, TNF-α, and lymphotactin [341]. 
 Another frequent co-pathogen of influenza is Klebsiella oxytoca, often associated 
with opportunistic infection of hospitalized patients during the influenza season [342]. In 
a mouse model, co-infection with these pathogens significantly increased weight loss, 
pulmonary inflammation, and mortality [342]. The pulmonary inflammatory response to 
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this co-infection was characterized by macrophage skewing to an inflammatory 
phenotype, however this robust response did not effectively reduce the pathogen load in 
co-infected mice [343].  
Mice co-infected with influenza and methicillin-resistant Staphylococcus aureus 
(MRSA) rely on an effective pro-inflammatory response to clear infection. Influenza 
infection alone induces a strong type I interferon response which represses TH17 
activation, and this signaling is controlled by the transcription factor STAT1. Mice 
lacking STAT1 are significantly more susceptible to airway inflammation following 
infection with influenza or MRSA but are protected against co-infection via reduced 
MRSA colonization and mortality [343]. In mice lacking STAT2, another transcription 
factor of type I interferons, a similar phenomenon exists during influenza and MRSA co-
infection as well as increased accumulation of M1 and M2 macrophages [344].  
 Perhaps the most widely studied co-pathogen relationship is between influenza 
virus and Strepcococcus pneumoniae. These two pathogens each have an active 
neuraminidase, and these viral and bacterial neuraminidases work synergistically during 
infection [345]. When the neuraminidase inhibitor oseltamivir is used to disrupt viral 
neuraminidase activity, the survival of co-infected animals significantly increases [345]. 
During co-infection, influenza neuraminidase cleaves sialic acid moieties on the surface 
of host lung cells to expose S. pneumoniae receptors, and this enhanced colonization is 
the underlying basis for the development of secondary bacterial pneumonia [345]. The 
S. pneumoniae neuraminidase gene, nanA, enhances bacterial biofilm formation during 
co-infection with influenza virus [346].  
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Host sialic acids are the primary host-derived metabolite used by S. pneumoniae 
for growth and persistence in the host [347]. Infection with influenza increases the 
availability of these sialic acids via sialylated mucins and the desialylation of host 
glycoproteins [347]. S. pneumoniae mutants lacking the genes for sialic acid 
metabolism do not exhibit enhanced growth during co-infection with influenza virus 
compared to wild-type S. pneumoniae [347]. A sialidase, or neuraminidase, fusion 
protein can be utilized as a broad-spectrum influenza therapeutic with significant 
reduction in the development of secondary S. pneumoniae infection in mice co-infected 
with influenza [348]. Perhaps most notably, S. pneumoniae neuraminidase activity is 
able to rescue influenza replication in the presence of the viral neuraminidase inhibitors 
zanamivir and DANA in vitro [349].  
 Co-infection with S. pneumoniae and influenza also induces increased activation 
of TLR2, MyD88 and the NLRP3 inflammasome in mice [350]. Other key immune gene 
modulation includes the upregulation of TGF-β, fibronectin, and integrins during 
influenza infection of human epithelial cells which enhances S. pneumoniae attachment 
to host cells [351]. TLR4 signaling is also key in the development of respiratory 
pathology in rats infected with influenza [352]. Mice co-infected with influenza and S. 
pneumoniae exhibited more severe lung pathology and mortality over mono-infected 
mice, however this enhanced pathology was reversed when mice were treated with a 
TLR4 agonist between influenza and S. pneumoniae infections [352]. Treatment with 
this TLR4 agonist also reversed the suppression of IFN-β, CXCL1, and CXCL2 by 
influenza infection, allowing for proper neutrophil activation and pathogen clearance 
[352]. Another key inflammatory molecule is IL-17A, which reduces S. pneumoniae 
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colonization in mice but enhances respiratory inflammation when these mice are co-
infected with influenza virus [353].  
 
 
Avian Respiratory Co-Infections 
 Viral and bacterial co-infections of the respiratory tract are also of great 
relevance to avian species, and in light of the impact of AIV on avian populations these 
co-infections are even more worthy of understanding. LPAIV H9N2 enhances 
respiratory distress in birds co-infected with the foodborne pathogen Bacillus cereus 
[354]. H9N2 also induces move severe airsacculitus in SPF birds co-infected with 
bacterial pathogens such as Chlamydia psittaci, Ornithobacterium rhinotracheale, and 
the fungal pathogen Aspergillus fumigatus which are all pathogens found in the Chinese 
poultry industry [355].  
 Another prominent co-pathogen of influenza in avian species is Eschericia coli. 
Turkeys co-infected with LPAIV H6N1 and E. coli exhibit enhanced disease severity in 
terms of respiratory lesion development and mortality [356]. Similar impacts on 
pathogenesis are seen in chickens co-infected with LPAIV H3N8 and E. coli or LPAIV 
H9N2 and E. coli [357,358]. The order and timing of this co-infection impacts measures 
of disease severity differently, however all combinations exacerbate disease over mono-
infected chickens [359]. Chickens infected first with LPAIV H9N2 followed by E. coli 
yielded increased lung lesions up to 3 days post-infection compared to mono-infection, 
with phagocytic infiltrates of the respiratory tract increasing with E. coli load [360]. Avian 
macrophages infected with LPAIV H9N2 followed by a stimulation with E. coli 
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lipopolysaccharide increased the expression of IL-6, IL-1β, CXCL1, CXCL2, TLR4, and 
MDA5 compared to macrophages infected with H9N2 alone [361].  
 Other relevant LPAIV co-pathogens include Staphylococcus aureus, 
Haemophilus paragallinarum, and Ornithobacterium rhinotracheale, all of which 
increase disease severity in chickens over mono-infected animals [362,363]. In wild 
birds, AIV infection is commonly associated with pathogens such as Mycobacterium, 
Salmonella, and Mycoplasma [364,365]. Vaccination of commercial layer hens with M. 
synoviae leads to an increased replication of LPAIV H9N2 [366]. Mycoplasmas, such as 
M. synoviae and M. gallisepticum, are also associated with co-infection with infectious 
bronchitis virus (IBV) and avian metapneumovirus in poultry flocks [367]. Vaccination of 
chickens with M. gallisepticum ts-11 and 6/85 also imparts some non-specific protection 
against IBV infection, and this vaccination significantly decreased ciliary damage during 
co-infection [368].  
 
 
Co-Infection with M. gallisepticum and Low Pathogenic Avian Influenza Virus 
 Within the category of avian viral and bacterial co-infections, the synergistic 
pathogenesis of Mycoplasma gallisepticum and low pathogenic avian influenza virus 
(LPAIV) is the focus of this dissertation. In the literature, it has been established that 
infection with both M. gallisepticum and LPAIV exacerbates disease both in vitro and in 
vivo.  
 Stipkovits et al. demonstrated this co-infection relationship in vivo in two separate 
publications using M. gallisepticum strain 1226 and LPAIV H3N8 
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(A/mallard/Hungary/19616/07) [367,368]. Both publications used an aerosol challenge 
method to inoculate chickens with either M. gallisepticum 1226, LPAIV H3N8, or M. 
gallisepticum followed by H3N8 7 days later [369,370]. After 8 days of observation 
following the secondary infection, chickens were sacrificed in both published studies 
[369,370].  
In one publication, Stipkovits et al. observed that clinical signs, such as 
respiratory rales and difficulty breathing, were more severe in co-infected chickens than 
mono-infected chickens [369]. These co-infected chickens also exhibited a reduction in 
weight gain compared to mono-infected chickens over the course of the experiment 
[369]. Finally, isolation of M. gallisepticum 1226 was enhanced in sampling from co-
infected chickens in the respiratory and inner organs over M. gallisepticum mono-
infected chickens in this experiment [369]. 
In a similar publication, Stipkotivs et al. instead focused more on the pathologic 
lesions induced by co-infection with M. gallisepticum and H3N8. Chickens co-infected 
with these pathogens exhibited more severe gross pathologic lesions, such as 
airsacculitis and peritonitis, when compared to chickens infected with either pathogen 
alone [370]. Macroscopic lesions in the trachea, left and right thoracic air sacs, and 
peritoneum were also enhanced in co-infected chickens over mono-infected chickens in 
these experiments [370]. These data corresponded to more severe clinical scoring of 
histopathologic lesions of tracheitis, bronchitis, and interstitial pneumonia in the co-
infected chickens of this publication [370]. This pathology was characterized by 
increased tracheal and bronchial mucosal thickness as well as lymphocytic and 
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histiocytic infiltration accompanied by degeneration and metaplasia of the respiratory 
epithelium [370].  
To examine the co-pathogenesis relationship in vitro, Sid et al. utilized both 
chicken and turkey tracheal organ cultures (TOCs) to model co-infection with M. 
gallisepticum and LPAIV H9N2 (A/chicken/Saudi Arabia/CP7/1998) [371]. These TOCs 
were first infected with M. gallisepticum followed by H9N2 either 24 or 72 hours after the 
primary infection [371]. After 48 or 96 hours following the primary infection, data were 
collected from all groupings of TOCs [371]. Isolation of M. gallisepticum was increased 
in co-infected chicken and turkey TOCs, and H9N2 isolation was differentially affected 
by co-infection across time points [371]. TOCs co-infected with both pathogens also 
exhibited a larger proportion of apoptotic cells per tracheal ring compared to mono-
infected TOCs [371]. In turkey TOCs, IFN-α and IFN-β expression measured by qRT-
PCR were increased over mono-infected TOCs [371]. IFN-γ expression, however, was 
suppressed in co-infected chicken TOCs when compared to mono-infection with H9N2 
[371]. Most notably, co-infection with both pathogens significantly increased the degree 
of ciliostasis in both chicken and turkey TOCs when compared to mono-infected TOCs 
[371].  
These scientific works illustrate potential contributing factors to M. gallisepticum 
and LPAIV co-pathogenesis. However, there are still openings in our understanding of 
the precise nature of the relationship between these pathogens and what mechanisms 
underly their co-pathogenesis in the natural, avian host. Both M. gallisepticum and 
LPAIV are of great relevance to the agricultural industry and merit further elucidation of 
their synergistic infection to treat or prevent this phenomenon from occurring. On a 
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larger scale, the mechanisms of this particular co-pathogen dynamic may further inform 
other co-infection scenarios in humans or other animals. The experimental hypothesis 
and specific aims to address these openings in knowledge will be discussed in the 
following chapters of this dissertation. 
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Section 4 – Hypothesis and Specific Aims 
Hypothesis 
 The synergistic pathogenesis of Mycoplasma gallisepticum and low-pathogenic 
avian influenza virus (LPAIV) is contingent upon the shared bacterial sialidase and viral 
neuraminidase activity. Co-infection of chickens with virulent or attenuated M. 
gallisepticum and LPAIV will induce differential pathological and transcriptional 
responses in the host at early time points compared to mono-infection. This co-infection 
will allow for the chronic persistence of attenuated M. gallisepticum mutants in vivo. 
 
Specific Aims 
Aim 1: Characterize the significance of sialic acids in M. gallisepticum adherence to 
host cells and effect of the viral neuraminidase inhibitor oseltamivir on M. gallisepticum 
neuraminidase activity. 
Sub-aim 1A: Determine the role of sialic acid moieties in the cytadherance of M. 
gallisepticum to host cells. 
Sub-aim 1B: Investigate the efficacy of oseltamivir on M. gallisepticum growth 
and neuraminidase activity and LPAIV H3N8 neuraminidase activity. 
 
Aim 2: Evaluate the co-pathogenesis of M. gallisepticum and LPAIV in vivo within the 
natural chicken host.  
Sub-aim 2A: Observe potential gross and histopathological differences in co-
pathogenesis determined by the order of infection with each co-pathogen as well 
as a neuraminidase-negative M. gallisepticum mutant. 
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Sub-aim 2B: Utilize RNA-sequencing to characterize the chicken transcriptomic 
response to mono- and co-infection with M. gallisepticum and LPAIV. 
Sub-aim 2C: Observe differences in the chronic persistence in vivo of attenuated 
M. gallisepticum mutants in a co-infection with LPAIV. 
 
Aim 3: Evaluate the potential compensatory relationship between M. gallisepticum 
neuraminidase and LPAIV neuraminidase in vivo in the presence of the viral 
neuraminidase inhibitor oseltamivir.   
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Chapter 2 - The significance of sialic acids in Mycoplasma gallisepticum 
adherence to host cells and effect of the viral neuraminidase inhibitor oseltamivir 
on M. gallisepticum enzymatic activity. 
 
Methods  
 
-3H-Labeled Mycoplasma Binding Assay: To investigate the importance of sialic acid 
moieties on M. gallisepticum binding to eukaryotic cells, M. gallisepticum Rlow were 
grown in complete Hayflick’s medium with 10 µCi/mL of 3H-methyl thymidine (Perkin 
Elmer) at 37°C to mid-log phase. MRC-5 human lung fibroblasts and Madin-Darby 
Canine Kidney (MDCK) cell monolayers were cultivated in complete Eagle’s Minimal 
Essential Medium (MEM) and seeded in 24-well tissue culture plates at a density of 1 x 
105 cells per well in triplicate. These cell lines are appropriate for use because MRC-5 
cells effectively bind M. gallisepticum in vitro and MDCK cells are the conventional host 
cell for influenza A virus growth [1,2,3].  
Wells of each cell type were pre-treated with Type VI neuraminidase (Sigma-
Aldrich) for 30 minutes at 37°C in 5% CO2 and washed. 3H-labeled M. gallisepticum Rlow 
cells was then washed and used to inoculate MRC-5 and MDCK monolayers and 
incubated for 1 hour at 37°C in 5% CO2 and washed again at the end of the incubation. 
Bound M. gallisepticum and eukaryotic cells were then be lysed with 0.05 M NaOH and 
collected for reading in duplicate for counts per minute on the Beckman LS 3801 
scintillation counter. A Student’s T-Test was used to determine statistically significant 
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differences between neuraminidase treated and untreated control eukaryotic cell 
monolayers in their ability to bind M. gallisepticum at a significant level of p < 0.05. 
 
-Mycoplasma Growth Inhibition Assay: To evaluate any effect of oseltamivir on the 
growth of Mycoplasma gallisepticum in vitro, cultures of M. gallisepticum Rlow were 
grown to mid-log phase in Hayflick’s medium and resuspended to a concentration of 1 x 
108 CFU/mL in fresh Hayflick’s medium. Oseltamivir carboxylate (Cayman Chemical) 
was dissolved in PBS, sterile-filtered and added to M. gallisepticum Rlow at 
concentrations of 0.1 µM, 1 µM, 10 µM, 100 µM and 1 mM. Tetracycline was then 
added to M. gallisepticum Rlow at concentrations of 5 mg/L and 10 mg/L in Hayflick’s 
medium as a control for antibiotic growth inhibition, as well as untreated M. 
gallisepticum Rlow included as a positive growth control. All cultures were incubated 
overnight at 37°C and growth was observed by color change in the medium compared 
to un-inoculated control medium. 
 
-Mycoplasma Neuraminidase Inhibition Assay: In order to determine the potential 
effect of oseltamivir on M. gallisepticum neuraminidase activity in vitro, cultures of 
Mycoplasma gallisepticum Rlow and Tn4001mod insertional mutant P1C5 were grown to 
mid-log phase in Hayflick’s complete medium [4]. This mutant has been documented to 
be negative for neuraminidase activity and is attenuated in vivo [4]. The mutant P1C5 
was grown in this medium supplemented with 200µg/mL of gentamicin for Tn4001mod 
transposon insertion maintenance. In addition, Mycoplasma sturnii UCMF was 
cultivated in Hayflick’s complete medium for use as a neuraminidase negative 
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Mycoplasma in these assays [5]. Bacterial cells were then pelleted, washed, and 
resuspended in 1x PBS at 1 x 108 CFU/mL with concentrations of oseltamivir 
carboxylate (Cayman Chemical) at 0.1 µM, 10 µM, 100 µM and 1 mM with untreated 
suspensions of each culture included as a negative control and incubated for 30 
minutes at 37°C. Each of these treatments were done in triplicate and seeded in a 
black-walled 96-well plate.  
After incubation, Mycoplasma cells were then incubated with a buffer of sodium 
acetate and the fluorogenic substrate 20-(4-methy-lumbelliferyl)-a-D-N-acetylneuraminic 
acid (MUAN) (Sigma-Aldrich) and read on a fluorescent microplate reader at 360 nm 
excitation and 460 nm emission [6]. Fluorescence values were normalized by protein 
content and background fluorescence seen in neuraminidase-negative Mycoplasma M. 
sturnii UCMF. In order to determine statistically significant differences in neuraminidase 
activity among treatments, a one-way ANOVA with a Tukey’s post-hoc test was utilized 
at a significance threshold of p < 0.05. 
 
-Viral Neuraminidase Inhibition Assay: Analysis of the neuraminidase inhibitor, 
oseltamivir, and its ability to inhibit H3N8 (A/duck/Ukraine/1963) was performed in vitro 
with adaptations from the methods described by Eichelberger et al. [7]. The active 
metabolite form of oseltamivir, oseltamivir carboxylate (Cayman Chemical) was 
incubated on washed MDCK cells mono-layers seeded in a 96-well plate at 
concentrations ranging from 0 to 1000 nanomoles. These cell monolayers were then 
infected with H3N8 (A/duck/Ukraine/1963) at an MOI of 0.075 and 0.02 and incubated 
overnight at 37°C and 5% CO2. After incubation, 25 µl of the supernatant was collected 
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from each well and incubated with the fluorogenic substrate MUAN (Sigma-Aldrich) in a 
black-walled 96-well plate for 1 hour at 37°C. After the addition of a stop solution of 0.1 
M glycine and 25% ethanol, the plate was read at 355 nm excitation and 460 nm 
emission on a fluorescent microplate reader. Statistically significant differences between 
neuraminidase activity levels were calculated using a mixed effects one-way ANOVA 
with Tukey’s post-hoc test and a significance threshold of p < 0.05. 
 
Results 
 
In the case of both MRC-5 and MDCK cell monolayers, type VI neuraminidase 
pre-treatment significantly decreased 3H-labeled M. gallisepticum Rlow binding (p < 0.01 
and p < 0.0001 respectively) (Figures 1A and 1B). This particular type VI neuraminidase 
is derived from C. perfringens and preferentially cleaves α-2,3 linked sialic acids over α-
2,6 linked sialic acids (Sigma Aldrich). It can be surmised that these α-2,3 linked sialic 
acid moieties on the eukaryotic host cells are important in M. gallisepticum Rlow 
cytadherance. These α-2,3 linked sialic acids are the primary binding target for avian 
influenza A viruses, which has great relevance in the context of an avian influenza virus 
and M. gallisepticum co-infection scenario in an avian system [8]. 
 
Figure 1 – 3H-labeled M. gallisepticum binding to MRC-5 (Figure 1A) and MDCK 
(Figure 1B) monolayers with and without neuraminidase (NA) treatment quantified by 
counts per minute (CPM). Error bars represent SEM. Significant differences calculated 
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using an Unpaired T-test. Statistical significance markers ** indicate p < 0.01 and **** 
indicate p < 0.0001.  
 
 
At all concentrations of oseltamivir carboxylate tested (0.1 µM, 1 µM, 10 µM, 100 
µM and 1 mM), there was no inhibition of M. gallisepticum Rlow growth as indicated by 
Hayflick’s medium color change when compared to M. gallisepticum Rlow grown in the 
absence of any antibiotic treatment (data not shown). This suggests that any effects on 
M. gallisepticum Rlow neuraminidase activity in subsequent experiments using 
oseltamivir can be attributed to effects on the neuraminidase enzyme and not the 
growth kinetics of M. gallisepticum.  
When incubated with oseltamivir carboxylate, there were no significant 
differences between M. gallisepticum Rlow neuraminidase activity among un-treated 
control Rlow and Rlow treated with 0.1 µM, 10 µM, 100 µM and 1 mM oseltamivir 
carboxylate (Figure 2). These concentrations range above and below the concentration 
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of oseltamivir used commonly to inhibit neuraminidase activity of other bacterial 
organisms, such as Streptococcus pneumoniae [9]. This indicates that oseltamivir 
carboxylate does not have an inhibitory effect on the neuraminidase activity of M. 
gallisepticum Rlow. In a co-infection environment with influenza A virus, oseltamivir 
inhibition would likely act solely on the influenza virions and open the possibility for M. 
gallisepticum neuraminidase activity to compensate or augment the neuraminidase 
activity of influenza. Such a mechanism could contribute to the exacerbated 
pathogenesis seen in models of M. gallisepticum and LPAIV co-infection. 
 
Figure 2 – M. gallisepticum neuraminidase activity with and without treatment with 
oseltamivir carboxylate (OC). No significant differences found using One-Way ANOVA 
and Tukey’s Post-Hoc test.  
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 In contrast to the data in Figure 2 pertaining to M. gallisepticum neuraminidase 
activity, oseltamivir carboxylate does effectively inhibit H3N8 neuraminidase activity 
(Figure 3). At an MOI of 0.02, H3N8 neuraminidase activity was significantly different 
between the highest dose, 1000 nM, and 0.01 nM, 0.1 nM, and 1.0 nM oseltamivir 
carboxylate treatment (Figure 3). This effect was even more pronounced at an MOI of 
0.075, in that H3N8 neuraminidase activity was significantly different between the 
highest dose of 1000 nM and 0 nM, 0.001 nM, 0.1 nM, 1.0 nM, 10 nM, and 100 nM 
(Figure 3). These concentrations represent a spectrum of relevant neuraminidase 
inhibitor concentrations used in neuraminidase inhibition in vitro assays [7]. 
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Figure 3 -  LPAIV H3N8 neuraminidase activity when incubated with oseltamivir 
carboxylate (0 to 1000 nanomolar). MDCK cells were infected with H3N8 at two MOI 
(0.075 and 0.02), as well as MDCK monolayers infected with no virus as a negative 
control. Significant differences in neuraminidase activity calculated using mixed-effects 
one-way ANOVA and Tukey’s post-hoc test. Statistically significant differences are 
notated as * = p < 0.05 and ** = p < 0.005. The statistical markers on the upper-most 
portion of the figure pertain to cells infected at an MOI of 0.075, and the markers on the 
bottom portion of the figure relate to cells infected at an MOI of 0.02.  
 
 
 
 
 
0 n
M
0.0
01
nM
0.0
1 n
M
0.1
nM
1.0
nM
10
nM
10
0 n
M
10
00
nM
0
10000
20000
30000
40000
H3N8 Neuraminidase Inhibition
Oseltamivir  Carboxylate (nanomolar)
U
ni
ts
of
Fl
uo
re
se
nc
e 0.02 MOI
0.075 MOI
Negative Control
0 n
M
0.0
01
nM
0.0
1 n
M
0.1
nM
1.0
nM
10
nM
10
0 n
M
10
00
nM
0
10000
20000
30000
40000
H3N8 Neuraminidase Inhibition
Oseltamivir  Carboxylate (nanomolar)
Un
its
of
Fl
uo
re
se
nc
e 0.02 MOI
0.075 MOI
Negative Control
0 n
M
0.0
01
nM
0.0
1 n
M
0.1
nM
1.0
nM
10
nM
10
0 n
M
10
00
nM
0
10000
20000
30000
40000
H3N8 Neuraminidase Inhibition
Oseltamivir  Carboxylate (nanomolar)
U
ni
ts
of
Fl
uo
re
se
nc
e 0.02 MOI
0.075 MOI
Negative Control
0 n
M
0.0
01
nM
0.0
1 n
M
0.1
nM
1.0
nM
10
nM
10
0 n
M
10
00
nM
0
10000
20000
30000
40000
H3N8 Neuraminidase Inhibition
Oseltamivir  Carboxylate (nanomolar)
Un
its
of
Fl
uo
re
se
nc
e 0.02 MOI
0.075 MOI
Negative Control
***
**
*
*
* * *
*
 123 
Discussion 
 
 The data presented above elude to possible factors contributing to the co-
pathogenesis of LPAIV and M. gallisepticum in terms of host cell tropism and possible 
compensatory neuraminidase activity. The significant disruption in cytadherance to host 
cells by M. gallisepticum in the absence of α-2,3 linked sialic acids is a novel finding. In 
the context of a co-infection with LPAIV, this result holds even more significance in that 
LPAIVs preferentially bind host tissues at α-2,3 linked sialic acid moieties common in 
the avian respiratory and gastrointestinal tract [10].  
A common host cell ligand could indicate potential competition between M. 
gallisepticum and LPAIV for proximity to the host cell. However, the data from in vitro 
and in vivo studies examining these co-pathogens indicates that there is more benefit to 
replication and persistence when these two pathogens are present over a hampering of 
one’s survival in favor of the other [11,12,13].  
The shared importance of α-2,3 linked sialic acids in these co-pathogens 
interaction with the host more likely indicates that these two pathogens may bind in 
close proximity to one another on host tissues. This proximity facilitates an array of 
potential mechanisms of mutual benefit during co-pathogenesis. These mechanisms 
could include host metabolites, the availability of host cell receptors, or the shared 
activity of enzymes such as the viral and bacterial neuraminidases.  
As seen in other viral and bacterial co-pathogen relationships, neuraminidase 
activity can be pivotal in the mutualistic dynamic during the disease process. For 
instance, Streptococcus pneumoniae has potent neuraminidase activity that can rescue 
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influenza viral replication in the presence of viral neuraminidase inhibitors [14]. The 
ability of M. gallisepticum and LPAIV to attach to host cells in potentially close-quarters 
would allow for this same dynamic of neuraminidase activity compensation during 
infection.  
This hypothesis garners further merit in that M. gallisepticum Rlow is not 
susceptible to oseltamivir carboxylate neuraminidase inhibition, whereas LPAIV H3N8 
neuraminidase is susceptible to this inhibitor at a range of concentrations. In a case of 
this co-infection in an avian population, neuraminidase inhibitor treatment could be 
rendered useless if M. gallisepticum neuraminidase can effectively compensate for 
LPAIV and further the progression of disease.  
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Chapter 3 – Transcriptional and pathological host responses to co-infection with 
virulent or attenuated Mycoplasma gallisepticum and low pathogenic avian 
influenza A virus in chickens. 
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Abstract 
 The avian pathogen Mycoplasma gallisepticum, the etiologic agent of chronic 
respiratory disease in chickens, exhibits enhanced pathogenesis in the presence of a 
co-pathogen such as low-pathogenic avian influenza virus (LPAIV). To further 
investigate the intricacies of this co-pathogenesis, chickens were mono- or co-infected 
with either virulent M. gallisepticum strain Rlow, attenuated M. gallisepticum mutant 
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P1C5, or LPAIV H3N8 (A/duck/Ukraine/1963) and assessed for tracheal histopathology, 
pathogen load, and transcriptomic host response to infection using RNA-sequencing. 
Chickens co-infected with M. gallisepticum Rlow followed by H3N8 exhibited significantly 
more severe tracheal lesions and mucosal thickening in response to infection than 
chickens infected with H3N8 alone. Viral load was also significantly increased in this 
group over chickens who were infected first with H3N8 and subsequently with M. 
gallisepticum Rlow. The attenuated M. gallisepticum mutant P1C5, previously shown to 
be cleared 14 days post-infection, was able to persist 6 days post-infection in the 
presence and absence of co-infection with H3N8. The transcriptional response to mono- 
and co-infection with M. gallisepticum and LPAIV highlighted the involvement of 
differential expression of genes such as TLR4, TLR15, TLR21, IL-1β, IRF4, MMP1, and 
MMP9. Pathway and gene ontology analysis of these differentially expressed genes 
suggests that co-infection with virulent M. gallisepticum and LPAIV induces a 
downregulation of ciliary activity in vivo and alters the multiple immune-related signaling 
cascades. These data aid in the understanding of the relationship between M. 
gallisepticum and LPAIV during co-pathogenesis in the natural host and may contribute 
to the further understanding of co-pathogen infections of humans and other animals. 
 
 
Introduction 
The bacterial pathogen Mycoplasma gallisepticum causes significant avian 
diseases such as sinusitis in turkeys, conjunctivitis in passerines, and chronic 
respiratory disease in chickens [1,2]. Pathogenesis of M. gallisepticum in chickens 
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involves severe inflammation in components of the respiratory system, as well as 
deleterious effects on egg production in these birds, making M. gallisepticum a 
pathogen of great relevance and concern to the agricultural industry [1]. Infection of 
chickens with virulent M. gallisepticum Rlow has been shown to induce a dysregulated 
immune response in the chicken host with differential gene expression in the trachea 
peaking 3 days post-infection over the first 7 days [3]. Toll-like receptor (TLR) 
responses, most notably TLR4 and TLR15, were significantly upregulated in the trachea 
during infection, as were IL-1β, MMP7, and an array of inflammatory cytokines and 
chemokines [3]. An additional report demonstrated that the lipoproteins of M. 
gallisepticum stimulate a TLR2-mediated response in primary chicken tracheal epithelial 
cells [4]. 
 Another avian pathogen of great importance is avian influenza A virus. Avian 
influenza viruses occur in two main categories; highly-pathogenic avian influenza 
viruses (HPAIV) and low-pathogenic avian influenza viruses (LPAIV) [5]. HPAIV causes 
severe disease in a multitude of avian species with an extremely high mortality rate [6]. 
In contrast, LPAIV causes little-to-no disease in birds and, without rigorous surveillance, 
could go unnoticed in wild or domestic populations of birds [6].  
 Co-infections consisting of M. gallisepticum and LPAIV in chickens exacerbates 
disease compared to either pathogen in isolation]. Chickens challenged with both M. 
gallisepticum strain 1226 and LPAIV H3N8 (A/mallard/Hungary/19616/07) showed 
significantly more severe clinical signs and increased recovery of M. gallisepticum [7]. 
Co-infection with these two pathogens also yields significantly more severe clinical 
scores of gross and histopathologic lesions of infected chickens [8]. Ex vivo 
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experiments with M. gallisepticum strain S6 and H9N2 (A/chicken/Saudi 
Arabia/CP7/1998) in an avian tracheal organ culture system showed significant 
differences in replication of M. gallisepticum and H9N2 between mono- and co-infected 
tracheas [9]. Ciliostasis was also observed in these co-infected tracheal cultures at a 
significantly higher rate and severity over mono-infected tracheas as well [9].  
 A possible mechanism underlying this co-pathogenesis phenomenon is the 
common functionality of the glycosidic enzymes neuraminidase of influenza A virus, and 
sialidase of M. gallisepticum. Influenza A virus utilizes neuraminidase to cleave N-
acetylneuraminic acids, or sialic acids, on host cells to release progeny virions during 
infection. In M. gallisepticum, sialidase performs this same enzymatic reaction and 
transposon insertional disruption of this gene in virulent M. gallisepticum Rlow results in 
attenuation of the pathogen in vivo [10,11]. The true role of sialidase in the life cycle and 
pathogenesis of M. gallisepticum is still yet to be elucidated. For the remainder of this 
manuscript, both influenza A virus neuraminidase and Mycoplasma sialidase will be 
referred to as neuraminidases for the sake of continuity. 
Instances of influenza A virus co-infection with bacterial pathogens in humans, 
such as Streptococcus pneumoniae, yield evidence that the neuraminidases of 
influenza virus and S. pneumoniae work in concert during infection to enhance disease 
[12,13].  In the presence of a viral neuraminidase inhibitor zanamivir, S. pneumoniae 
neuraminidase can compensate for the hampered neuraminidase activity of influenza 
virus to enhance viral replication and further co-pathogenesis in mice [14].  
In the case of M. gallisepticum and LPAIV co-infection, there is strong evidence 
that the presence of both pathogens enhances various markers of disease over 
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infection with either pathogen alone. However, the host-pathogen dynamics involved in 
this co-pathogenesis relationship remain unexplored. It is our hypothesis that M. 
gallisepticum neuraminidase works to support LPAIV neuraminidase during co-infection. 
We also hypothesize that co-infection of chickens with Mycoplasma gallisepticum and 
LPAIV H3N8 results in more severe disease than mono-infection, and that this 
difference in pathogenesis will yield changes in pathologic lesions, pathogen load, and 
transcriptional changes in the host. To examine this, we utilized an in vivo infection 
model in chickens, a natural host of both M. gallisepticum and LPAIV. In addition, we 
hypothesize that co-infection with LPAIV H3N8 would cultivate an environment to 
sustain the chronic persistence of an attenuated M. gallisepticum mutant in vivo.  
The co-pathogenesis of M. gallisepticum and LPAIV is of great relevance to the 
agricultural industry for the prevention and treatment of viral and bacterial infections in 
avian flocks [11]. Either pathogen alone may go un-detected in a population of birds for 
a sufficient period of time to set the stage for severe losses due to later infection with 
the other pathogen. The dynamics involved in this system of co-infection may also 
prove beneficial in understanding the factors contributing to instances of viral and 
bacterial co-pathogenesis in other animals and humans. 
 
Methods 
-Animals: For each study, four-week old female specific pathogen-free (SPF) White 
Leghorn chickens (SPAFAS, North Franklin, CT, USA) were procured and separated 
randomly into experimental groups for placement in HEPA-filtered housing isolators. 
These chickens then acclimated in this habitat for a period of one week before the start 
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of the experiment. For this acclimation period, as well as the remainder of the 
experiment, the chickens were maintained on non-medicated feed and water ad libitum. 
These animal experiments were performed with approval from the University of 
Connecticut Institutional Animal Care and Use Committee under protocol #A18-057. 
 
-Mycoplasma gallisepticum and LPAIV Preparation: Influenza A virus isolate H3N8 
(A/duck/Ukraine/1963) (BEI Resources) was used to inoculate 10-day old SPF 
embryonated chicken eggs (SPAFAS, North Franklin, CT, USA) at 10-fold dilutions of 
viral stock [15,16]. After 48 hours, allantoic fluid was collected from these eggs and viral 
titer was determined by TCID50 on Madin Darby Canine Kidney (MDCK) cells using the 
Reed-Meunch method [15,16]. Viral stocks were frozen at -80° C and diluted in 
complete Hayflick’s medium to a concentration of 5 x 106 TCID50/200 µL at the time of 
use as an experimental inoculum. 
Mycoplasma gallisepticum strain Rlow passage 17 was propagated from stock 
cultures frozen at -80°C in complete Hayflick’s medium overnight at 37°C until mid-log 
phase. The attenuated M. gallisepticum tn4001 mutants P1C5 and P1H9 were also 
grown from frozen stock cultures in complete Hayflick’s medium with the addition of 150 
µg/mL for the maintain the position of tn4001 transposon insertion [11,17]. Mycoplasma 
cultures were quantified by optical density at 620 nm and then centrifuged for 10 
minutes at 10,000 x g to pellet the cultures. Mycoplasma pellets were then resuspended 
in fresh complete Hayflick’s medium to a density of 1 x 108 CFU/200 µL to create the 
experimental inoculum for each of the chicken infection experiments. 
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-Chicken Infection Experiments: 5 week old chickens were challenged intratracheally 
by pipetting 200 µL of either 1 x 108 CFU M. gallisepticum Rlow, 1 x 108 CFU M. 
gallisepticum mutant P1C5, 5 x 106 TCID50 LPAIV H3N8, or mock-challenged with fresh 
complete Hayflick’s medium according to the following schedule (n = 5 per group): 
Experiment #1 
Primary Infection (Day 0) Secondary Infection (Day 3) 
Sacrifice (Day 6) 
Mock (Hayflick’s medium) M. gallisepticum Rlow  
H3N8 M. gallisepticum Rlow 
M. gallisepticum Rlow H3N8 
M. gallisepticum P1C5 H3N8 
Mock (Hayflick’s medium) H3N8 
 
In two companion challenge studies, additional set of chickens (n = 5 per group in 
experiment #2, n = 10 in experiment #3) were challenged as described above in the 
following groups: 
Experiment #2 
Primary Infection (Day 0) 
Sacrifice (Day 6) M. gallisepticum Rlow M. gallisepticum P1C5 
Mock (Hayflick’s medium) 
 
Experiment #3 
Primary Infection 
(Day 0) 
Secondary Infection  
(Day 3) 
 
Sacrifice 
(Day 14) 
M. gallisepticum P1C5 Mock (Hayflick’s medium) 
M. gallisepticum P1C5 H3N8 
M. gallisepticum P1H9 Mock (Hayflick’s medium) Sacrifice (Day 7) 
M. gallisepticum P1H9 H3N8  
 
Another attenuated mutant, mslA mutant P1H9, was incorporated into this model 
of co-infection as a means to compare changes in M. gallisepticum mutant co-infection 
over the course of disease and be able to attribute the possible changes in 
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pathogenesis to the specific relationship between P1C5 and LPAIV neuraminidase 
activity [17]. The mutant P1C5 persists in the trachea of chickens 6 days post-infection, 
however the previous studies utilizing the mutant P1H9 only examined Mycoplasma 
recovery 14 days post-infection [17]. 
 
- Sample Collection, Mycoplasma Recovery and RNA Extraction: In each of the 
above experiments, all chickens from each of the groups were humanely sacrificed by 
cervical dislocation and the tracheas were excised. Three tracheal rings from each 
chicken were taken from the proximal, middle, and distal portion of each trachea and 
fixed in neutral buffered formalin for pathological assessments. An additional ring was 
taken from the distal end of the trachea of each bird and placed into complete Hayflick’s 
medium for mycoplasma recovery and incubated for 3 hours at 37°C. After incubation, 
these cultures were filtered through 0.45 µm filter and diluted 10-fold for color changing 
unit (CCU) quantification, as done previously [18]. Statistically significant differences 
among groups for M. gallisepticum CCU recovery were calculated using using a 
Kruskal-Wallis ANOVA On Ranks with Dunn’s Post-Hoc test (GraphPad Prism 8.0). 
The remaining sections of excised tracheas from each bird were washed with 1 
mL of TriZol (Zymo Research, Carlsbad, CA, USA) pipetted 4 times through the lumen 
for RNA collection as described previously [18]. RNA was extracted from these TriZol 
washes using the Zymo DirectZol RNA MiniPrep Kit (Zymo Research, Carlsbad, CA, 
USA) and quantified using a Qubit 2.0 Fluorometer (ThermoFisher Scientific). 
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-Tracheal Thickness and Lesion Scoring: Tracheal rings were embedded and 
sectioned for hematoxylin and eosin (H&E) staining as described previously [19].  These 
rings were measured for tracheal thickness and lesions were scored by an AAVP board-
certified veterinary pathologist. These lesions were scored on a scale of 0 to 4, denoting 
no inflammation, mild inflammation, moderate inflammation, marked inflammation, and 
severe inflammation, respectively, as described previously [19]. Significant differences 
among challenge groups for tracheal thickness measurements were calculated using a 
one-way analysis of variance (ANOVA) and Tukey’s Post-Hoc test and differences in 
tracheal lesion scores were calculated using a Kruskal-Wallis ANOVA On Ranks with 
Dunn’s Post-Hoc test (GraphPad Prism 8.0). 
 
-Viral Load Quantification: RNA collected from the tracheas of infected chickens in 
experiment #1 was assayed using qRT-PCR of the influenza matrix gene in a 25 µL 
reaction volume (Applied Biosystems 75000 Fast Real-Time PCR System) by the 
Connecticut Veterinary Medical Diagnostic Laboratory. Cycling conditions for this 
reaction were 45.0°C for 10 minutes, 95.0°C for 10 minutes, 94.0°C for 1 second, cycled 
at this step 45 times before a final step at 60.0°C for 30 seconds. A standard curve of 
H3N8 (A/duck/Ukraine/1963) RNA was used in 10-fold dilutions for calculation of viral 
genomes per microliter. 
 
-Illumina Sequencing: RNA extracted from tracheal washes of each bird from 
experiment #1 were used as templates for cDNA library synthesis using the Illumina 
TruSeq Stranded mRNA Library Preparation Kit (Illumina, San Diego, CA). Each library 
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was quantified and assessed for quality using the Agilent TapeStation 2200 (Agilent 
Technologies). These libraries were then normalized and pooled for sequencing on the 
Illumina NextSeq 500 (Illumina, San Diego, CA) with paired-end, 75 base pair reads 
with 5 to 10 million reads per sample [3]. 
 
-RNA-seq Analysis: Read data from each bird sample in the Fastq format were 
mapped to the Gallus gallus reference genome using the TopHat package and Bowtie2 
engine to produce sequence alignments [20]. Alignment files were pooled by 
experimental infection groups using Cufflinks to map to reference transcript files. Cuffdiff 
was utilized to determine expression values and statistically significant differences of 
these values between experimental infection groups. These expression values per 
transcript are normalized within group via calculation of fragments per kilobase per exon 
per million fragments mapped (FPKM). Benjamini-Hochberg analysis then generates a 
p-value for statistical significance also accounting for a false discovery rate of <5% to 
yield a q-value of significance. Fold change differences between experimental infection 
groups were calculated by a log2 calculation of FPKM values from each group [20]. 
Significantly differentially expressed genes with greater than, or equal to, a positive or 
negative 2 log2 fold change will be displayed for between-group comparisons. 
 
-Pathway and Functional Gene Ontology Analysis: Significantly differentially 
expressed genes (DEGs) were used as an input for analysis using the Database for 
Annotation, Visualization and Integrated Discovery (DAVID) version 6.8 to assemble 
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these DEGs into biological pathways defined by the Kyoto Encyclopedia of Genes and 
Genomes (KEGG) and functional gene ontologies using GO Term BP Direct [21]. 
 
Results 
-Tracheal Thickness and Lesion Scores: Significant differences were found in the 
tracheal mucosal thickness (p < 0.05) between Mock/H3N8 and M. gallisepticum 
Rlow/H3N8 infected chickens in experiment #1 (One-Way ANOVA with Tukey’s Post-Hoc 
test). Significant differences were observed in histopathologic tracheal lesion scores (p 
< 0.05) between Mock/H3N8 and M. gallisepticum Rlow/H3N8 infected chickens of 
experiment #1 (Kruskal-Wallis ANOVA On Ranks with Dunn’s Post-Hoc test) (Figures 
1A and 1B). Although not statistically significant at this timepoint, tracheal thickness (p = 
0.3901) exhibits a trend of increased severity in the H3N8/M. gallisepticum Rlow group 
compared to the Mock/M. gallisepticum Rlow group (Figures 1A and 1B).  
  In experiment #2, significant differences exist between mock infected chickens 
and Rlow infected chickens as well as mock infected and P1C5 infected chickens for 
both tracheal thickness (Figure 1C) and tracheal lesion scores (Figure 1D). These data 
indicate that although no lesions or live M. gallisepticum P1C5 were observed 14 days 
post-infection in previous studies from our laboratory, this mutant appears to persist in 
the chicken host 6 days post-infection and induces a moderate pathologic response in 
the lumen of the trachea [11]. 
 
Figure 1 – Tracheal lesion scores (A) and thickness measurements (B) from M. 
gallisepticum and H3N8 mono- and co-infected chickens. Statistically significant 
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differences among group tracheal lesion scores were calculated using a Kruskal-Wallis 
ANOVA On Ranks with Dunn’s Post-Hoc test. Statistically significant differences among 
group tracheal thickness measurements were calculated using a One-Way ANOVA with 
Tukey’s Post-Hoc test. Significant differences are denoted using “a” and “b” indicating a 
significant difference of p < 0.05. Tracheal histopathology (C and D) from experiment 
#2. Statistically significant differences among tracheal thickness for experimental groups 
were calculated using a One-Way ANOVA with Tukey’s Post-Hoc Test and are 
indicated by ** = p < 0.05, *** = p < 0.0005. For tracheal lesion scores in experiment #2, 
significant differences were calculated using a Kruskal-Wallis ANOVA On Ranks with 
Dunn’s Post-Hoc test and using “a” and “b” indicating a significant difference of  p < 0.01 
and p <0.05. 
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-Mycoplasma and Viral Load M. gallisepticum was recovered from birds in all groups 
that received an M. gallisepticum inoculation in experiment #1 (Figure 2A).  The 
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bacterial loads recovered from H3N8/M. gallisepticum Rlow infected chickens were 
significantly higher than the Mock/M. gallisepticum Rlow group (p < 0.05) (Kruskal-Wallis 
ANOVA On Ranks with Dunn’s Post-Hoc test) (Figure 2A). Although tracheal pathology 
did not differ significantly between the H3N8/M. gallisepticum Rlow group and Mock/M. 
gallisepticum Rlow group (Figure 1A and 1B), M. gallisepticum was recovered from 80% 
of chickens within the H3N8/M. gallisepticum Rlow group (Figure 2A), 20% of chickens in 
the Mock/M. gallisepticum Rlow group and , 100% from chickens in the M. gallisepticum 
Rlow/H3N8 group (Figure 2A).  
In a similar vein, H3N8 was detected in chickens within all groups receiving an 
inoculation with H3N8 in experiment #1, with the exception of chickens in the H3N8/M. 
gallisepticum Rlow infection group (Figure 2B). H3N8 was detected in 80% of chickens in 
the Mock/H3N8 group and the M. gallisepticum Rlow/H3N8 group, both having been 
challenged with H3N8 for the final3 days of the experiment. H3N8 was not detected in 
the H3N8/M. gallisepticum Rlow group after 6 days of H3N8 infection. H3N8 load was 
significantly higher in the M. gallisepticum Rlow/H3N8 group over the H3N8/M. 
gallisepticum Rlow group of experiment #1 (p < 0.01, One-Way ANOVA with Tukey’s 
Post-Hoc test) (Figure 2B).  
In experiment #2, M. gallisepticum was recovered from the tracheae of all M. 
gallisepticum infected birds for both M. gallisepticum Rlow and P1C5 (Figure 2C). This 
bacterial recovery follows a similar pattern to the tracheal histopathology displayed in 
Figure 1, in that M. gallisepticum Rlow was the most abundant in the trachea at 6 days 
post-infection and induced more severe tracheal lesions and thickening than the mutant 
P1C5, which was recovered at a lesser abundance at that time (Figure 2C).  
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Experiment #3 demonstrated that M. gallisepticum was recovered from all M. 
gallisepticum P1H9 infected chickens, with the exception of P1H9/Mock infected birds 
sacrificed at 14 days post-infection (Figure 3). The difference in M. gallisepticum 
recovery between these two groups is statistically significant (p < 0.001) (Kruskal-Wallis 
ANOVA On Ranks with Dunn’s Post-Hoc test). P1H9 was previously shown to fail to 
persist at 14 days post-infection [17], however these data show that this attenuated 
mutant does survive in the chicken trachea at 7 days post-infection in 90% of infected 
chickens. Persistence in the host trachea to 14 days post-infection was partially rescued 
only in the presence of a co-infection with H3N8 in 40% of infected chickens (Figure 
2D).  
 
Figure 2 – Recovery of M. gallisepticum (A) and H3N8 (B) from the tracheas of mono- 
and co-infected chickens of experiment #1. M. gallisepticum recovery (C) from the 
tracheas of infected chickens of experiment #2 and experiment #3 (D). Bacterial 
recovery was quantified using color changing unit (CCU) dilutions. Statistically 
significant differences in M. gallisepticum recovery were determined using a Kruskal-
Wallis ANOVA On Ranks with Dunn’s Post-Hoc test and denoted using “a” and “b” 
indicating a significant difference of p <0.05 (C). Significany differences in H3N8 load 
were calculated using One-Way ANOVA with Tukey’s Post-Hoc test and denoted using 
“a” and “b” indicating a significant difference of p < 0.05 (B). 
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-Significantly Differentially Expressed Gene (DEG) Analysis: CuffDiff differential 
expression analysis between challenge groups of experiment #1 determined that there 
are 260 significant DEGs increased in expression and 286 significant DEGs decreased 
in expression between M. gallisepticum Rlow/H3N8 and Mock/H3N8 infected chickens. 
Lists of DEGs between experimental groups of experiment #1 with a greater than 2 log2 
fold change can be found in Supplemental Tables 10 through 14. 
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-Toll-Like Receptor (TLR) Genes 
Table 1: 
Significantly Differentially Expressed Toll-Like Receptors > 2 Fold Change (FC) 
Experimental Group 
Comparison Ensemble Gene ID Gene Name Log2 FC q Value 
P1C5/H3N8 vs. Rlow/H3N8 ENSGALG00000007001 TLR4 3.020 0.0044 
P1C5/H3N8 vs. Rlow/H3N8 ENSGALG00000008166 TLR15 2.981 0.0044 
Mock/H3N8 vs. Mock/Rlow ENSGALG00000008166 TLR15 -2.028 0.0115 
Mock/H3N8 vs. Rlow/H3N8 ENSGALG00000000774 TLR21 -2.100 0.0184 
Mock/H3N8 vs. P1C5/H3N8 ENSGALG00000000774 TLR21 -2.346 0.0097 
 
 Various TLR genes are significantly differentially expressed between groups of 
infected chickens in experiment #1. TLR4, which recognizes bacterial 
lipopolysaccharide, is significantly upregulated between M. gallisepticum P1C5/H3N8 
and M. gallisepticum Rlow/H3N8 infected chickens (Table 1). This increased expression 
is unusual due to the absence of lipopolysaccharide in Mycoplasmas, however TLR4 
has also been shown to be upregulated in response to M. gallisepticum Rlow infection in 
vivo [3].  
TLR15, an avian and reptile-specific TLR, is shown to be upregulated in 
response to yeast and bacterial pathogen-associated molecular patterns (PAMPS) [25]. 
TLR15 is increased in expression between M. gallisepticum P1C5/H3N8 and M. 
gallisepticum Rlow/H3N8 infected chickens and decreased between Mock/H3N8 and M. 
gallisepticum Rlow/H3N8 infected chickens (Table 1).  
TLR21 is decreased in expression between Mock/H3N8 and M. gallisepticum Rlow/H3N8 
infected chickens as well as Mock/H3N8 and M. gallisepticum P1C5/H3N8 infected 
chickens (Table 1). TLR21 is an avian functional homolog of human TLR9 and 
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recognizes CpG oligodeoxynucleotides [24]. The suppression of these two TLR 
transcripts during mono- or co-infection with M. gallisepticum Rlow compared to mono-
infection with H3N8 suggests potential immune signaling dysregulation induced by M. 
gallisepticum in this model. 
 
Table 2: 
Significantly Differentially Expressed Genes > 2 Fold Change (FC) 
Experimental Group 
Comparison Ensemble Gene ID Gene Name Log2 FC q Value 
P1C5/H3N8 vs. Rlow/H3N8 ENSGALG00000019061 MMP1 3.801 0.0044 
Mock/H3N8 vs. P1C5/H3N8 ENSGALG00000019061 MMP1 -2.809 0.0097 
Mock/H3N8 vs. Mock/Rlow ENSGALG00000019061 MMP1 -2.054 0.0115 
P1C5/H3N8 vs. Rlow/H3N8 ENSGALG00000006992 MMP9 3.704 0.0044 
Mock/H3N8 vs. P1C5/H3N8 ENSGALG00000006992 MMP9 -2.224 0.0097 
P1C5/H3N8 vs. Rlow/H3N8 ENSGALG00000012830 IRF-4 2.154 0.004 
P1C5/H3N8 vs. Rlow/H3N8 ENSGALG00000000534 IL-1BETA 3.508 0.0044 
Mock/H3N8 vs. P1C5/H3N8 ENSGALG00000000534 IL-1BETA -2.262 0.0097 
 
 
Matrix Metalloproteinase (MMP) Genes 
 The expression of MMP genes is differentially affected among comparisons of 
groups in experiment #1. MMP1 and MMP9 are both decreased in expression between 
Mock/H3N8 and M. gallisepticum P1C5/H3N8 infected chickens (Table 2). In addition, 
MMP1 is upregulated between M. gallisepticum P1C5/H3N8 and M. gallisepticum 
Rlow/H3N8 infected birds and downregulated between Mock/H3N8 and Mock/M. 
gallisepticum Rlow infected birds (Table 2). MMP9 is upregulated between M. 
gallisepticum P1C5/H3N8 and M. gallisepticum Rlow/H3N8 infected chickens (Table 2). 
Differences in the expression of these two MMP genes may indicate alterations in the 
rates of tissue damage and repair among experimental groups. Upregulation of these 
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MMPs in M. gallisepticum Rlow/H3N8 infected chickens associates with the enhanced 
tracheal histopathology seen in Figure 1. 
 
Interferon and Interleukin Genes 
 Interferon regulatory factor 4 (IRF4) is significantly upregulated between M. 
gallisepticum P1C5/H3N8 and M. gallisepticum Rlow/H3N8 infected chickens (Table 2). 
This indicates an activation of the type I interferon response to influenza virus in 
chickens co-infected with virulent M. gallisepticum Rlow. 
 Interleukin 1 beta (IL-1β) is significantly upregulated between M. gallisepticum 
P1C5/H3N8 and M. gallisepticum Rlow/H3N8 infected chickens but downregulated 
between Mock/H3N8 and M. gallisepticum P1C5/H3N8 infected birds (Table 2). This 
differential regulation of IL-1β expression could indicate an enhanced activation of the 
NLRP3 inflammasome during co-infection with virulent M. gallisepticum Rlow and overall 
increased inflammatory signaling unique to the presence of a pathogenic M. 
gallisepticum.  
 
-Functional Gene Ontology:  
Between Mock/H3N8 and M. gallisepticum Rlow/H3N8 infected chickens these DEGs 
can be grouped into an array of functional pathways. Significant DEGs decreased in 
expression between these two challenge groups belong mostly to functional pathways 
involved in cilium organization and macromolecule metabolic processes (Supplemental 
Table 1). Significant DEGs increased in expression belong mainly to positive regulation 
of the immune system processes (Supplemental Table 2). Between M. gallisepticum 
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P1C5/H3N8 and M. gallisepticum Rlow/H3N8 infected chickens, pathways increased in 
expression belong foremost to response to lipopolysaccharide and signal transduction 
(Supplemental Table 3), and pathways decreased in expression belong mainly to 
cellular component assembly involved in morphogenesis, microtubule-based movement 
and cilium organization (Supplemental Table 4).  
 
-Pathway Analysis: KEGG pathway analysis of significant DEGs between 
experimental groups illuminated key pathways differentially regulated during mono- and 
co-infection. The toll-like receptor, phagosome, and cytokine-cytokine receptor 
pathways are significantly downregulated between Mock/H3N8 and Mock/M. 
gallisepticum Rlow infected chickens as well as between Mock/H3N8 and M. 
gallisepticum P1C5/H3N8 infected chickens (Supplemental Tables 6 and 7). Metabolic 
pathways are significantly downregulated between the groups stated above as well as 
Mock/H3N8 and M. gallisepticum Rlow/H3N8 infected chickens and M. gallisepticum 
P1C5/H3N8 and M. gallisepticum Rlow/H3N8 infected chickens (Supplemental Tables 8 
and 9). 
Notable upregulated pathways between M. gallisepticum P1C5/H3N8 and M. 
gallisepticum Rlow/H3N8 infected chickens (Supplemental Table 9) and Mock/H3N8 and 
M. gallisepticum Rlow/H3N8 infected chickens include the toll-like receptor, phagosome, 
metabolic, apoptosis, RIG-I-like receptor signaling, focal adhesion, and ECM-receptor 
interaction pathways (Supplemental Table 8).  
The influenza A response pathway is significantly affected across multiple 
comparisons. This pathway is significantly upregulated between M. gallisepticum 
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P1C5/H3N8 and M. gallisepticum Rlow/H3N8 infected chickens (SupplementalTable 9) 
and Mock/H3N8 and M. gallisepticum Rlow/H3N8 infected chickens (Supplemental Table 
8) and is downregulated between Mock/H3N8 and M. gallisepticum P1C5/H3N8 
infected chickens (Supplemental Table 7). Regulation of the actin cytoskeleton is also 
significantly upregulated between M. gallisepticum P1C5/H3N8 and M. gallisepticum 
Rlow/H3N8 infected chickens (Supplemental Table 9) and Mock/H3N8 and M. 
gallisepticum Rlow/H3N8 infected chickens (Supplemental Table 8).  
 
Discussion 
 These data presented contribute to our further understanding of the co-
pathogenesis of Mycoplasma gallisepticum and LPAIV. the exacerbated disease 
phenotype produced by these co-pathogens has been described using an ex vivo model 
system and in vivo at a later time point of 15 days post-infection with alternate strains of 
M. gallisepticum and LPAIV [7,8,9]. In our in vivo model examining this co-pathogenesis 
at an early timepoint, tracheal histopathology was significantly more severe in M. 
gallisepticum Rlow/H3N8 co-infected chickens compared to Mock/H3N8 mono-infected 
chickens, both infected with H3N8 for a total of 3 days (Figure 1A and 1B). 
In contrast, the inverse order of infection yielded no significant differences in 
tracheal histopathology between H3N8/M. gallisepticum Rlow co-infected chickens and 
Mock/M. gallisepticum Rlow mono-infected chickens both receiving M. gallisepticum Rlow 
infection for 3 days (Figure 1A and 1B). Although we could not discern exacerbation of 
pathologic lesions due to co-pathogenesis between these groups, the recovery of live 
M. gallisepticum Rlow from the tracheas of H3N8/M. gallisepticum Rlow co-infected 
 148 
chickens was notably higher than in Mock/M. gallisepticum Rlow mono-infected chickens 
(Figure 2A). Previous in vivo studies by Stipkovits et al. yielded significant differences 
between mono- and co-infected chickens in a similar model of M. gallisepticum and 
H3N8 co-pathogenesis, however our model examines co-infection at a more acute 
stage, 6 days post-infection, as seen in experiment #1 [7, 8]. The increased persistence 
of M. gallisepticum Rlow in H3N8/M. gallisepticum Rlow co-infected chickens at 6 days 
post-infection may contribute to more dramatic differences in tracheal pathology 
between mono- and co-infected birds over a longer period. 
Although previous works have utilized the transcriptomic approach to monitor M. 
gallisepticum infection of chickens, our work furthers the use of these techniques in an 
M. gallisepticum co-infection experiment in vivo [3,18,22,23]. This method of capturing 
the global response to infection in the airway highlighted a number of critical host 
responses during this co-infection model. One of these responses was the significant 
downregulation of pathways contributing to ciliary activity and integrity in the trachea. 
Although prior works have examined this ex vivo, the data presented here provides 
evidence of deleterious impact on the ciliary mucosa function in the natural chicken host 
at a transcript level [9]. This reduction of ciliary activity was shown between M. 
gallisepticum P1C5/H3N8 and M. gallisepticum Rlow/H3N8 infected chickens as well as 
Mock/H3N8 and M. gallisepticum Rlow/H3N8 infected chickens, indicating that there is a 
unique relationship between co-infection with a virulent M. gallisepticum and LPAIV over 
an attenuated M. gallisepticum, such as the mutant P1C5, or infection with LPAIV alone. 
Loss of the integrity of the mucociliary elevator could heavily contribute to the 
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exacerbated co-pathogenesis by inhibiting pathogen clearing and promoting the 
inflammatory immune response due to damage in the tracheal mucosa.  
 Another novel aspect of these experiments is the differential expression of TLR 
genes in response to mono- and co-infection with M. gallisepticum and LPAIV. TLR15, 
which is significantly decreased in expression in Mock/M. gallisepticum Rlow infected 
chickens compared to Mock/H3N8 infected chickens (Table 1), has also been shown to 
be abundantly expressed in response to M. gallisepticum Rlow infection in chickens [3]. 
Our current findings suggest that modulation in the expression of TLR15 remains critical 
in response to M. gallisepticum, however it is more highly expressed in response to 
LPAIV H3N8 alone. This could indicate that a TLR15-mediated response is more 
relevant in response to influenza virus mono-infection and is not enhanced in the 
presence of co-infection with M. gallisepticum. 
TLR21 expression is suppressed during co-infection, in that between both 
Mock/H3N8 and M. gallisepticum co-infection, TLR21 was significantly decreased in 
expression (Table 1). This suppression of TLR21 during M. gallisepticum co-infection 
negatively correlates with the significantly enhanced tracheal pathology and viral loads 
in co-infected chickens (Figure 1A, 1B, and 2B).  In ducks, TLR21 is upregulated in the 
blood, spleen, bursa, and cecum in response to duck plague virus (DPV) and serves to 
activate NFκB and the transcription of IL-6, IFNα, and IL-1β [24].  
In chicken bone marrow macrophages, TLR21 and TLR4 co-stimulation induces 
increases in pro-inflammatory genes such as IL-1β, IL-12p40, and IL-10 and nitric oxide 
production [25]. Therefore, suppression of TLR21 signaling in response to CpG 
deoxynucleotides and potential disruption of the association with TLR4 during co-
 150 
infection with Mycoplasma gallisepticum may also be a critical factor in our model of co-
pathogenesis. 
  Increased expression of IL-1β was also documented between M. gallisepticum 
Rlow/H3N8 and M. gallisepticum P1C5/H3N8 infected experimental groups, indicating a 
possible differential effect on activation of the NLRP3 inflammasome by IL-1β during co-
infection. Two MMP genes, MMP1 and MMP9, were also differentially expressed 
among experimental groups. MMP1, was differentially expressed between Mock/H3N8 
and Mock/M gallisepticum Rlow infected groups in experiment #1. These data can be 
associated with the increased tracheal pathology seen in the Mock/M. gallisepticum Rlow 
group over the Mock/H3N8 group, although this increase is not statistically significant 
(Figure 1A and 1B). MMP7 was among the highest expressed genes in the trachea in 
response to M. gallisepticum Rlow infection of chickens [3]. MMP1 and MMP7 have both 
been implicated as biomarkers of human idiopathic pulmonary fibrosis and are 
overexpressed in the lungs of patients with chronic pulmonary disease [26]. Therefore, 
a precedent exists for these MMP genes being involved in tissue remodeling in 
response to ongoing inflammatory challenge such as that induced by M. gallisepticum 
infection and potential association with the manifestation of pathologic lesions in the 
airway.  
 Functional pathway analysis also determined the differential regulation of the 
response to influenza A virus pathway among comparisons between mono- and co-
infected chickens illustrates the importance of modulation of this specific response 
mechanism. Co-infection with virulent M. gallisepticum appears to have a unique effect 
on this response, as the pathway was upregulated M. gallisepticum P1C5/H3N8 and M. 
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gallisepticum Rlow/H3N8 infected chickens and Mock/H3N8 and M. gallisepticum 
Rlow/H3N8 infected chickens and downregulated between Mock/H3N8 and M. 
gallisepticum P1C5/H3N8 infected chickens. Although this influenza A response 
pathway is increased in expression, it may not yield a productive immune response to 
clear the virus during co-infection, as evidenced by the highest tracheal viral load being 
present in the M. gallisepticum Rlow/H3N8 infected group of experiment #1 (Figure 2B).  
 A final novel finding of these experiments was the persistence of attenuated M. 
gallisepticum mutants P1C5 6 days post-infection and P1H9 7 days post-infection in the 
chicken trachea in experiments #2 and #3. Previously, these mutants have been shown 
to be completely cleared from the birds at 14 days post-infection [11,17]. The ability of 
these attenuated mutants to persist in the shorter term illustrates that the absence of a 
functional neuraminidase gene and the Mycoplasma specific lipoprotein A (MslA) in M. 
gallisepticum do not prohibit early colonization and replication in the chicken trachea. 
The M. gallisepticum MslA mutant P1H9 was only able to persist to a chronic state at 14 
days post-infection when in the presence of H3N8 co-infection. Although the M. 
gallisepticum mutant P1C5 did persist at low titers 14 days post-infection in experiment 
#3, this survival did not appear to be impacted by co-infection with H3N8. This contrast 
to previous findings on the chronic persistence of P1C5 in vivo could be attributed to 
experimental variation.  
Co-infection with H3N8 likely induces changes in the host environment, such as 
alterations in the immune response and changes in the tracheal architecture that 
partially rescue the mutant phenotype to allow for the its persistence. The capacity of 
LPAIV to rescue persistence of an attenuated mutant to levels of its parent strain 
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indicate that co-infection in populations of chickens infected with a sub-clinical M. 
gallisepticum field isolate are still susceptible to potential deleterious effects of co-
pathogenesis. Furthermore, these findings have profound implications for potential 
consequences of LPAIV outbreaks in flocks recently immunized with live, attenuated M. 
gallisepticum vaccines (e.g., TS-11, 6/85). 
 Overall, our findings contribute to the understanding of what underlies the co-
pathogenesis of M. gallisepticum and LPAIV in chickens. This co-pathogen relationship 
does not appear to be neuraminidase dependent as previously hypothesized. In 
addition to impacting commercial flocks, these findings are relevant to backyard free 
range flocks exposed to a primary infection with either M. gallisepticum or LPAIV 
isolates of various virulence that may evade common clinical surveillance measures, 
and could result in severe economic losses to farmers and increased loads of the 
secondary pathogen if not properly addressed. Overall, our findings contribute to the 
understanding of host-microbe interactions during the co-pathogenesis of M. 
gallisepticum and LPAIV in chickens and indicate that the co-pathogenesis of M. 
gallisepticum and LPAIV is a complex dynamic that warrants further experimental 
analysis. 
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Supplemental Data 
Supplemental Table 1 
Mock/H3N8 vs. R(low)/H3N8 Downregulated DEG DAVID Gene Ontology 
Term Count % P-Value Benjamini 
cilium assembly 17 5.9 1.10E-13 4.90E-11 
intraciliary transport 4 1.4 3.30E-04 6.90E-02 
microtubule-based movement 6 2.1 6.20E-04 8.60E-02 
cilium movement 4 1.4 1.10E-03 1.10E-01 
neural tube patterning 3 1 1.50E-03 1.30E-01 
nonmotile primary cilium assembly 4 1.4 3.40E-03 2.20E-01 
intraciliary retrograde transport 3 1 3.80E-03 2.10E-01 
epithelial cilium movement 3 1 5.20E-03 2.50E-01 
inner dynein arm assembly 3 1 6.90E-03 2.80E-01 
motile cilium assembly 3 1 6.90E-03 2.80E-01 
sperm motility 4 1.4 8.30E-03 3.00E-01 
cilium morphogenesis 4 1.4 1.00E-02 3.30E-01 
fat cell differentiation 4 1.4 2.80E-02 6.50E-01 
smoothened signaling pathway 4 1.4 3.40E-02 6.90E-01 
multi-ciliated epithelial cell differentiation 2 0.7 4.80E-02 7.80E-01 
cilium movement involved in cell motility 2 0.7 4.80E-02 7.80E-01 
prostaglandin metabolic process 2 0.7 4.80E-02 7.80E-01 
epithelial cilium movement involved in determination of left/right 
asymmetry 2 0.7 6.30E-02 8.50E-01 
retina development in camera-type eye 3 1 7.10E-02 8.60E-01 
determination of left/right symmetry 3 1 9.00E-02 9.10E-01 
UTP biosynthetic process 2 0.7 1.20E-01 9.60E-01 
CTP biosynthetic process 2 0.7 1.20E-01 9.60E-01 
GTP biosynthetic process 2 0.7 1.20E-01 9.60E-01 
ventricular system development 2 0.7 1.50E-01 9.80E-01 
intracellular transport 2 0.7 1.50E-01 9.80E-01 
protein localization to cilium 2 0.7 1.60E-01 9.80E-01 
glycogen metabolic process 2 0.7 1.60E-01 9.80E-01 
transcription from RNA polymerase III promoter 2 0.7 1.80E-01 9.80E-01 
transcription from RNA polymerase I promoter 2 0.7 1.80E-01 9.80E-01 
muscle cell differentiation 2 0.7 1.90E-01 9.90E-01 
multicellular organism growth 3 1 2.00E-01 9.90E-01 
small GTPase mediated signal transduction 5 1.7 2.40E-01 9.90E-01 
positive regulation of macroautophagy 2 0.7 2.70E-01 1.00E+00 
glycolytic process 2 0.7 2.80E-01 1.00E+00 
tricarboxylic acid cycle 2 0.7 2.80E-01 1.00E+00 
mitotic spindle assembly 2 0.7 3.00E-01 1.00E+00 
lens development in camera-type eye 2 0.7 3.10E-01 1.00E+00 
dorsal/ventral pattern formation 2 0.7 3.10E-01 1.00E+00 
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skeletal system morphogenesis 2 0.7 3.30E-01 1.00E+00 
cytoplasmic microtubule organization 2 0.7 3.60E-01 1.00E+00 
protein folding 3 1 3.60E-01 1.00E+00 
homophilic cell adhesion via plasma membrane adhesion 
molecules 3 1 3.90E-01 1.00E+00 
defense response to bacterium 2 0.7 4.20E-01 1.00E+00 
cartilage development 2 0.7 4.30E-01 1.00E+00 
heart looping 2 0.7 4.30E-01 1.00E+00 
spermatid development 2 0.7 4.30E-01 1.00E+00 
protein autophosphorylation 3 1 4.40E-01 1.00E+00 
hematopoietic progenitor cell differentiation 2 0.7 4.70E-01 1.00E+00 
heart development 3 1 4.70E-01 1.00E+00 
male gonad development 2 0.7 4.80E-01 1.00E+00 
kidney development 2 0.7 5.00E-01 1.00E+00 
embryonic digit morphogenesis 2 0.7 5.10E-01 1.00E+00 
positive regulation of sequence-specific DNA binding 
transcription factor activity 2 0.7 5.10E-01 1.00E+00 
transforming growth factor beta receptor signaling pathway 2 0.7 5.20E-01 1.00E+00 
Golgi organization 2 0.7 5.70E-01 1.00E+00 
palate development 2 0.7 5.90E-01 1.00E+00 
vesicle-mediated transport 2 0.7 6.10E-01 1.00E+00 
brain development 2 0.7 6.30E-01 1.00E+00 
intracellular signal transduction 4 1.4 6.60E-01 1.00E+00 
mitophagy in response to mitochondrial depolarization 2 0.7 6.90E-01 1.00E+00 
negative regulation of cell proliferation 3 1 7.00E-01 1.00E+00 
visual perception 2 0.7 7.20E-01 1.00E+00 
spermatogenesis 2 0.7 7.30E-01 1.00E+00 
carbohydrate metabolic process 2 0.7 7.30E-01 1.00E+00 
protein phosphorylation 2 0.7 7.40E-01 1.00E+00 
cell migration 2 0.7 7.80E-01 1.00E+00 
transcription, DNA-templated 6 2.1 7.90E-01 1.00E+00 
transcription from RNA polymerase II promoter 2 0.7 7.90E-01 1.00E+00 
regulation of transcription from RNA polymerase II promoter 3 1 8.10E-01 1.00E+00 
positive regulation of transcription, DNA-templated 3 1 8.20E-01 1.00E+00 
inflammatory response 2 0.7 8.70E-01 1.00E+00 
cell adhesion 2 0.7 8.80E-01 1.00E+00 
positive regulation of transcription from RNA polymerase II 
promoter 5 1.7 8.90E-01 1.00E+00 
regulation of transcription, DNA-templated 4 1.4 9.40E-01 1.00E+00 
 
Supplemental Table 2 
Mock/H3N8 vs. R(low)/H3N8 Upregulated DEG DAVID Gene Ontology 
Term Count % P-Value Benjamini 
immune response 16 6.2 8.80E-09 7.50E-06 
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B cell receptor signaling pathway 9 3.5 9.20E-09 3.90E-06 
inflammatory response 15 5.8 3.50E-07 1.00E-04 
regulation of cell proliferation 13 5 2.20E-06 4.60E-04 
transmembrane receptor protein tyrosine kinase signaling pathway 9 3.5 2.90E-05 4.80E-03 
T cell receptor signaling pathway 6 2.3 1.90E-04 2.70E-02 
innate immune response 10 3.8 3.20E-04 3.80E-02 
apoptotic cell clearance 4 1.5 1.00E-03 1.00E-01 
antigen processing and presentation 5 1.9 1.50E-03 1.30E-01 
neutrophil chemotaxis 5 1.9 1.80E-03 1.40E-01 
apoptotic signaling pathway 5 1.9 2.40E-03 1.70E-01 
germinal center formation 3 1.2 2.60E-03 1.70E-01 
endodermal cell differentiation 4 1.5 4.40E-03 2.50E-01 
peptidyl-tyrosine autophosphorylation 5 1.9 4.50E-03 2.40E-01 
brown fat cell differentiation 4 1.5 5.20E-03 2.60E-01 
positive regulation of interleukin-2 biosynthetic process 3 1.2 8.90E-03 3.80E-01 
extracellular matrix organization 6 2.3 9.50E-03 3.80E-01 
I-kappaB kinase/NF-kappaB signaling 4 1.5 9.60E-03 3.60E-01 
positive regulation of apoptotic process 7 2.7 1.40E-02 4.80E-01 
negative thymic T cell selection 3 1.2 1.50E-02 4.70E-01 
proteolysis involved in cellular protein catabolic process 4 1.5 1.60E-02 4.70E-01 
regulation of apoptotic process 7 2.7 1.60E-02 4.60E-01 
positive regulation of B cell proliferation 4 1.5 1.90E-02 5.10E-01 
response to lipopolysaccharide 5 1.9 2.60E-02 6.10E-01 
defense response to virus 5 1.9 2.60E-02 6.10E-01 
cell differentiation 8 3.1 3.60E-02 7.10E-01 
positive regulation of I-kappaB kinase/NF-kappaB signaling 6 2.3 3.80E-02 7.20E-01 
intrinsic apoptotic signaling pathway in response to endoplasmic 
reticulum stress 3 1.2 4.00E-02 7.20E-01 
granuloma formation 2 0.8 4.20E-02 7.30E-01 
cyclooxygenase pathway 2 0.8 4.20E-02 7.30E-01 
positive regulation of interferon-gamma production 3 1.2 5.00E-02 7.80E-01 
chemokine-mediated signaling pathway 3 1.2 5.50E-02 8.00E-01 
antigen processing and presentation of endogenous peptide 
antigen via MHC class I via ER pathway, TAP-dependent 2 0.8 6.30E-02 8.30E-01 
antigen processing and presentation of endogenous peptide 
antigen via MHC class Ib via ER pathway, TAP-dependent 2 0.8 6.30E-02 8.30E-01 
positive regulation of platelet activation 2 0.8 6.30E-02 8.30E-01 
immunological synapse formation 2 0.8 6.30E-02 8.30E-01 
positive regulation of antigen processing and presentation of 
peptide antigen via MHC class I 2 0.8 6.30E-02 8.30E-01 
positive regulation of tumor necrosis factor biosynthetic process 2 0.8 6.30E-02 8.30E-01 
positive regulation of protein kinase B signaling 4 1.5 6.30E-02 8.20E-01 
positive regulation of protein kinase activity 3 1.2 6.70E-02 8.30E-01 
integrin-mediated signaling pathway 4 1.5 6.70E-02 8.20E-01 
toll-like receptor signaling pathway 3 1.2 7.30E-02 8.40E-01 
negative regulation of leukocyte apoptotic process 2 0.8 8.30E-02 8.70E-01 
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cotranslational protein targeting to membrane 2 0.8 8.30E-02 8.70E-01 
positive regulation of MHC class II biosynthetic process 2 0.8 8.30E-02 8.70E-01 
dsRNA transport 2 0.8 8.30E-02 8.70E-01 
antigen processing and presentation of exogenous protein antigen 
via MHC class Ib, TAP-dependent 2 0.8 8.30E-02 8.70E-01 
protein N-linked glycosylation via asparagine 3 1.2 8.60E-02 8.70E-01 
intrinsic apoptotic signaling pathway in response to DNA damage 3 1.2 8.60E-02 8.70E-01 
chemotaxis 3 1.2 9.90E-02 9.00E-01 
positive regulation of alpha-beta T cell proliferation 2 0.8 1.00E-01 9.00E-01 
positive regulation of keratinocyte migration 2 0.8 1.00E-01 9.00E-01 
toll-like receptor 3 signaling pathway 2 0.8 1.00E-01 9.00E-01 
negative regulation of interleukin-17 production 2 0.8 1.00E-01 9.00E-01 
secretion by cell 2 0.8 1.00E-01 9.00E-01 
positive regulation of NF-kappaB transcription factor activity 4 1.5 1.00E-01 9.00E-01 
positive regulation of MAP kinase activity 3 1.2 1.10E-01 9.00E-01 
response to endoplasmic reticulum stress 3 1.2 1.10E-01 9.10E-01 
cellular response to amino acid stimulus 3 1.2 1.20E-01 9.20E-01 
complement activation, classical pathway 2 0.8 1.20E-01 9.20E-01 
positive thymic T cell selection 2 0.8 1.20E-01 9.20E-01 
regulation of cytokine secretion 2 0.8 1.20E-01 9.20E-01 
negative regulation of protein phosphorylation 3 1.2 1.30E-01 9.20E-01 
regulation of blood pressure 3 1.2 1.30E-01 9.20E-01 
negative regulation of apoptotic process 7 2.7 1.30E-01 9.20E-01 
activation of cysteine-type endopeptidase activity involved in 
apoptotic process 3 1.2 1.30E-01 9.20E-01 
cell migration 5 1.9 1.40E-01 9.30E-01 
immunoglobulin mediated immune response 2 0.8 1.40E-01 9.30E-01 
activation of MAPKKK activity 2 0.8 1.40E-01 9.30E-01 
regulation of osteoclast differentiation 2 0.8 1.40E-01 9.30E-01 
adaptive immune response 3 1.2 1.40E-01 9.20E-01 
regulation of protein localization 3 1.2 1.40E-01 9.20E-01 
negative regulation of sequence-specific DNA binding transcription 
factor activity 3 1.2 1.50E-01 9.30E-01 
positive regulation of GTPase activity 4 1.5 1.50E-01 9.30E-01 
ossification 3 1.2 1.60E-01 9.30E-01 
intracellular signal transduction 8 3.1 1.60E-01 9.30E-01 
activation of NF-kappaB-inducing kinase activity 2 0.8 1.60E-01 9.30E-01 
B cell activation 2 0.8 1.60E-01 9.30E-01 
regulation of immune response 2 0.8 1.60E-01 9.30E-01 
chaperone mediated protein folding requiring cofactor 2 0.8 1.60E-01 9.30E-01 
negative regulation of B cell proliferation 2 0.8 1.60E-01 9.30E-01 
positive regulation of calcium-mediated signaling 2 0.8 1.60E-01 9.30E-01 
negative regulation of smoothened signaling pathway 2 0.8 1.60E-01 9.30E-01 
myeloid dendritic cell differentiation 2 0.8 1.60E-01 9.30E-01 
negative regulation of interferon-gamma production 2 0.8 1.60E-01 9.30E-01 
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defense response to protozoan 2 0.8 1.60E-01 9.30E-01 
T cell costimulation 2 0.8 1.60E-01 9.30E-01 
release of cytochrome c from mitochondria 2 0.8 1.60E-01 9.30E-01 
collagen catabolic process 2 0.8 1.60E-01 9.30E-01 
positive regulation of MAPK cascade 3 1.2 1.60E-01 9.30E-01 
positive regulation of JNK cascade 3 1.2 1.60E-01 9.30E-01 
positive regulation of protein phosphorylation 3 1.2 1.70E-01 9.40E-01 
superoxide anion generation 2 0.8 1.80E-01 9.40E-01 
positive regulation of transcription factor import into nucleus 2 0.8 1.80E-01 9.40E-01 
positive regulation of interleukin-4 production 2 0.8 1.80E-01 9.40E-01 
positive regulation of B cell differentiation 2 0.8 1.80E-01 9.40E-01 
cellular response to lipopolysaccharide 3 1.2 1.90E-01 9.50E-01 
positive regulation of pri-miRNA transcription from RNA polymerase 
II promoter 2 0.8 1.90E-01 9.50E-01 
lymphocyte chemotaxis 2 0.8 1.90E-01 9.50E-01 
positive regulation of receptor-mediated endocytosis 2 0.8 1.90E-01 9.50E-01 
positive regulation of peptidyl-tyrosine phosphorylation 3 1.2 2.10E-01 9.60E-01 
cell-matrix adhesion 3 1.2 2.10E-01 9.60E-01 
negative regulation of interleukin-6 production 2 0.8 2.10E-01 9.60E-01 
positive regulation of release of cytochrome c from mitochondria 2 0.8 2.10E-01 9.60E-01 
G-protein coupled receptor signaling pathway 5 1.9 2.20E-01 9.70E-01 
ER to Golgi vesicle-mediated transport 3 1.2 2.30E-01 9.70E-01 
extrinsic apoptotic signaling pathway in absence of ligand 2 0.8 2.30E-01 9.70E-01 
actin filament polymerization 2 0.8 2.30E-01 9.70E-01 
positive regulation of phosphatidylinositol 3-kinase signaling 3 1.2 2.30E-01 9.70E-01 
neural crest cell migration 3 1.2 2.30E-01 9.70E-01 
complement activation 2 0.8 2.40E-01 9.70E-01 
MyD88-dependent toll-like receptor signaling pathway 2 0.8 2.40E-01 9.70E-01 
regulation of G-protein coupled receptor protein signaling pathway 2 0.8 2.40E-01 9.70E-01 
positive regulation of phagocytosis 2 0.8 2.60E-01 9.80E-01 
positive regulation of vascular endothelial growth factor production 2 0.8 2.80E-01 9.80E-01 
positive regulation of DNA binding 2 0.8 2.80E-01 9.80E-01 
negative regulation of tumor necrosis factor production 2 0.8 2.80E-01 9.80E-01 
protein kinase B signaling 2 0.8 2.80E-01 9.80E-01 
endoplasmic reticulum organization 2 0.8 2.80E-01 9.80E-01 
cell redox homeostasis 3 1.2 2.80E-01 9.80E-01 
response to oxidative stress 3 1.2 2.90E-01 9.80E-01 
positive regulation of gene expression 5 1.9 2.90E-01 9.80E-01 
oligosaccharide metabolic process 2 0.8 2.90E-01 9.80E-01 
monocyte chemotaxis 2 0.8 2.90E-01 9.80E-01 
negative regulation of protein catabolic process 2 0.8 3.10E-01 9.90E-01 
positive regulation of inflammatory response 2 0.8 3.10E-01 9.90E-01 
angiogenesis 4 1.5 3.10E-01 9.90E-01 
phosphorylation 2 0.8 3.20E-01 9.90E-01 
signal transduction 7 2.7 3.20E-01 9.90E-01 
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transcription from RNA polymerase II promoter 4 1.5 3.30E-01 9.90E-01 
phosphatidylinositol dephosphorylation 2 0.8 3.40E-01 9.90E-01 
growth 2 0.8 3.40E-01 9.90E-01 
cell maturation 2 0.8 3.40E-01 9.90E-01 
cellular response to interferon-gamma 2 0.8 3.40E-01 9.90E-01 
glucose homeostasis 3 1.2 3.50E-01 9.90E-01 
regulation of transcription from RNA polymerase II promoter 6 2.3 3.60E-01 9.90E-01 
regulation of cell adhesion 2 0.8 3.60E-01 9.90E-01 
protein homooligomerization 4 1.5 3.70E-01 9.90E-01 
cellular response to drug 2 0.8 3.80E-01 9.90E-01 
mitotic spindle assembly 2 0.8 3.80E-01 9.90E-01 
platelet aggregation 2 0.8 3.90E-01 9.90E-01 
erythrocyte differentiation 2 0.8 4.00E-01 9.90E-01 
regulation of cell shape 3 1.2 4.10E-01 9.90E-01 
negative regulation of gene expression 3 1.2 4.10E-01 9.90E-01 
protein stabilization 3 1.2 4.10E-01 9.90E-01 
cellular response to mechanical stimulus 2 0.8 4.20E-01 9.90E-01 
defense response to Gram-negative bacterium 2 0.8 4.20E-01 9.90E-01 
cellular response to insulin stimulus 2 0.8 4.30E-01 1.00E+00 
calcium ion transport 2 0.8 4.40E-01 1.00E+00 
histone H3 acetylation 2 0.8 4.50E-01 1.00E+00 
cellular response to interleukin-1 2 0.8 4.50E-01 1.00E+00 
positive regulation of fat cell differentiation 2 0.8 4.50E-01 1.00E+00 
cell division 3 1.2 4.60E-01 1.00E+00 
cell chemotaxis 2 0.8 4.70E-01 1.00E+00 
protein homotetramerization 2 0.8 4.70E-01 1.00E+00 
regulation of inflammatory response 2 0.8 4.80E-01 1.00E+00 
response to virus 2 0.8 4.80E-01 1.00E+00 
protein folding 3 1.2 5.00E-01 1.00E+00 
chloride transmembrane transport 2 0.8 5.10E-01 1.00E+00 
defense response to bacterium 2 0.8 5.10E-01 1.00E+00 
protein import into nucleus 2 0.8 5.10E-01 1.00E+00 
cellular response to hypoxia 2 0.8 5.10E-01 1.00E+00 
B cell differentiation 2 0.8 5.20E-01 1.00E+00 
cell adhesion 4 1.5 5.20E-01 1.00E+00 
cellular response to tumor necrosis factor 2 0.8 5.30E-01 1.00E+00 
positive regulation of ERK1 and ERK2 cascade 3 1.2 5.40E-01 1.00E+00 
activation of MAPK activity 2 0.8 5.50E-01 1.00E+00 
positive regulation of protein binding 2 0.8 5.60E-01 1.00E+00 
skeletal system development 2 0.8 5.70E-01 1.00E+00 
fat cell differentiation 2 0.8 5.90E-01 1.00E+00 
negative regulation of protein kinase activity 2 0.8 6.20E-01 1.00E+00 
cell surface receptor signaling pathway 3 1.2 6.30E-01 1.00E+00 
regulation of cell cycle 2 0.8 6.30E-01 1.00E+00 
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cellular calcium ion homeostasis 2 0.8 6.50E-01 1.00E+00 
positive regulation of angiogenesis 2 0.8 6.50E-01 1.00E+00 
positive regulation of cell proliferation 4 1.5 6.50E-01 1.00E+00 
protein glycosylation 2 0.8 6.80E-01 1.00E+00 
cytokine-mediated signaling pathway 2 0.8 6.80E-01 1.00E+00 
response to hypoxia 2 0.8 6.80E-01 1.00E+00 
cell proliferation 3 1.2 6.90E-01 1.00E+00 
osteoblast differentiation 2 0.8 7.00E-01 1.00E+00 
transport 2 0.8 7.20E-01 1.00E+00 
transmembrane transport 2 0.8 7.20E-01 1.00E+00 
negative regulation of cell growth 2 0.8 7.30E-01 1.00E+00 
brain development 2 0.8 7.30E-01 1.00E+00 
cytoskeleton organization 2 0.8 7.40E-01 1.00E+00 
positive regulation of transcription from RNA polymerase II 
promoter 8 3.1 7.50E-01 1.00E+00 
negative regulation of neuron apoptotic process 2 0.8 7.50E-01 1.00E+00 
transcription, DNA-templated 8 3.1 7.60E-01 1.00E+00 
protein transport 2 0.8 7.80E-01 1.00E+00 
proteolysis 2 0.8 7.80E-01 1.00E+00 
spermatogenesis 2 0.8 8.20E-01 1.00E+00 
carbohydrate metabolic process 2 0.8 8.20E-01 1.00E+00 
negative regulation of cell proliferation 3 1.2 8.30E-01 1.00E+00 
small GTPase mediated signal transduction 3 1.2 8.40E-01 1.00E+00 
apoptotic process 2 0.8 8.50E-01 1.00E+00 
protein autophosphorylation 2 0.8 8.60E-01 1.00E+00 
positive regulation of cell migration 2 0.8 8.80E-01 1.00E+00 
oxidation-reduction process 2 0.8 8.90E-01 1.00E+00 
protein ubiquitination 2 0.8 8.90E-01 1.00E+00 
multicellular organism development 3 1.2 9.00E-01 1.00E+00 
positive regulation of transcription, DNA-templated 3 1.2 9.20E-01 1.00E+00 
regulation of transcription, DNA-templated 5 1.9 9.60E-01 1.00E+00 
negative regulation of transcription, DNA-templated 2 0.8 9.70E-01 1.00E+00 
negative regulation of transcription from RNA polymerase II 
promoter 3 1.2 9.80E-01 1.00E+00 
 
Supplemental Table 3 
P1C5/H3N8 vs. R(low)/H3N8 Upregulated DEG DAVID Gene Ontology 
Term Count % P-Value Benjamini 
inflammatory response 15 5.9 1.80E-07 1.70E-04 
immune response 14 5.5 2.70E-07 1.20E-04 
regulation of cell proliferation 12 4.7 8.20E-06 2.50E-03 
innate immune response 10 4 2.10E-04 4.70E-02 
response to lipopolysaccharide 7 2.8 6.60E-04 1.10E-01 
toll-like receptor signaling pathway 5 2 7.40E-04 1.10E-01 
germinal center formation 3 1.2 2.40E-03 2.70E-01 
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endodermal cell differentiation 4 1.6 3.80E-03 3.50E-01 
cellular response to hypoxia 5 2 4.20E-03 3.40E-01 
defense response to virus 6 2.4 4.20E-03 3.20E-01 
brown fat cell differentiation 4 1.6 4.50E-03 3.10E-01 
regulation of cytokine secretion 3 1.2 5.80E-03 3.50E-01 
transmembrane receptor protein tyrosine kinase signaling pathway 6 2.4 6.20E-03 3.50E-01 
cell differentiation 9 3.6 9.10E-03 4.50E-01 
positive regulation of apoptotic process 7 2.8 1.10E-02 5.00E-01 
integrin-mediated signaling pathway 5 2 1.20E-02 4.90E-01 
neutrophil chemotaxis 4 1.6 1.40E-02 5.20E-01 
apoptotic cell clearance 3 1.2 1.60E-02 5.70E-01 
positive regulation of pri-miRNA transcription from RNA polymerase 
II promoter 3 1.2 1.60E-02 5.70E-01 
apoptotic signaling pathway 4 1.6 1.70E-02 5.50E-01 
negative regulation of smooth muscle cell proliferation 3 1.2 2.00E-02 6.00E-01 
peptide cross-linking 3 1.2 2.40E-02 6.40E-01 
peptidyl-tyrosine autophosphorylation 4 1.6 2.60E-02 6.70E-01 
MyD88-dependent toll-like receptor signaling pathway 3 1.2 2.70E-02 6.70E-01 
positive regulation of axon extension 3 1.2 3.20E-02 7.00E-01 
positive regulation of smooth muscle cell proliferation 3 1.2 3.60E-02 7.30E-01 
protein kinase B signaling 3 1.2 3.60E-02 7.30E-01 
cell migration 6 2.4 4.00E-02 7.60E-01 
cyclooxygenase pathway 2 0.8 4.00E-02 7.50E-01 
negative regulation of regulatory T cell differentiation 2 0.8 4.00E-02 7.50E-01 
heme catabolic process 2 0.8 4.00E-02 7.50E-01 
hypermethylation of CpG island 2 0.8 4.00E-02 7.50E-01 
tolerance induction to lipopolysaccharide 2 0.8 4.00E-02 7.50E-01 
granuloma formation 2 0.8 4.00E-02 7.50E-01 
positive regulation of inflammatory response 3 1.2 4.50E-02 7.80E-01 
positive regulation of macroautophagy 3 1.2 5.60E-02 8.30E-01 
regulation of innate immune response 2 0.8 5.90E-02 8.40E-01 
positive regulation of platelet activation 2 0.8 5.90E-02 8.40E-01 
positive regulation of tumor necrosis factor biosynthetic process 2 0.8 5.90E-02 8.40E-01 
B-1 B cell homeostasis 2 0.8 5.90E-02 8.40E-01 
positive regulation of interleukin-12 biosynthetic process 2 0.8 5.90E-02 8.40E-01 
negative regulation of B cell activation 2 0.8 5.90E-02 8.40E-01 
I-kappaB kinase/NF-kappaB signaling 3 1.2 6.70E-02 8.70E-01 
B cell receptor signaling pathway 3 1.2 7.20E-02 8.80E-01 
platelet aggregation 3 1.2 7.80E-02 8.90E-01 
secretion 2 0.8 7.90E-02 8.90E-01 
detection of lipopolysaccharide 2 0.8 7.90E-02 8.90E-01 
response to oxidative stress 4 1.6 8.00E-02 8.80E-01 
antigen processing and presentation 3 1.2 8.40E-02 8.90E-01 
cellular response to mechanical stimulus 3 1.2 9.00E-02 9.00E-01 
proteolysis involved in cellular protein catabolic process 3 1.2 9.00E-02 9.00E-01 
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positive regulation of MAP kinase activity 3 1.2 9.60E-02 9.10E-01 
secretion by cell 2 0.8 9.70E-02 9.10E-01 
extracellular matrix disassembly 2 0.8 9.70E-02 9.10E-01 
endoderm formation 2 0.8 9.70E-02 9.10E-01 
negative regulation of interleukin-17 production 2 0.8 9.70E-02 9.10E-01 
positive regulation of keratinocyte migration 2 0.8 9.70E-02 9.10E-01 
positive regulation of I-kappaB kinase/NF-kappaB signaling 5 2 9.90E-02 9.10E-01 
substrate adhesion-dependent cell spreading 3 1.2 1.00E-01 9.10E-01 
negative regulation of apoptotic process 7 2.8 1.10E-01 9.20E-01 
cellular response to amino acid stimulus 3 1.2 1.10E-01 9.10E-01 
natural killer cell differentiation 2 0.8 1.20E-01 9.20E-01 
cellular response to interferon-beta 2 0.8 1.20E-01 9.20E-01 
negative regulation of interleukin-2 production 2 0.8 1.20E-01 9.20E-01 
positive regulation of receptor biosynthetic process 2 0.8 1.20E-01 9.20E-01 
regulation of blood pressure 3 1.2 1.20E-01 9.20E-01 
positive regulation of gene expression 6 2.4 1.20E-01 9.10E-01 
response to virus 3 1.2 1.20E-01 9.20E-01 
regulation of inflammatory response 3 1.2 1.20E-01 9.20E-01 
regulation of apoptotic process 5 2 1.30E-01 9.20E-01 
regulation of I-kappaB kinase/NF-kappaB signaling 2 0.8 1.30E-01 9.30E-01 
regulation of cell adhesion mediated by integrin 2 0.8 1.30E-01 9.30E-01 
positive regulation of interleukin-2 biosynthetic process 2 0.8 1.30E-01 9.30E-01 
DNA methylation involved in gamete generation 2 0.8 1.30E-01 9.30E-01 
regulation of osteoclast differentiation 2 0.8 1.30E-01 9.30E-01 
fatty acid transport 2 0.8 1.30E-01 9.30E-01 
positive regulation of macrophage cytokine production 2 0.8 1.30E-01 9.30E-01 
negative regulation of sequence-specific DNA binding transcription 
factor activity 3 1.2 1.40E-01 9.30E-01 
ossification 3 1.2 1.40E-01 9.40E-01 
positive regulation of MAPK cascade 3 1.2 1.50E-01 9.40E-01 
release of cytochrome c from mitochondria 2 0.8 1.50E-01 9.40E-01 
negative regulation of interferon-gamma production 2 0.8 1.50E-01 9.40E-01 
myeloid dendritic cell differentiation 2 0.8 1.50E-01 9.40E-01 
defense response to protozoan 2 0.8 1.50E-01 9.40E-01 
chaperone mediated protein folding requiring cofactor 2 0.8 1.50E-01 9.40E-01 
collagen catabolic process 2 0.8 1.50E-01 9.40E-01 
deadenylation-dependent decapping of nuclear-transcribed mRNA 2 0.8 1.50E-01 9.40E-01 
protein maturation 2 0.8 1.70E-01 9.50E-01 
cell-substrate adhesion 2 0.8 1.70E-01 9.50E-01 
signal peptide processing 2 0.8 1.70E-01 9.50E-01 
superoxide anion generation 2 0.8 1.70E-01 9.50E-01 
astrocyte development 2 0.8 1.80E-01 9.70E-01 
positive regulation of phosphorylation 2 0.8 1.80E-01 9.70E-01 
G-protein coupled receptor signaling pathway 5 2 2.00E-01 9.70E-01 
fat cell differentiation 3 1.2 2.00E-01 9.70E-01 
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acute-phase response 2 0.8 2.00E-01 9.70E-01 
negative regulation of interleukin-6 production 2 0.8 2.00E-01 9.70E-01 
positive regulation of release of cytochrome c from mitochondria 2 0.8 2.00E-01 9.70E-01 
morphogenesis of an epithelium 2 0.8 2.00E-01 9.70E-01 
JAK-STAT cascade 2 0.8 2.00E-01 9.70E-01 
cytoplasmic mRNA processing body assembly 2 0.8 2.00E-01 9.70E-01 
positive regulation of phosphatidylinositol 3-kinase signaling 3 1.2 2.20E-01 9.80E-01 
neural crest cell migration 3 1.2 2.20E-01 9.80E-01 
protein targeting to plasma membrane 2 0.8 2.20E-01 9.80E-01 
spermatogenesis 4 1.6 2.20E-01 9.70E-01 
negative regulation of protein kinase activity 3 1.2 2.30E-01 9.80E-01 
regulation of G-protein coupled receptor protein signaling pathway 2 0.8 2.30E-01 9.80E-01 
positive regulation of extrinsic apoptotic signaling pathway 2 0.8 2.50E-01 9.80E-01 
apoptotic process 4 1.6 2.60E-01 9.80E-01 
intrinsic apoptotic signaling pathway in response to endoplasmic 
reticulum stress 2 0.8 2.60E-01 9.90E-01 
positive regulation of DNA binding 2 0.8 2.60E-01 9.90E-01 
endoplasmic reticulum organization 2 0.8 2.60E-01 9.90E-01 
negative regulation of extrinsic apoptotic signaling pathway via 
death domain receptors 2 0.8 2.60E-01 9.90E-01 
negative regulation of tumor necrosis factor production 2 0.8 2.60E-01 9.90E-01 
extrinsic apoptotic signaling pathway 2 0.8 2.80E-01 9.90E-01 
signal transduction 7 2.8 2.80E-01 9.90E-01 
cytokine-mediated signaling pathway 3 1.2 2.90E-01 9.90E-01 
negative regulation of endothelial cell apoptotic process 2 0.8 2.90E-01 9.90E-01 
positive regulation of interferon-gamma production 2 0.8 2.90E-01 9.90E-01 
transcription, DNA-templated 11 4.3 2.90E-01 9.90E-01 
chemokine-mediated signaling pathway 2 0.8 3.10E-01 9.90E-01 
regulation of mitotic cell cycle 2 0.8 3.10E-01 9.90E-01 
osteoblast differentiation 3 1.2 3.10E-01 9.90E-01 
cellular iron ion homeostasis 2 0.8 3.20E-01 9.90E-01 
cell maturation 2 0.8 3.20E-01 9.90E-01 
glucose homeostasis 3 1.2 3.30E-01 9.90E-01 
protein homooligomerization 4 1.6 3.40E-01 9.90E-01 
one-carbon metabolic process 2 0.8 3.40E-01 9.90E-01 
negative regulation of protein ubiquitination 2 0.8 3.40E-01 9.90E-01 
regulation of cell adhesion 2 0.8 3.50E-01 9.90E-01 
extracellular matrix organization 3 1.2 3.50E-01 9.90E-01 
cytoskeleton organization 3 1.2 3.60E-01 9.90E-01 
cellular response to drug 2 0.8 3.60E-01 9.90E-01 
endosome organization 2 0.8 3.60E-01 9.90E-01 
positive regulation of GTPase activity 3 1.2 3.70E-01 9.90E-01 
negative regulation of neuron apoptotic process 3 1.2 3.70E-01 9.90E-01 
regulation of cell shape 3 1.2 3.90E-01 9.90E-01 
protein stabilization 3 1.2 3.90E-01 9.90E-01 
 168 
negative regulation of gene expression 3 1.2 3.90E-01 9.90E-01 
response to heat 2 0.8 3.90E-01 9.90E-01 
defense response to Gram-negative bacterium 2 0.8 4.00E-01 1.00E+00 
outflow tract morphogenesis 2 0.8 4.00E-01 1.00E+00 
positive regulation of transcription from RNA polymerase II promoter 10 4 4.10E-01 1.00E+00 
T cell receptor signaling pathway 2 0.8 4.10E-01 1.00E+00 
positive regulation of B cell proliferation 2 0.8 4.20E-01 1.00E+00 
positive regulation of fat cell differentiation 2 0.8 4.40E-01 1.00E+00 
histone H3 acetylation 2 0.8 4.40E-01 1.00E+00 
cellular response to interleukin-1 2 0.8 4.40E-01 1.00E+00 
wound healing 2 0.8 4.40E-01 1.00E+00 
neuromuscular process controlling balance 2 0.8 4.40E-01 1.00E+00 
cell chemotaxis 2 0.8 4.50E-01 1.00E+00 
protein homotetramerization 2 0.8 4.50E-01 1.00E+00 
negative regulation of protein phosphorylation 2 0.8 4.50E-01 1.00E+00 
circadian regulation of gene expression 2 0.8 4.60E-01 1.00E+00 
activation of cysteine-type endopeptidase activity involved in 
apoptotic process 2 0.8 4.60E-01 1.00E+00 
cell adhesion 4 1.6 4.90E-01 1.00E+00 
chloride transmembrane transport 2 0.8 4.90E-01 1.00E+00 
defense response to bacterium 2 0.8 4.90E-01 1.00E+00 
positive regulation of JNK cascade 2 0.8 5.00E-01 1.00E+00 
positive regulation of ERK1 and ERK2 cascade 3 1.2 5.10E-01 1.00E+00 
positive regulation of protein phosphorylation 2 0.8 5.10E-01 1.00E+00 
positive regulation of osteoblast differentiation 2 0.8 5.20E-01 1.00E+00 
lipid catabolic process 2 0.8 5.20E-01 1.00E+00 
activation of MAPK activity 2 0.8 5.30E-01 1.00E+00 
cellular response to lipopolysaccharide 2 0.8 5.30E-01 1.00E+00 
positive regulation of transcription, DNA-templated 5 2 5.30E-01 1.00E+00 
positive regulation of protein binding 2 0.8 5.40E-01 1.00E+00 
skeletal system development 2 0.8 5.50E-01 1.00E+00 
protein autophosphorylation 3 1.2 5.50E-01 1.00E+00 
cell-matrix adhesion 2 0.8 5.60E-01 1.00E+00 
transcription from RNA polymerase II promoter 3 1.2 5.80E-01 1.00E+00 
ER to Golgi vesicle-mediated transport 2 0.8 5.80E-01 1.00E+00 
positive regulation of protein kinase B signaling 2 0.8 5.90E-01 1.00E+00 
positive regulation of cell migration 3 1.2 5.90E-01 1.00E+00 
positive regulation of cell proliferation 4 1.6 6.10E-01 1.00E+00 
positive regulation of angiogenesis 2 0.8 6.30E-01 1.00E+00 
cell redox homeostasis 2 0.8 6.30E-01 1.00E+00 
cell proliferation 3 1.2 6.60E-01 1.00E+00 
response to hypoxia 2 0.8 6.60E-01 1.00E+00 
positive regulation of NF-kappaB transcription factor activity 2 0.8 6.60E-01 1.00E+00 
metabolic process 2 0.8 6.90E-01 1.00E+00 
negative regulation of cell growth 2 0.8 7.10E-01 1.00E+00 
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regulation of transcription from RNA polymerase II promoter 4 1.6 7.30E-01 1.00E+00 
proteolysis 2 0.8 7.60E-01 1.00E+00 
protein transport 2 0.8 7.60E-01 1.00E+00 
intracellular signal transduction 4 1.6 8.00E-01 1.00E+00 
protein folding 2 0.8 8.00E-01 1.00E+00 
negative regulation of transcription from RNA polymerase II 
promoter 5 2 8.00E-01 1.00E+00 
cilium assembly 2 0.8 8.10E-01 1.00E+00 
negative regulation of cell proliferation 3 1.2 8.10E-01 1.00E+00 
negative regulation of transcription, DNA-templated 3 1.2 8.30E-01 1.00E+00 
angiogenesis 2 0.8 8.50E-01 1.00E+00 
protein ubiquitination involved in ubiquitin-dependent protein 
catabolic process 2 0.8 8.50E-01 1.00E+00 
multicellular organism development 3 1.2 8.80E-01 1.00E+00 
protein ubiquitination 2 0.8 8.80E-01 1.00E+00 
regulation of transcription, DNA-templated 5 2 9.50E-01 1.00E+00 
 
Supplemental Table 4 
 
P1C5/H3N8 vs. R(low)/H3N8 Gene Downregulated DEG DAVID Gene Ontology 
Term Count % P-Value Benjamini 
cilium assembly 6 5.7 1.60E-04 4.10E-02 
inner dynein arm assembly 3 2.8 1.10E-03 1.40E-01 
intraciliary transport 3 2.8 1.40E-03 1.20E-01 
sperm motility 3 2.8 1.20E-02 5.60E-01 
retina development in camera-type eye 3 2.8 1.30E-02 5.10E-01 
determination of left/right symmetry 3 2.8 1.70E-02 5.40E-01 
prostaglandin metabolic process 2 1.9 1.90E-02 5.30E-01 
cilium movement involved in cell motility 2 1.9 1.90E-02 5.30E-01 
neural tube patterning 2 1.9 2.60E-02 5.90E-01 
intraciliary transport involved in cilium morphogenesis 2 1.9 3.80E-02 6.90E-01 
intraciliary retrograde transport 2 1.9 3.80E-02 6.90E-01 
epithelial cilium movement 2 1.9 4.40E-02 7.10E-01 
motile cilium assembly 2 1.9 5.00E-02 7.20E-01 
GTP biosynthetic process 2 1.9 5.00E-02 7.20E-01 
CTP biosynthetic process 2 1.9 5.00E-02 7.20E-01 
UTP biosynthetic process 2 1.9 5.00E-02 7.20E-01 
aorta development 2 1.9 8.10E-02 8.50E-01 
coronary vasculature development 2 1.9 9.30E-02 8.70E-01 
lens development in camera-type eye 2 1.9 1.40E-01 9.40E-01 
spermatid development 2 1.9 2.00E-01 9.80E-01 
microtubule-based movement 2 1.9 2.40E-01 9.90E-01 
Notch signaling pathway 2 1.9 2.60E-01 9.90E-01 
Golgi organization 2 1.9 2.90E-01 9.90E-01 
mitotic nuclear division 2 1.9 3.10E-01 9.90E-01 
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heart development 2 1.9 4.70E-01 1.00E+00 
cell proliferation 2 1.9 5.10E-01 1.00E+00 
positive regulation of transcription, DNA-templated 2 1.9 7.10E-01 1.00E+00 
intracellular signal transduction 2 1.9 7.40E-01 1.00E+00 
positive regulation of transcription from RNA polymerase II promoter 2 1.9 9.30E-01 1.00E+00 
 
 
Supplemental Table 5 
 
Mock/H3N8 vs. P1C5/H3N8 Downregulated DEG DAVID Gene Ontology 
Term Count % P-Value Benjamini 
toll-like receptor signaling pathway 4 5.6 2.50E-04 8.70E-02 
inflammatory response 6 8.3 8.50E-04 1.40E-01 
MyD88-dependent toll-like receptor signaling pathway 3 4.2 2.60E-03 2.70E-01 
tolerance induction to lipopolysaccharide 2 2.8 1.20E-02 6.60E-01 
response to virus 3 4.2 1.40E-02 6.30E-01 
smooth muscle cell migration 2 2.8 1.80E-02 6.60E-01 
innate immune response 4 5.6 2.30E-02 7.00E-01 
detection of lipopolysaccharide 2 2.8 2.40E-02 6.60E-01 
positive regulation of keratinocyte migration 2 2.8 3.00E-02 7.00E-01 
skeletal muscle contraction 2 2.8 3.50E-02 7.30E-01 
positive regulation of chemokine production 2 2.8 4.10E-02 7.50E-01 
positive regulation of wound healing 2 2.8 4.70E-02 7.70E-01 
negative regulation of smooth muscle cell proliferation 2 2.8 6.40E-02 8.40E-01 
negative regulation of interleukin-6 production 2 2.8 6.40E-02 8.40E-01 
negative regulation of tumor necrosis factor production 2 2.8 8.60E-02 9.00E-01 
cardiac muscle contraction 2 2.8 8.60E-02 9.00E-01 
negative regulation of extrinsic apoptotic signaling pathway via 
death domain receptors 2 2.8 8.60E-02 9.00E-01 
positive regulation of smooth muscle cell proliferation 2 2.8 8.60E-02 9.00E-01 
endodermal cell differentiation 2 2.8 9.20E-02 9.00E-01 
protein homotrimerization 2 2.8 9.20E-02 9.00E-01 
positive regulation of I-kappaB kinase/NF-kappaB signaling 3 4.2 9.60E-02 9.00E-01 
negative regulation of endothelial cell apoptotic process 2 2.8 9.70E-02 8.90E-01 
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Supplemental Table 7 
 
 
 
Supplemental Table 8 
Term Count % P-Value Benjamini
Cardiac muscle contraction 4 5.1 1.20E-02 4.20E-01
Oxidative phosphorylation 5 6.3 1.30E-02 2.60E-01
Focal adhesion 5 6.3 5.90E-02 6.00E-01
ECM-receptor interaction 3 3.8 1.20E-01 7.50E-01
Toll-like receptor signaling pathway 3 3.8 1.40E-01 7.50E-01
Porphyrin and chlorophyll metabolism 2 2.5 1.80E-01 7.80E-01
Phagosome 3 3.8 2.60E-01 8.60E-01
Protein processing in endoplasmic reticulum 3 3.8 3.30E-01 9.00E-01
PPAR signaling pathway 2 2.5 3.80E-01 9.10E-01
Lysosome 2 2.5 6.00E-01 9.80E-01
Cytokine-cytokine receptor interaction 2 2.5 7.00E-01 9.90E-01
Regulation of actin cytoskeleton 2 2.5 7.70E-01 1.00E+00
Metabolic pathways 8 10 7.90E-01 1.00E+00
Mock/H3N8 vs. Mock/Rlow
Downregulated KEGG Pathways
Term Count % P-Value Benjamini
Cardiac muscle contraction 4 5.6 5.90E-03 2.30E-01
NOD-like receptor signaling pathway 3 4.2 2.50E-02 4.40E-01
Oxidative phosphorylation 4 5.6 3.40E-02 4.00E-01
Salmonella infection 3 4.2 6.30E-02 5.20E-01
Phenylalanine metabolism 2 2.8 8.40E-02 5.50E-01
Toll-like receptor signaling pathway 3 4.2 9.40E-02 5.20E-01
Phagosome 3 4.2 1.80E-01 7.10E-01
Tyrosine metabolism 2 2.8 1.80E-01 6.70E-01
Influenza A 3 4.2 1.90E-01 6.50E-01
Cytosolic DNA-sensing pathway 2 2.8 2.20E-01 6.80E-01
Cytokine-cytokine receptor interaction 3 4.2 2.30E-01 6.60E-01
PPAR signaling pathway 2 2.8 3.10E-01 7.50E-01
Metabolic pathways 7 9.7 6.80E-01 9.80E-01
Focal adhesion 2 2.8 6.90E-01 9.80E-01
Neuroactive ligand-receptor interaction 2 2.8 8.20E-01 9.90E-01
Mock/H3N8 vs. P1C5/H3N8
Downregulated KEGG Pathways
 172 
 
Supplemental Table 9 
 
Term Count % P-Value Benjamini Term Count % P-Value Benjamini
Phagosome 12 4.6 1.30E-04 1.00E-02 Cardiac muscle contraction 5 1.7 5.10E-03 3.00E-01
Cell adhesion molecules (CAMs) 11 4.2 2.30E-04 9.30E-03 Purine metabolism 7 2.4 7.60E-03 2.30E-01
Intestinal immune network for IgA production 6 2.3 7.20E-04 2.00E-02 Oxidative phosphorylation 6 2.1 1.10E-02 2.20E-01
Lysosome 10 3.8 1.10E-03 2.20E-02 Metabolic pathways 21 7.3 1.40E-02 2.10E-01
Jak-STAT signaling pathway 10 3.8 1.50E-03 2.40E-02 Biosynthesis of antibiotics 7 2.4 1.90E-02 2.30E-01
Toll-like receptor signaling pathway 8 3.1 3.30E-03 4.50E-02 Pyrimidine metabolism 4 1.4 8.00E-02 6.20E-01
Protein processing in endoplasmic reticulum 10 3.8 7.50E-03 8.40E-02 Drug metabolism - cytochrome P450 2 0.7 2.80E-01 9.60E-01
Cytokine-cytokine receptor interaction 10 3.8 7.50E-03 8.40E-02 Metabolism of xenobiotics by cytochrome P450 2 0.7 3.10E-01 9.60E-01
Influenza A 9 3.5 1.10E-02 1.00E-01 Cysteine and methionine metabolism 2 0.7 3.20E-01 9.50E-01
Herpes simplex infection 8 3.1 5.00E-02 3.70E-01 Glycine, serine and threonine metabolism 2 0.7 3.40E-01 9.40E-01
Nicotinate and nicotinamide metabolism 3 1.2 1.30E-01 6.90E-01 Adrenergic signaling in cardiomyocytes 3 1 3.80E-01 9.50E-01
VEGF signaling pathway 4 1.5 1.50E-01 7.10E-01 Fatty acid metabolism 2 0.7 4.10E-01 9.50E-01
Cytosolic DNA-sensing pathway 3 1.2 2.50E-01 8.60E-01 Valine, leucine and isoleucine degradation 2 0.7 4.10E-01 9.50E-01
ECM-receptor interaction 4 1.5 2.50E-01 8.40E-01 Arachidonic acid metabolism 2 0.7 4.50E-01 9.60E-01
Focal adhesion 7 2.7 2.70E-01 8.50E-01 PPAR signaling pathway 2 0.7 5.10E-01 9.70E-01
Glycosaminoglycan degradation 2 0.8 3.50E-01 9.10E-01 ECM-receptor interaction 2 0.7 5.80E-01 9.80E-01
Phosphatidylinositol signaling system 4 1.5 3.70E-01 9.10E-01 TGF-beta signaling pathway 2 0.7 5.90E-01 9.80E-01
RIG-I-like receptor signaling pathway 3 1.2 3.80E-01 9.00E-01 Tight junction 2 0.7 6.00E-01 9.80E-01
Protein export 2 0.8 4.10E-01 9.10E-01 Insulin resistance 2 0.7 6.80E-01 9.90E-01
Porphyrin and chlorophyll metabolism 2 0.8 4.50E-01 9.30E-01 Vascular smooth muscle contraction 2 0.7 7.00E-01 9.90E-01
Drug metabolism - other enzymes 2 0.8 4.70E-01 9.20E-01 Cell adhesion molecules (CAMs) 2 0.7 7.30E-01 9.90E-01
Cysteine and methionine metabolism 2 0.8 5.50E-01 9.60E-01 Cell cycle 2 0.7 7.30E-01 9.90E-01
ErbB signaling pathway 3 1.2 5.50E-01 9.50E-01 Insulin signaling pathway 2 0.7 7.50E-01 9.90E-01
MAPK signaling pathway 6 2.3 5.70E-01 9.50E-01 FoxO signaling pathway 2 0.7 7.60E-01 9.90E-01
ABC transporters 2 0.8 5.90E-01 9.50E-01 Calcium signaling pathway 2 0.7 8.60E-01 1.00E+00
N-Glycan biosynthesis 2 0.8 6.70E-01 9.70E-01 Focal adhesion 2 0.7 8.90E-01 1.00E+00
mTOR signaling pathway 2 0.8 7.00E-01 9.80E-01 Endocytosis 2 0.7 9.30E-01 1.00E+00
Arachidonic acid metabolism 2 0.8 7.00E-01 9.70E-01 Neuroactive ligand-receptor interaction 2 0.7 9.60E-01 1.00E+00
Apoptosis 2 0.8 7.20E-01 9.80E-01
PPAR signaling pathway 2 0.8 7.60E-01 9.80E-01
Insulin signaling pathway 3 1.2 7.70E-01 9.80E-01
p53 signaling pathway 2 0.8 7.70E-01 9.80E-01
Endocytosis 5 1.9 7.70E-01 9.80E-01
FoxO signaling pathway 3 1.2 7.90E-01 9.80E-01
Adipocytokine signaling pathway 2 0.8 7.90E-01 9.80E-01
Regulation of actin cytoskeleton 4 1.5 8.00E-01 9.80E-01
Inositol phosphate metabolism 2 0.8 8.10E-01 9.80E-01
Progesterone-mediated oocyte maturation 2 0.8 8.40E-01 9.80E-01
Purine metabolism 3 1.2 8.80E-01 9.90E-01
Pyrimidine metabolism 2 0.8 8.80E-01 9.90E-01
Calcium signaling pathway 3 1.2 9.00E-01 9.90E-01
Insulin resistance 2 0.8 9.00E-01 9.90E-01
Vascular smooth muscle contraction 2 0.8 9.10E-01 9.90E-01
Wnt signaling pathway 2 0.8 9.50E-01 1.00E+00
Metabolic pathways 18 6.9 9.80E-01 1.00E+00
Neuroactive ligand-receptor interaction 2 0.8 1.00E+00 1.00E+00
Upregulated KEGG Pathways
Mock/H3N8 vs. Rlow/H3N8Mock/H3N8 vs. Rlow/H3N8
Downregulated KEGG Pathways
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Supplemental Table 10 
 
 
Mock/H3N8 vs. R(low)/H3N8 > 2 log2 FC Sig DEG 
Gene ID Gene Protein Name Log2 FC q value 
ENSGALG00000019478 ENSGALG00000019478 Uncharacterized protein #NAME? 0.0048 
ENSGALG00000023458 ENSGALG00000023458 Uncharacterized protein #NAME? 0.0048 
ENSGALG00000023937 ENSGALG00000023937 Uncharacterized protein #NAME? 0.0263 
ENSGALG00000025628 ENSGALG00000025628 Uncharacterized protein 2.465 0.0048 
ENSGALG00000017790 5S_rRNA 5S ribosomal RNA 2.019 0.0442 
ENSGALG00000024292 MEF2B myocyte enhancer factor 2B 2.009 0.0212 
Term Count % P-Value Benjamini Term Count % P-Value Benjamini
Cytokine-cytokine receptor interaction 16 6.3 1.90E-06 1.40E-04 Metabolic pathways 10 9.4 6.60E-02 9.00E-01
Toll-like receptor signaling pathway 11 4.3 2.80E-05 1.10E-03 Drug metabolism - cytochrome P450 2 1.9 1.30E-01 9.10E-01
Intestinal immune network for IgA production 7 2.8 8.40E-05 2.10E-03 Retinol metabolism 2 1.9 1.40E-01 8.20E-01
Jak-STAT signaling pathway 12 4.7 9.60E-05 1.80E-03 Tyrosine metabolism 2 1.9 1.50E-01 7.30E-01
Cell adhesion molecules (CAMs) 11 4.3 2.90E-04 4.40E-03 Fatty acid degradation 2 1.9 1.60E-01 6.70E-01
Phagosome 10 4 2.80E-03 3.40E-02 Purine metabolism 3 2.8 1.70E-01 6.50E-01
Influenza A 10 4 3.80E-03 4.10E-02 Valine, leucine and isoleucine degradation 2 1.9 2.00E-01 6.50E-01
PPAR signaling pathway 6 2.4 1.40E-02 1.30E-01 Biosynthesis of antibiotics 3 2.8 2.40E-01 6.70E-01
Lysosome 8 3.2 1.80E-02 1.40E-01 Pyrimidine metabolism 2 1.9 3.60E-01 8.00E-01
Protein processing in endoplasmic reticulum 8 3.2 6.60E-02 4.00E-01 Phagosome 2 1.9 4.70E-01 8.80E-01
Herpes simplex infection 7 2.8 1.30E-01 6.20E-01 RNA transport 2 1.9 4.90E-01 8.70E-01
VEGF signaling pathway 4 1.6 1.60E-01 6.80E-01
Cytosolic DNA-sensing pathway 3 1.2 2.60E-01 8.20E-01
NOD-like receptor signaling pathway 3 1.2 2.60E-01 8.20E-01
ECM-receptor interaction 4 1.6 2.70E-01 8.10E-01
Fatty acid biosynthesis 2 0.8 2.80E-01 8.10E-01
Fatty acid metabolism 3 1.2 2.90E-01 8.10E-01
Focal adhesion 7 2.8 3.00E-01 7.90E-01
Nitrogen metabolism 2 0.8 3.40E-01 8.30E-01
Glycosaminoglycan biosynthesis 2 0.8 3.80E-01 8.50E-01
RIG-I-like receptor signaling pathway 3 1.2 3.90E-01 8.50E-01
MAPK signaling pathway 7 2.8 4.20E-01 8.60E-01
Protein export 2 0.8 4.20E-01 8.50E-01
Regulation of actin cytoskeleton 6 2.4 4.40E-01 8.50E-01
Porphyrin and chlorophyll metabolism 2 0.8 4.60E-01 8.60E-01
Adipocytokine signaling pathway 3 1.2 4.70E-01 8.50E-01
Salmonella infection 3 1.2 4.80E-01 8.60E-01
Alanine, aspartate and glutamate metabolism 2 0.8 5.50E-01 8.90E-01
Cysteine and methionine metabolism 2 0.8 5.60E-01 8.90E-01
Fatty acid degradation 2 0.8 5.60E-01 8.90E-01
ErbB signaling pathway 3 1.2 5.70E-01 8.90E-01
Pyrimidine metabolism 3 1.2 6.30E-01 9.20E-01
Sphingolipid metabolism 2 0.8 7.10E-01 9.50E-01
Arachidonic acid metabolism 2 0.8 7.10E-01 9.50E-01
Apoptosis 2 0.8 7.30E-01 9.50E-01
Endocytosis 4 1.6 9.10E-01 1.00E+00
Insulin signaling pathway 2 0.8 9.40E-01 1.00E+00
Oxidative phosphorylation 2 0.8 9.40E-01 1.00E+00
Wnt signaling pathway 2 0.8 9.50E-01 1.00E+00
Ubiquitin mediated proteolysis 2 0.8 9.50E-01 1.00E+00
Purine metabolism 2 0.8 9.80E-01 1.00E+00
Metabolic pathways 16 6.3 1.00E+00 1.00E+00
P1C5/H3N8 vs. Rlow/H3N8P1C5/H3N8 vs. Rlow/H3N8
Downregulated KEGG PathwaysUpregulated KEGG Pathways
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Mock/H3N8 vs. R(low)/H3N8 < -2 log2 FC Sig DEG 
Gene ID Gene Protein Name Log2 FC q value 
ENSGALG00000012997 DNAH5 dynein, axonemal, heavy chain 5 -2.007 0.013 
ENSGALG00000005500 HSBP1 heat shock factor-binding protein 1 -2.007 0.005 
ENSGALG00000002553 PCDH1 Gallus gallus protocadherin 1 (PCDH1), mRNA -2.013 0.021 
ENSGALG00000019164 CXORF30   -2.019 0.021 
ENSGALG00000000451 ENSGALG00000000451 Uncharacterized protein -2.031 0.023 
ENSGALG00000019240 GGA.46624   -2.037 0.005 
ENSGALG00000013247 CCDC83 coiled-coil domain containing 83 -2.037 0.008 
ENSGALG00000008109 CDHR3 cadherin related family member 3 -2.040 0.013 
ENSGALG00000004121 GPR23 lysophosphatidic acid receptor 4 -2.084 0.025 
ENSGALG00000015214 AKD1   -2.089 0.027 
ENSGALG00000000774 TLR21 Toll-like receptor 21 precursor -2.100 0.018 
ENSGALG00000005601 ENSGALG00000005601 Uncharacterized protein -2.104 0.005 
ENSGALG00000008910 CERKL ceramide kinase like -2.110 0.005 
ENSGALG00000010712 NDUFA4   -2.112 0.005 
ENSGALG00000011277 PLEKHG7 
pleckstrin homology and RhoGEF domain 
containing G7 -2.114 0.008 
ENSGALG00000006048 FAM64A family with sequence similarity 64 member A -2.122 0.011 
ENSGALG00000017226 CCDC67 coiled-coil domain containing 67 -2.129 0.005 
ENSGALG00000000287 AGPAT1   -2.151 0.020 
ENSGALG00000008879 CCDC39   -2.163 0.011 
ENSGALG00000022869 TMEM200C   -2.187 0.018 
ENSGALG00000020920 ENSGALG00000020920 Uncharacterized protein -2.190 0.036 
ENSGALG00000017190 KIAA1377 centrosomal protein 126kDa -2.201 0.028 
ENSGALG00000000447 KCNA3 
potassium voltage-gated channel subfamily A 
member 3 -2.230 0.013 
ENSGALG00000008519 NR2C2 nuclear receptor subfamily 2 group C member 2 -2.248 0.022 
ENSGALG00000003239 ENSGALG00000003239 Uncharacterized protein -2.258 0.005 
ENSGALG00000017023 NEK5 NIMA-related kinase 5 -2.301 0.014 
ENSGALG00000006841 POLR2L 
polymerase (RNA) II (DNA directed) polypeptide L, 
7.6kDa -2.314 0.046 
ENSGALG00000022714 C11ORF75   -2.333 0.045 
ENSGALG00000003615 ENSGALG00000003615 Uncharacterized protein -2.339 0.014 
ENSGALG00000015272 ENSGALG00000015272 Uncharacterized protein -2.356 0.015 
ENSGALG00000011410 ENSGALG00000011410 Uncharacterized protein -2.395 0.014 
ENSGALG00000015358 MYH15 myosin heavy chain, cardiac muscle isoform -2.440 0.035 
ENSGALG00000009732 PCDH18 protocadherin 18 -2.445 0.005 
ENSGALG00000015164 PCSK5 proprotein convertase subtilisin/kexin type 5 -2.468 0.008 
ENSGALG00000022741 ENSGALG00000022741 Uncharacterized protein -2.473 0.005 
ENSGALG00000009620 FSIP1   -2.507 0.048 
ENSGALG00000016962 ENSGALG00000016962 Uncharacterized protein -2.537 0.005 
ENSGALG00000007537 INCENP inner centromere protein -2.567 0.005 
ENSGALG00000016281 DMD dystrophin -2.575 0.005 
ENSGALG00000015329 ENSGALG00000015329 Uncharacterized protein -2.608 0.005 
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ENSGALG00000008848 SOX2 Transcription factor SOX-2 -2.690 0.028 
ENSGALG00000002552 COL1A1 
Gallus gallus collagen, type III, alpha 1 (COL3A1), 
mRNA -2.692 0.005 
ENSGALG00000021544 ENSGALG00000021544 Uncharacterized protein -2.703 0.015 
ENSGALG00000020228 ENSGALG00000020228 Uncharacterized protein -2.727 0.015 
ENSGALG00000023137 SPTSSA   -2.788 0.005 
ENSGALG00000023229 H2B-VIII   -3.031 0.011 
ENSGALG00000022740 ENSGALG00000022740 Uncharacterized protein -3.069 0.047 
ENSGALG00000020982 BPIFB3 BPI fold containing family B member 3 -3.097 0.005 
ENSGALG00000014843 TPD52L1 
Gallus gallus tumor protein D52-like 1 (TPD52L1), 
mRNA -3.372 0.005 
ENSGALG00000005843 EEF1A2 eukaryotic translation elongation factor 1 alpha 2 -3.374 0.005 
ENSGALG00000006010 FAM103A1 protein FAM103A1 -3.543 0.005 
ENSGALG00000015741 ENSGALG00000015741 Uncharacterized protein -4.074 0.026 
ENSGALG00000013193 IRX2 iroquois-class homeodomain protein IRX-2 -4.435 0.045 
 
Supplemental Table 11 
Mock/H3N8 vs. P1C5/H3N8 > 2 log2 Fold Change (FC) Significant DEG 
Gene ID Gene Protein Name Log2 FC q value 
ENSGALG00000009262 FGB fibrinogen beta chain 3.331 0.010 
ENSGALG00000003519 CHIA chitinase, acidic 2.999 0.010 
ENSGALG00000005278 CDH11 cadherin 11 2.809 0.039 
ENSGALG00000025628 ENSGALG00000025628 Uncharacterized protein 2.417 0.010 
ENSGALG00000016682 CRISP1 Cysteine Rich Secretory Protein 1 2.173 0.010 
Mock/H3N8 vs. P1C5/H3N8 < -2 log2 Fold Change (FC) Significant DEG 
Gene ID Gene Protein Name Log2 FC q value 
ENSGALG00000023521 ADRA2A adrenoceptor alpha 2A -5.373 0.035 
ENSGALG00000002553 PCDH1 protocadherin 1 -3.658 0.010 
ENSGALG00000015446 POU2F1 POU class 2 homeobox 1 -3.056 0.010 
ENSGALG00000006010 FAM103A1 family with sequence similarity 103 member A1 -3.021 0.010 
ENSGALG00000020228 ENSGALG00000020228 Uncharacterized protein -2.812 0.010 
ENSGALG00000019061 MMP1 matrix metallopeptidase 1 -2.809 0.010 
ENSGALG00000004167 SRGN serglycin -2.705 0.010 
ENSGALG00000006841 POLR2L 
polymerase (RNA) II (DNA directed) polypeptide L 
7.6kDa -2.621 0.027 
ENSGALG00000020920 ENSGALG00000020920 Uncharacterized protein -2.619 0.010 
ENSGALG00000004159 GGA.38350   -2.585 0.050 
ENSGALG00000014997 PLA1A phospholipase A1 member A -2.455 0.044 
ENSGALG00000004041 ENSGALG00000004041 Uncharacterized protein -2.448 0.010 
ENSGALG00000016112 NOV nephroblastoma overexpressed gene -2.441 0.010 
ENSGALG00000006295 ENSGALG00000006295 Uncharacterized protein -2.368 0.010 
ENSGALG00000014412 CSTA cystatin A -2.356 0.010 
ENSGALG00000000774 TLR21 similar to Toll-like receptor 21 -2.346 0.010 
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Supplemental Table 12 
Mock/R(low) vs. H3N8/R(low) > 2 log2 Fold Change (FC) Significant DEG 
Gene ID Gene Protein Name Log2 FC q value 
ENSGALG00000006593 CLDN18 claudin 18 #NAME? 0.037 
ENSGALG00000012928 ENSGALG00000012928 Uncharacterized protein inf 0.037 
ENSGALG00000005278 CDH11 cadherin-11 precursor 6.757 0.037 
ENSGALG00000009732 PCDH18 protocadherin 18 2.870 0.037 
ENSGALG00000007945 CRYAB Alpha-crystallin B chain 2.707 0.037 
ENSGALG00000011469 IGFBP2 
Gallus gallus insulin-like growth factor binding protein 2, 
36kDa (IGFBP2), mRNA 2.582 0.037 
ENSGALG00000005172 ENSGALG00000005172 Uncharacterized protein 2.237 0.037 
ENSGALG00000002435 DUOX2 Dual Oxidase 2 2.053 0.037 
Mock/R(low) vs. H3N8/R(low) < -2 log2 Fold Change (FC) Significant DEG 
Gene ID Gene Protein Name Log2 FC q value 
ENSGALG00000014843 TPD52L1 Gallus gallus tumor protein D52-like 1 (TPD52L1), mRNA -2.334 0.037 
ENSGALG00000013811 NCAPH2 non-SMC condensin II complex subunit H2 -2.309 0.037 
ENSGALG00000016171 PTK2 Focal adhesion kinase 1 -2.208 0.037 
 
Supplemental Table 13 
ENSGALG00000016782 IL1R2 interleukin 1 receptor type II -2.313 0.010 
ENSGALG00000021490 GPR97 G protein-coupled receptor 97 -2.313 0.022 
ENSGALG00000014182 ADORA2B adenosine A2b receptor  -2.278 0.044 
ENSGALG00000000534 IL-1BETA il-1beta -2.262 0.010 
ENSGALG00000017033 MRPS31 mitochondrial ribosomal protein S31 -2.251 0.010 
ENSGALG00000006992 MMP9 matrix metalloproteinase-9 precursor -2.224 0.010 
ENSGALG00000019657 GGA.52241 Uncharacterized protein -2.157 0.039 
ENSGALG00000005599 ENSGALG00000005599 Uncharacterized protein -2.140 0.039 
ENSGALG00000006326 MIF 
macrophage migration inhibitory factor 
(glycosylation-inhibiting factor) -2.139 0.027 
ENSGALG00000016693 ENSGALG00000016693 Uncharacterized protein -2.120 0.017 
ENSGALG00000017214 HEPHL1 hephaestin like 1 -2.101 0.039 
ENSGALG00000023340 ENSGALG00000023340 Uncharacterized protein -2.054 0.010 
ENSGALG00000022740 ENSGALG00000022740 Uncharacterized protein -2.044 0.010 
ENSGALG00000002234 UNC13D unc-13 homolog D (C. elegans) -2.034 0.010 
ENSGALG00000003615 ENSGALG00000003615 Uncharacterized protein -2.024 0.017 
ENSGALG00000007463 HBAD Gallus gallus alpha-D-globin (HBAD), mRNA -2.016 0.039 
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P1C5/H3N8 vs. R(low)/H3N8 > 2 log2 Fold Change (FC) Significant DEG 
Gene ID Gene Protein Name Log2 FC q value 
ENSGALG00000019061 MMP1 matrix metallopeptidase 1 3.801 0.004 
ENSGALG00000006992 MMP9 matrix metallopeptidase 9 3.704 0.004 
ENSGALG00000000534 IL-1BETA interleukin 1, beta (IL1B), mRNA 3.508 0.004 
ENSGALG00000011668 K60 interleukin-8 precursor 3.338 0.004 
ENSGALG00000002234 UNC13D unc-13 homolog D (C. elegans) 3.315 0.004 
ENSGALG00000000081 IL4I1 L-amino-acid oxidase precursor 3.287 0.004 
ENSGALG00000016782 IL1R2 interleukin 1 receptor, type II 3.253 0.004 
ENSGALG00000004041 ENSGALG00000004041 Uncharacterized protein 3.208 0.004 
ENSGALG00000002112 CSF3R granulocyte colony-stimulating factor receptor 3.190 0.004 
ENSGALG00000005599 ENSGALG00000005599 Uncharacterized protein 3.164 0.047 
ENSGALG00000004582 MYL2 
myosin regulatory light chain 2A, cardiac muscle 
isoform 3.042 0.004 
ENSGALG00000007001 TLR4 toll-like receptor 4 precursor 3.020 0.004 
ENSGALG00000008166 TLR15 toll-like receptor 15 (TLR15), mRNA 2.981 0.004 
ENSGALG00000002766 MLKL mixed lineage kinase domain-like 2.901 0.004 
ENSGALG00000023818 ENSGALG00000023818 Uncharacterized protein 2.893 0.004 
ENSGALG00000001905 DTX2 deltex 2, E3 ubiquitin ligase 2.875 0.004 
ENSGALG00000004167 SRGN serglycin 2.873 0.014 
ENSGALG00000021142 ENSGALG00000021142 Uncharacterized protein 2.869 0.004 
ENSGALG00000015666 TNIP2 TNFAIP3-interacting protein 2 2.862 0.004 
ENSGALG00000010892 ANTXR2 anthrax toxin receptor 2 2.820 0.004 
ENSGALG00000017214 HEPHL1 hephaestin like 1 2.779 0.035 
ENSGALG00000010362 SUCNR1 succinate receptor 1 2.773 0.004 
ENSGALG00000016919 IRG1 immunoresponsive 1 homolog 2.742 0.004 
ENSGALG00000014412 CSTA cystatin A 2.736 0.004 
ENSGALG00000015446 POU2F1 POU domain, class 2, transcription factor 1 2.700 0.025 
ENSGALG00000023370 ENSGALG00000023370 Uncharacterized protein 2.690 0.004 
ENSGALG00000023933 G0S2 G0/G1switch 2 2.676 0.010 
ENSGALG00000020316 IL13RA2 interleukin-13 receptor subunit alpha-2 precursor 2.658 0.004 
ENSGALG00000000949 HBEGF 
Proheparin-binding EGF-like growth factor Heparin-
binding EGF-like growth factor 2.653 0.004 
ENSGALG00000011670 IL8  interleukin 8 [Gallus gallus] 2.651 0.008 
ENSGALG00000011221 AGPAT9 Glycerol-3-phosphate acyltransferase 3 2.631 0.004 
ENSGALG00000004060 RGS9 regulator of G-protein signaling 9 2.621 0.004 
ENSGALG00000002383 CD72 CD72 antigen 2.612 0.004 
ENSGALG00000005172 ENSGALG00000005172 Uncharacterized protein 2.590 0.004 
ENSGALG00000005941 ENSGALG00000005941 Uncharacterized protein 2.583 0.041 
ENSGALG00000019148 CSF2RA   2.556 0.008 
ENSGALG00000023855 KRT14 keratin, type I cytoskeletal 14 2.554 0.004 
ENSGALG00000021340 CA9 carbonic anhydrase IX 2.552 0.004 
ENSGALG00000023622 AVD Avidin 2.551 0.004 
ENSGALG00000006106 TNFRSF6B tumor necrosis factor receptor superfamily member 6b 2.549 0.004 
ENSGALG00000002118 CO6 calcium-activated potassium channel subunit beta-1 2.545 0.004 
ENSGALG00000016693 ENSGALG00000016693 Uncharacterized protein 2.518 0.020 
ENSGALG00000022646 ENSGALG00000022646 Uncharacterized protein 2.515 0.025 
ENSGALG00000005086 PLAU urokinase-type plasminogen activator preproprotein 2.463 0.004 
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ENSGALG00000000837 FKBP6 FK506 binding protein 6 2.460 0.016 
ENSGALG00000010152 TSPAN8 tetraspanin-8 2.452 0.029 
ENSGALG00000014585 CCLI10 C-C motif chemokine ligand 26 2.450 0.004 
ENSGALG00000013568 NR4A3 nuclear receptor subfamily 4 group A member 3 2.447 0.004 
ENSGALG00000003123 CNTNAP1 contactin associated protein 1 2.430 0.028 
ENSGALG00000019147 CSF2RA 
granulocyte-macrophage colony-stimulating factor 
receptor subunit alpha-like 2.416 0.024 
ENSGALG00000004700 NCF2 neutrophil cytosolic factor 2 2.388 0.030 
ENSGALG00000021355 TROJAN   2.386 0.030 
ENSGALG00000000731 C1ORF38 thymocyte selection associated family member 2 2.349 0.025 
ENSGALG00000003282 STAT5B signal transducer and activator of transcription 5B 2.342 0.004 
ENSGALG00000007454 PDCD1 programmed cell death 1 2.329 0.014 
ENSGALG00000016788 IL18RAP interleukin 18 receptor accessory protein 2.329 0.034 
ENSGALG00000001710 ENSGALG00000001710 Uncharacterized protein 2.324 0.035 
ENSGALG00000006375 TM4SF19 transmembrane 4 L6 family member 19 2.324 0.016 
ENSGALG00000023340 ENSGALG00000023340 Uncharacterized protein 2.303 0.042 
ENSGALG00000008308 BHLHE40 class E basic helix-loop-helix protein 40 2.296 0.004 
ENSGALG00000003482 BHLHA15   2.283 0.004 
ENSGALG00000000974 ENSGALG00000000974 Uncharacterized protein 2.277 0.034 
ENSGALG00000013101 BG2   2.276 0.025 
ENSGALG00000002728 SLC16A3 Monocarboxylate transporter 4 2.273 0.004 
ENSGALG00000014962 FAM26F family with sequence similarity 26 member F 2.273 0.010 
ENSGALG00000019552 SERPINB2 
serpin peptidase inhibitor, clade B (ovalbumin), 
member 2 2.262 0.004 
ENSGALG00000015474 CD80 Gallus gallus CD80 molecule (CD80), mRNA 2.243 0.008 
ENSGALG00000005430 ALS2CL ALS2 C-terminal like 2.231 0.004 
ENSGALG00000021573 PIK3R5 Phosphoinositide 3-kinase regulatory subunit 5 2.231 0.004 
ENSGALG00000000736 MATK megakaryocyte-associated tyrosine kinase 2.229 0.004 
ENSGALG00000012550 HMOX1 heme oxygenase 1 2.224 0.004 
ENSGALG00000001314 PTGS1 
prostaglandin-endoperoxide synthase 1 (prostaglandin 
G/H synthase and cyclooxygenase) 2.224 0.016 
ENSGALG00000013548 GZMA granzyme A precursor 2.197 0.010 
ENSGALG00000006204 ENSGALG00000006204 Uncharacterized protein 2.182 0.033 
ENSGALG00000012830 IRF-4 interferon regulatory factor 4 2.154 0.004 
ENSGALG00000005727 SLC7A3 
solute carrier family 7 (cationic amino acid transporter, 
y+ system), member 3 2.152 0.004 
ENSGALG00000005638 IL2RG interleukin 2 receptor subunit gamma 2.149 0.004 
ENSGALG00000010323 BATF basic leucine zipper transcription factor, ATF-like 2.141 0.013 
ENSGALG00000005069 PTGS2 Prostaglandin G/H synthase 2 2.140 0.004 
ENSGALG00000013747 TAGAP T-cell activation RhoGTPase activating protein 2.135 0.004 
ENSGALG00000010171 NFKBIE 
nuclear factor of kappa light polypeptide gene 
enhancer in B-cells inhibitor, epsilon 2.127 0.004 
ENSGALG00000023820 OGCHI   2.123 0.020 
ENSGALG00000007210 ENSGALG00000007210 Uncharacterized protein 2.111 0.004 
ENSGALG00000000139 GGA.18046   2.106 0.018 
ENSGALG00000015022 FYN tyrosine-protein kinase Fyn 2.102 0.004 
ENSGALG00000003196 ANG Angiogenin 2.097 0.004 
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ENSGALG00000019251 LAG3   2.093 0.019 
ENSGALG00000023634 ENSGALG00000023634 Uncharacterized protein 2.090 0.021 
ENSGALG00000001076 LIMK1 LIM domain kinase 1 2.089 0.041 
ENSGALG00000004243 ENSGALG00000004243 Uncharacterized protein 2.087 0.004 
ENSGALG00000021616 MARCKSL1 MARCKS-related protein 2.082 0.008 
ENSGALG00000016524 CAD 
carbamoyl-phosphate synthetase 2, aspartate 
transcarbamylase, and dihydroorotase 2.082 0.016 
ENSGALG00000002540 RGS2 regulator of G-protein signaling 2 2.080 0.004 
ENSGALG00000003578 FN1 fibronectin precursor 2.080 0.024 
ENSGALG00000013698 EFHD2 EF-hand domain family member D2 2.072 0.010 
ENSGALG00000009768 CCRN4L nocturnin 2.053 0.019 
ENSGALG00000002343 ENSGALG00000002343 Uncharacterized protein 2.052 0.048 
ENSGALG00000016988 KIAA0226L KIAA0226-like 2.046 0.004 
ENSGALG00000002643 SELP selectin P 2.035 0.004 
ENSGALG00000003103 MST1R macrophage-stimulating protein receptor precursor 2.027 0.004 
ENSGALG00000013861 TNFAIP3 TNF alpha induced protein 3 2.010 0.004 
ENSGALG00000002549 RGS1 regulator of G-protein signaling 1 2.001 0.004 
ENSGALG00000012352 BLVRA biliverdin reductase A 2.000 0.008 
P1C5/H3N8 vs. R(low)/H3N8 < -2 log2 Fold Change (FC) Significant DEG 
Gene ID Gene Protein Name Log2 FC q value 
ENSGALG00000009262 FGB 
Fibrinogen beta chain Fibrinopeptide B Fibrinogen 
beta chain -4.653 0.028 
ENSGALG00000003519 CHIA   -4.561 0.004 
ENSGALG00000016962 ENSGALG00000016962 Uncharacterized protein -3.930 0.004 
ENSGALG00000005278 CDH11 cadherin-11 precursor -3.808 0.004 
ENSGALG00000015329 ENSGALG00000015329 Uncharacterized protein -3.752 0.004 
ENSGALG00000016682 CRISP1   -3.376 0.004 
ENSGALG00000002358 CDO1 cysteine dioxygenase type 1 -3.124 0.004 
ENSGALG00000007945 CRYAB Alpha-crystallin B chain -2.933 0.045 
ENSGALG00000003193 CRABP1 Cellular retinoic acid-binding protein 1 -2.910 0.004 
ENSGALG00000007537 INCENP inner centromere protein -2.856 0.040 
ENSGALG00000005843 EEF1A2 eukaryotic translation elongation factor 1 alpha 2 -2.840 0.004 
ENSGALG00000006693 ENSGALG00000006693 Uncharacterized protein -2.772 0.004 
ENSGALG00000014843 TPD52L1 tumor protein D52-like 1 (TPD52L1), mRNA -2.601 0.033 
ENSGALG00000000184 SLC27A6 
solute carrier family 27 (fatty acid transporter), 
member 6 -2.474 0.008 
ENSGALG00000016292 COL21A1 collagen, type XXI, alpha 1 -2.368 0.014 
ENSGALG00000023424 DMBT1   -2.344 0.004 
ENSGALG00000005601 ENSGALG00000005601 Uncharacterized protein -2.256 0.004 
ENSGALG00000010417 ENSGALG00000010417 Uncharacterized protein -2.243 0.042 
ENSGALG00000006048 FAM64A family with sequence similarity 64 member A -2.223 0.004 
ENSGALG00000020909 C20ORF85 chromosome 20 open reading frame 85 [Gallus gallus] -2.201 0.046 
ENSGALG00000010769 HPGD 15-hydroxyprostaglandin dehydrogenase -2.154 0.004 
ENSGALG00000011277 PLEKHG7 
pleckstrin homology and RhoGEF domain containing 
G7 -2.133 0.034 
ENSGALG00000009155 CHGB chromogranin B -2.089 0.008 
ENSGALG00000020876 AOX2P aldehyde oxidase 2 pseudogene -2.075 0.004 
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Supplemental Table 14 
ENSGALG00000012997 DNAH5 dynein, axonemal, heavy chain 5 -2.053 0.042 
ENSGALG00000006217 S100B S100 calcium binding protein B -2.033 0.032 
ENSGALG00000012250 GGA.45581 
alcohol dehydrogenase 1C (class I), gamma 
polypeptide -2.017 0.040 
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Mock/H3N8 vs. Mock/R(low) > 2 log2 Fold Change (FC) Significant DEG 
Gene ID Gene Protein Name Log2 FC q value 
ENSGALG00000009317 ENSGALG00000009317 Uncharacterized protein #NAME? 0.011 
ENSGALG00000025284 SNORD89 Small nucleolar RNA SNORD89 #NAME? 0.011 
Mock/H3N8 vs. Mock/R(low) < -2 log2 Fold Change (FC) Significant DEG 
Gene ID Gene Protein Name Log2 FC q value 
ENSGALG00000014412 CSTA cystatin A -3.537 0.011 
ENSGALG00000002553 PCDH1 Gallus gallus protocadherin 1 (PCDH1), mRNA -3.530 0.011 
ENSGALG00000000379 ITGB3 integrin beta-3 precursor -3.136 0.011 
ENSGALG00000017214 HEPHL1 hephaestin like 1 -3.087 0.011 
ENSGALG00000015446 POU2F1 POU domain, class 2, transcription factor 1 -2.993 0.011 
ENSGALG00000006010 FAM103A1 protein FAM103A1 -2.941 0.011 
ENSGALG00000005278 CDH11 cadherin-11 precursor -2.860 0.045 
ENSGALG00000023370 ENSGALG00000023370 Uncharacterized protein -2.850 0.011 
ENSGALG00000016782 IL1R2 interleukin 1 receptor, type II -2.849 0.011 
ENSGALG00000013548 GZMA granzyme A precursor -2.785 0.038 
ENSGALG00000021142 ENSGALG00000021142 Uncharacterized protein -2.766 0.019 
ENSGALG00000006054 CALCA 
calcitonin gene-related peptide isoform 3 
preproprotein -2.704 0.041 
ENSGALG00000004167 SRGN serglycin -2.575 0.011 
ENSGALG00000020920 ENSGALG00000020920 Uncharacterized protein -2.526 0.026 
ENSGALG00000006841 POLR2L 
polymerase (RNA) II (DNA directed) polypeptide L, 
7.6kDa -2.454 0.029 
ENSGALG00000005172 ENSGALG00000005172 Uncharacterized protein -2.438 0.011 
ENSGALG00000023933 G0S2 G0/G1switch 2 -2.438 0.011 
ENSGALG00000023340 ENSGALG00000023340 Uncharacterized protein -2.397 0.029 
ENSGALG00000005599 ENSGALG00000005599 Uncharacterized protein -2.357 0.029 
ENSGALG00000025698 5_8S_rRNA 5.8S ribosomal RNA -2.345 0.011 
ENSGALG00000019147 CSF2RA 
granulocyte-macrophage colony-stimulating factor 
receptor subunit alpha-like -2.336 0.026 
ENSGALG00000017033 MRPS31 mitochondrial ribosomal protein S31 -2.248 0.038 
ENSGALG00000014201 PARVB parvin beta -2.229 0.011 
ENSGALG00000003578 FN1 fibronectin precursor -2.155 0.011 
ENSGALG00000019553 SERPINB10 Heterochromatin-associated protein MENT -2.151 0.049 
ENSGALG00000006326 MIF 
macrophage migration inhibitory factor 
(glycosylation-inhibiting factor) -2.124 0.041 
ENSGALG00000010362 SUCNR1 succinate receptor 1 -2.124 0.026 
ENSGALG00000020228 ENSGALG00000020228 Uncharacterized protein -2.112 0.041 
ENSGALG00000002383 CD72 CD72 antigen -2.091 0.049 
ENSGALG00000019061 MMP1 matrix metallopeptidase 1 -2.054 0.011 
ENSGALG00000008166 TLR15 Gallus gallus toll-like receptor 15 (TLR15), mRNA -2.028 0.011 
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Chapter 4 - The potential contribution of M. gallisepticum neuraminidase activity 
to co-pathogenesis with LPAIV in vivo in the presence of the viral neuraminidase 
inhibitor, oseltamivir. 
 
Methods 
-Chicken Infection Experiment: To study the potential role of neuraminidase activity in 
the co-pathogenesis of M. gallisepticum and LPAIV, the viral neuraminidase inhibitor 
oseltamivir phosphate was utilized in an in vivo co-infection model. This inhibitor was 
used as a tool to observe any compensation by M. gallisepticum for the inhibited 
neuraminidase activity of LPAIV. As described in previous chapters, 10 SPF White 
Leghorn chickens per group were infected with combinations of M. gallisepticum Rlow, 
the M. gallisepticum mutant P1C5, Hayflick’s medium as a mock infection, and H3N8 
(A/duck/Ukraine/1963) as outlined in the table below.  
All chickens were infected intratracheally with 200 µl of either 1 x 108 CFU/mL of 
M. gallisepticum Rlow, 5 x 106 TCID50 of H3N8, or Hayflick’s medium as a mock 
infection. All inoculum cultures of M. gallisepticum and H3N8 were diluted in fresh 
Hayflick’s medium. Oseltamivir phosphate was administered at a dosage of 1 mg/kg per 
day, divided into 0.5 mg/mg twice per day, at a 1:1 ratio in phosphate buffered saline 
(PBS) [1]. 
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Primary Infection  
(Day 0) 
Oseltamivir Treatment  
(Day 2) 
Secondary 
Infection (Day 3) 
Sacrifice 
(Day 7) 
Mock (Hayflick’s medium) 1 mg/kg daily until day 6 H3N8 
Mock (Hayflick’s medium) Mock (PBS) H3N8 
M. gallisepticum Rlow 1 mg/kg daily until day 6 H3N8 
M. gallisepticum Rlow Mock (PBS) H3N8 
M. gallisepticum P1C5 1 mg/kg daily until day 6 H3N8 
M. gallisepticum P1C5 Mock (PBS) H3N8 
  
All birds were humanely sacrificed on day 7 of the experiment as described 
previously in this dissertation. At necropsy, gross pathologic observations were 
recorded and a tracheal ring from the distal end was collected for M. gallisepticum 
recovery in Hayflick’s medium using 10-fold CCU dilutions. In addition, 1 mL of TriZol 
(Zymo Research) was washed through the lumen of each trachea to collect RNA for 
qPCR analysis of H3N8 load in each bird at the end of the experiment, as described 
earlier in this dissertation. 
 To investigate the potential compensatory relationship between LPAIV and M. 
gallisepticum neuraminidase activity during the course of co-infection, the M. 
gallisepticum Rlow neuraminidase mutant, P1C5 was utilized. This mutant has been 
documented to be attenuated in vivo and unable to be recovered from infected birds at 
14 days post-infection [5]. However, in conjunction with active neuraminidase activity 
from LPAIV H3N8, the dynamics of P1C5 may change in vivo allowing the mutant to 
persist and induce disease.  
 
Results 
Figure 1 – Tracheal mucosal thickness, bacterial, and viral load. Statistically significant 
differences between tracheal thickness measurements and viral loads among groups 
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were calculated using a one-way ANOVA with Tukey’s post-hoc test and a threshold for 
significance at p < 0.05. Significant differences are indicated with **** = p < 0.0001, ** = 
p < 0.01, and * = p < 0.05. Statistically significant differncees in M. gallisepticum 
recovery among groups was calculated using a Kruskal-Wallis ANOVA On-Ranks with 
Dunn’s Post Hoc test. No significant differences were found among experimental groups 
for M. gallisepticum or H3N8 load. 
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-Tracheal Histopathology: Significant differences in tracheal mucosal thickness exist 
between multiple experimentally infected groups of chickens. As anticipated, tracheal 
mucosal thickness is significantly increased between Mock/H3N8 + PBS and M. 
gallisepticum Rlow/H3N8 + PBS infected birds (p < 0.01) due to enhanced disease due 
to the presence of both M. gallisepticum and H3N8 infection (Figure 1A).  
Similarly, a significant increase in tracheal thickness also exists between 
Mock/H3N8 + Oseltamivir and M. gallisepticum Rlow/H3N8 + Oseltamivir infected 
chickens (p < 0.0001) (Figure 1A). The difference between these groups is confounded 
by the treatment with oseltamivir, which has been previously shown to effectively reduce 
viral load in AIV infected chickens [1]. Although the M. gallisepticum Rlow/H3N8 + 
Oseltamivir infected group contains both co-pathogens, the oseltamivir treatment did not 
alter the pathologic response to this co-infection as originally hypothesized.  
To expand upon this, M. gallisepticum Rlow/H3N8 + Oseltamivir infected chickens 
in fact have significantly higher tracheal thickness measurements when compared to M. 
gallisepticum Rlow/H3N8 + PBS infected chickens (p < 0.01) (Figure 1A). This same 
phenomenon exists between M. gallisepticum P1C5/H3N8 + Oseltamivir and M. 
gallisepticum P1C5H3N8 + PBS infected chickens (p < 0.05), in that oseltamivir 
treatment appears to increase the tracheal thickness in response to infection (Figure 
1A). A significant difference also exists between tracheal thicknesses of M. 
gallisepticum Rlow/H3N8 + Oseltamivir and M. gallisepticum P1C5/H3N8 + Oseltamivir 
infected chickens (p < 0.05) (Figure 1A).  
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-Tracheal Mycoplasma gallisepticum Recovery: Although no statistically significant 
differences in M. gallisepticum recovery from the trachea emerge among experimentally 
infected groups of chickens, noteworthy trends still exist (Figure 1B). M. gallisepticum 
recovery was most abundant in M. gallisepticum Rlow/H3N8 + PBS infected chickens 
(Figure 1B). The remaining experimental groups which received an M. gallisepticum 
infection had similar levels of bacterial recovery from the trachea (Figure 1B). 
 
-Tracheal LPAIV H3N8 Load: Similar to the recovery of M. gallisepticum from the 
trachea (Figure 1B), no statistically significant differences exist between H3N8 load in 
the trachea of experimentally infected groups of chickens. This is perhaps the most 
notable finding in that, as mentioned previously, oseltamivir treatment has been 
documented to significantly decrease AIV load in the tracheal tissue of infected 
chickens [1]. The data presented here indicate that oseltamivir treatment had no effect 
on the load of H3N8 in the tracheal lumen of experimentally infected chickens used in 
this model (Figure 1C). 
 
Discussion 
 The failure of oseltamivir treatment to combat H3N8 infection in this chicken 
infection model was unexpected. The original hypothesis to be tested was that M. 
gallisepticum neuraminidase activity could effectively compensate for LPAIV 
neuraminidase in the presence of the inhibitor, oseltamivir. This relationship could also 
work in reverse, in that LPAIV neuraminidase may enhance the pathogenesis of a 
neuraminidase-deficient M. gallisepticum mutant, P1C5. However, the lack of 
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discernable difference in viral load between mock and oseltamivir treated, H3N8 
infected chickens makes the appropriate testing of these hypotheses impossible.  
 Although the cause for the failure of oseltamivir to effectively reduce viral load in 
this model is unknown, there are multiple possibilities that may contribute to the 
explanation. Previously, Lee et al. utilized oseltamivir as a treatment for infection of 
chickens with LPAIV strain H9N2 (A/ Chicken/Korea/310/01) [1]. The LPAIV isolate in 
our model is of a different subtype; H3N8 (A/duck/Ukraine/1963). This difference could, 
at least in part, explain the difference in sensitivity to oseltamivir treatment in vivo. This 
H3N8 strain is, however, susceptible to oseltamivir carboxylate neuraminidase inhibition 
in vitro, as shown in Chapter 2 of this dissertation.  
 Another potential factor of the outcome of this experiment is the difference in 
original form of oseltamivir used between the two studies. Lee et al. utilized oseltamivir 
from capsules which was later suspended in PBS, whereas our model incorporated 
oseltamivir intended for oral suspension administration and these two drugs could have 
originated from different suppliers due to geographic differences [1].  
Additionally, although the dosages of oseltamivir used was consistent between 
the two studies, the precise timing of administration could potentially contribute to 
changes in active bioavailability of the drug in vivo. Finally, viral isolation may have 
differed among tissues in our model. Sampling of other areas, such as ceacal tissues or 
the lung, may have illuminated potential differences in viral load in animals from this 
experiment. 
 Another interesting observation is the similarity between tracheal mucosal 
thickness (Figure 1A) and viral load (Figure 1C). Although no statistically significant 
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differences exist between the amount of virus among experimental groups, the groups 
with the most severe tracheal mucosal thickening are also the groups with the highest 
viral titer in the trachea and vice versa (Figures 1A and 1C). Although M. gallisepticum 
recovery was increased in M. gallisepticum Rlow infected birds over M. gallisepticum 
P1C5 infected birds, the pattern seen between tracheal thickness and viral load does 
not apply as seamlessly to M. gallisepticum recovery.  
 These data, as well as the data presented in chapter 3 of this dissertation, 
indicate that the co-pathogen relationship between M. gallisepticum and LPAIV is not 
neuraminidase-dependent as originally hypothesized. Instead, as indicated by the host 
transcriptional response to mono- and co-infection, this pathobiological phenomenon is 
much more complex.  
Alterations in transcription of genes related to tracheal ciliary activity, 
inflammatory immune signaling, and tissue remodeling all exist between mono- and co-
infected chickens and likely contribute to differences in disease manifestation. Although 
some of these factors have been discussed in other publications, such as ciliostasis and 
cytokine levels observed in M. gallisepticum and LPAIV tracheal explants [2], the data 
presented in this dissertation are the first to examine these responses in the airway of 
the natural host during co-infection.  
 Examples of relevant transcriptional responses include significant alterations in 
TLR expression. TLR4 and TLR15 are increased in expression during co-infection with 
M. gallisepticum Rlow and LPAIV H3N8 compared to mono-infected chickens, or 
chickens instead co-infected with attenuated M. gallisepticum P1C5 (Chapter 3). These 
two TLR genes were also abundantly expressed in the chicken trachea during infection 
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with M. gallisepticum Rlow alone over the course of the first 7 days of infection [3]. 
TLR21 is significantly decreased in expression in chickens co-infected with M. 
gallisepticum Rlow or P1C5 and H3N8 over birds infected with H3N8 alone (Chapter 3). 
This suppression of TLR21 signaling is a novel finding and correlates with increases in 
tracheal histopathology in those infected chickens (Chapter 3). It is possible that, during 
co-infection, TLR21 suppression prevents association with TLR4 signaling that 
contributes to an appropriate immune response [4].  
KEGG pathway analysis also indicates differential effects on signaling pathway 
responses to co-infection. Noteworthy examples include differential effects on the 
Influenza A response pathway, extracellular matrix receptor signaling, metabolic 
pathways, phagocytosis, and TLR signaling (Chapter 3). Alterations in these processes 
in response to co-infection all contribute to the understanding of the mechanisms of the 
host response to co-infection with M. gallisepticum and LPAIV. 
 Another novel finding presented is the ability of attenuated M. gallisepticum 
mutants P1C5 and P1H9 to persist 6 to 7 days post-infection in the chicken trachea. 
These mutants were previously thought to be cleared early in infection due to their lack 
of survival to 14 days post-infection [5,6]. However, examination of their survival at a 
more acute time point suggests that both neuraminidase and MslA contribute to chronic 
persistence in the host, however are not required for short-term survival in the chicken 
airway. Co-infection with H3N8 has a more pronounced effect on chronic persistence of 
the MslA mutant P1H9 to 14 days post-infection than the neuraminidase mutant P1C5. 
This result contributes to the conclusion that the co-infection dynamic between these 
pathogens is more complex than originally anticipated.  
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Chapter 5 - Future Directions 
 
 The experiments described within this dissertation provide multiple avenues for 
future experimental exploration of M. gallisepticum and LPAIV co-pathogenesis. In 
attempt to reconcile the lack of efficacy of oseltamivir treatment in our chicken model, 
continued examination of dose, routes, and administration schedules can be performed 
on chickens infected with H3N8 alone. Additional tissues from these animals can be 
sampled to discern if other target tissues are more appropriate for changes in viral load 
due to this oseltamivir treatment.  
 In a similar vein, alternate neuraminidase inhibitors can be employed to replace 
oseltamivir in our model. Such inhibitors include zanamivir or DANA, as described in 
chapter 1 of this dissertation. Alternate isolates of LPAIV can also be utilized in our 
model. Our lab is in possession of another LPAIV isolate, H9N2 
(A/turkey/Wisconsin/1/1966) (BEI Reagent Resources). This virus is of the same 
subtype as the LPAIV used by Sid et al. in co-infection of tracheal organ cultures with 
M. gallisepticum and LPAIV [2]. H9N2 is also growing in relevance due to its global 
presence in poultry and zoonotic potential [7].   
 Another area of interest is the transcriptomic response in M. gallisepticum during 
co-infection with LPAIV. Publications out of our laboratory have used RNA-sequencing 
to find coordinated changes in the expression of genes by M. gallisepticum during early 
time points of infection, and these coordinated changes may differ during a co-infection 
scenario due to alterations in the host environment [8,9]. Genomic changes may also 
occur in both M. gallisepticum and LPAIV in response to co-infection, and sequencing of 
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recovered isolates after co-infection may illuminate mutations relevant to adaptation to 
that co-pathogen relationship over time.  
 There are also multiple avenues of co-pathogenesis in this model that have yet to 
be explored. For instance, co-infection of alveolar cells in vitro with the 2009 pandemic 
influenza virus, pdm2009, and methicillin-resistant Staphylococcus aureus contributes 
to disruption in the barrier function of the alveolar cells [10]. This damage to a primary 
host defense, along with alterations in host immune signaling, contribute to the severely 
of disease. Although the avian respiratory tract is unique in its structure, a similar 
phenomenon may be occurring during co-infection with M. gallisepticum and LPAIV in 
other areas of the respiratory tract, such as the air sac.  
 The targeting of certain host immune molecules could also be a promising route 
of further investigation. In mice, alterations in TGF-β and IFNγ in a model of allergic 
airway disease effects the severity of co-infection of those mice with Streptococcus 
pneumoniae and influenza A virus [11]. Another example is the inhibition of IL-10 
signaling in reducing disease exacerbation during co-infection of mice with 
Mycobacterium tuberculosis and influenza A virus [12].  
Finally, TLR9 has been implicated in the co-pathogenesis of Staphylococcus 
aureus and influenza A virus [13]. This relationship in particular, is noteworthy in that the 
chicken TLR21, which is suppressed during co-infection with M. gallisepticum and 
LPAIV (Chapter 3), is a homolog of human TLR9 [14]. Therefore, TLR21, among others, 
could be a novel target host immune molecule for intervention of co-pathogenesis in our 
model with M. gallisepticum and LPAIV.  
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  Other facets of viral and bacterial co-pathogenesis such as alterations in the host 
microbiome, biofilm formation, nutrient availability, and the availability of host receptors 
also provide potential routes of investigation within our co-pathogenesis model [15]. 
Other economically relevant viral pathogens, such as infectious bronchitis virus (IBV) 
could serve as viral co-pathogens of M. gallisepticum for other novel mechanisms of co-
infection in chickens [16].  
 Both M. gallisepticum and LPAIV are pathogens of great concern to the poultry 
industry, with a foremost impact on small-scale backyard flocks. Farmers and hobbists 
keeping these smaller flocks likely do not have access to the same surveillance and 
prevention measures as large broiler or layer industry operations. This scenario has the 
potential to become even more dangerous if the flock becomes infected by a virulent 
field isolate of M. gallisepticum that can persist to a chronic state in chickens. In 
addition, LPAIV isolates of sub-clinical pathogenicity could propagate within a flock 
without being detected.  
If both pathogens infect chickens within the flock, as demonstrated by the data 
presented here, the resulting disease could be severe. By better understanding the 
host-pathogen interations of this co-pathogenesis, such as the binding substrates and 
host immunological response, we can aid in the development of prevention and 
treatment efforts. This has the potential to greatly benefit the poultry industry, in that it 
could prevent drastic economic losses to backyard poultry farmers due to exacerbated 
disease during M. gallisepticum and LPAIV co-pathogenesis. In addition, these host-
pathogen dynamics could contribute to other bacterial and viral co-pathogen 
relationships in other animals or humans. In summary, the data presented in this 
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dissertation contribute novel and interesting findings to the community of knowledge on 
the co-pathogenesis of Mycoplasma gallisepticum and LPAIV. 
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